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ABSTRACT
Classical swine fever virus (CSFV) causes a serious disease of pigs that is a major 
threat to pork production industries worldwide. Due to the limitations of available 
vaccines there is a need for alternative strategies to aid CSF outbreak control. One 
such alternative could be through the use of type I interferon (IFN). During the acute 
phase of CSFV infection, high levels of systemic porcinelFNa (PolFNa) are detected in 
pigs and one recombinant PolFNa subtype has been reported to have anti-viral 
activities against CSFV in vitro. The aim of this study was to express and characterize 
the full panel of recombinant PolFN-a subtypes and to establish an in vitro model to 
assess their anti-CSFV activity if given prophylactically. All 17 PolFN-a subtypes were 
cloned, expressed in Chinese hamster ovary cells and purified. The biological activity 
of each subtype was confirmed using a VSV bioassay. Following the optimisation of 
an infection model using a commercial preparation of PolFNa, differential activity 
was observed between subtypes following treatment of porcine monocytes prior to 
infection with CSFV. The subtypes were subsequently grouped as having high, 
medium or low anti-CSFV activity. The potency of representative members of the 
active subtypes was investigated over a 72hr pre-treatment assay which confirmed 
PolFNal2 as the most potent subtype against CSFV in vitro. An additive effect was 
observed when equal ratios of subtypes within an activity group were used in 
combination. The expression of each subtype was then assessed during the course of 
a primary CSFV infection in vivo. When comparing the relative patterns of expression 
of the PolFNa subtypes in individual pigs, several subtypes appeared to be expressed 
at higher levels. However, the only consistent increase post CSFV infection was that
of PolFNcxS. In conclusion, this study has shown that PolFNa subtypes possess 
differential anti-CSFV activities in vitro, and that PolFNal2 represents a possible 
candidate for investigation as a me°taphylactic treatment against CSFV infection.
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1.1 Classical swine fever
Classical swine fever (CSF) or hog cholera causes serious worldwide economic 
loss to the swine industry and is notifiable to the World Organisation for Animal 
Health (OIE) (Moennig and Plagemann 1992). It is a highly contagious viral disease of 
pigs with high mortality and morbidity (Raton et al. 2000). CSF is commonly spread 
by the movement of infected pigs as well as contaminated feed (Fritzemeier et al, 
2000; Mintiens et al, 2003). Due to the high economic impact of this disease, the 
rules of the European Union (EU) Directive 80/217/EEC; containing measures to 
prevent, control and eradicate CSF, have been made valid in all EU member states. 
This legislation is based on a non-vaccination policy, stamping out of infected and in­
contact animals and the restriction of animal movement or their products and this 
has resulted in a large number of pigs being euthanized (80/217/EEC, 1980; Edwards, 
2000; Moennig, 1992). Using this and similar strategies most member states of the 
EU, Australia, Canada, New Zealand and the United States of America have 
succeeded in eradicating this virus, however, other countries with significant pig 
production are still experiencing economic damage (Edwards 2000). Recent 
outbreaks of CSF have been recorded in countries such as Brazil (2009), Russia (2009- 
2011) Lithuania (2009 and 2011), and China (2009-2012) (OIE, 2013). The distribution 
of CSFV from January 2013 to June 2013 is illustrated in Figure 1-1.
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Figure 1-1 Disease distribution map of Classical swine fever according to OIE during the 
periods January -June 2013.
Figure is taken from http://www.oie.int (Disease and distribution maps).
1.1.1 Pathogenesis of classical swine fever
In order to develop appropriate control measures, it is important to understand 
the pathogenesis of this virus. The main route of infection is oronasal and pigs have 
been known to contract the disease either directly or indirectly, through contact with 
infected pigs, pig feed or pig products and via contaminated equipment or clothing 
(Fritzemeier et al. 2000; Moennig et al. 2003). The incubation period in individual 
pigs may vary from 7-10 days while the age, breed, immune status of the pig and 
strain of the virus usually determines the severity of the disease and the clinical signs 
displayed (Mittelholzer et al. 2000). Decreased activity, anorexia, conjunctivitis, 
lethargy, huddling together, respiratory symptoms, constipation followed by 
diarrhea, usually indicate the acute form of the disease in pigs. Neurological signs 
such as lameness, in-coordination of movement and convulsion are often observed
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(Moennig et al. 2003). Redness of the ear, tail, abdomen and the inner limbs are also 
observed within 2-3 after weeks of infection followed usually by death. In most 
cases where the pigs display acute infection, they tend to die within 10-20 days after 
infection. In all cases the most common pathological changes seen post mortem are 
in the spleen, lymph nodes and kidneys (Van Oirschot, 1986). In such cases, infected 
livers appear dark and swollen while the spleen show infarction with dark blebs on 
the apex and periphery. In infected kidneys, small petechial haemorrahages on the 
subcapsular surface are seen while button ulcers developing from small necrotic 
areas are commonly observed in the colon (Trautwein, 1988).
Viral shedding in acutely infected pigs is usually in all secretions and excretions. 
Secondary enteric and respiratory infections that arise from severe leukopenia and 
immunosuppression often mask typical CSF signs thereby misleading diagnosis. Older 
pigs tend to show less specific clinical symptoms and recovery is frequent, as a strong 
humoral response capable of terminating the infection is raised by the pigs, with the 
neutralizing antibodies being detected 2-3weeks after infection (Lowings et al, 1996; 
Moennig et al, 2003; Raton & Greiser-Wilke, 2003).
The chronic form of the infection is usually fatal and observed in pigs unable to 
mount an effective immune response to the virus, with the immunosuppression 
leading to secondary infections. In such cases, animals tend to shed virus from the 
onset of clinical symptoms (Mengeling & Packer, 1969; Moennig et al, 2003). Also in 
response to the infection, the immune system produces antibodies, which although 
they are unable to eliminate virus, are temporarily detected in serum samples before 
the virus is cleared by the antibody. As a result of the constant shedding of virus over
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this period and the ineffective immune response, chronic infection often leads to 
death after 2-4months of infection. Initial symptoms are similar to those displayed 
during the acute stage of the infection; however, affected pigs usually improve after 
several weeks after which they develop recurrent symptoms such as pyrexia, 
anorexia, diarrhoea, and skin lesions (Artois et al, 2002; Depner et al, 1997).
In some cases, a late onset of disease has been reported in piglets infected in 
utero that become infected via cross-placental transmission (Dewulf et al, 2001; Van 
Oirschot & Terpstra, 1977). Through this means, the virus can infect the fetuses at 
different stages of pregnancy thereby resulting in several outcomes depending on 
the virulence of the strain and the time of gestation. At early stages of pregnancy 
abortion, mummification, still birth and malformation are seen while a reduction in 
fertility arises in breeding herds. Unlike the previous forms of infection, a late onset 
of infection is typically detected most frequently when infection occurs in sows at 50- 
70 day of pregnancy. These sows birth clinically virulent but persistently viremic 
piglets that appear healthy at birth but following several months, tend to show poor 
growth, wasting and occasional congenital tremor. These piglets also survive to 
become virus reservoirs as they are constantly shedding and maintaining the virus 
infection within the pig population. Although these piglets initially appear 
uninfected, they go on to develop the infection and die at about llm onths of age. In 
other cases, this prenatal infection can either result in mortality of porcine fetus and 
newborn pigs or normal and non viraemic pigs (Kramer-Schadt et al, 2007; Moennig 
et al, 2003).
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1.1.2 Classification and genomic structure of classical swine fever virus
CSFV belongs to the family Flaviviridae, genus Pestivirus (Raton et al, 2000; 
Wengler & Flaviviridae. In: Murphy, 1995) and is an enveloped (40-60nm), single­
stranded, positive-sense RNA virus with a genome of approximately 12.3kb (Raton & 
Greiser-Wilke, 2003; Vanderhallen et al, 1999). The genome encodes one open 
reading frame (ORF) flanked by two untranslated (UTR) or Non-translated (NTR) 
regions at the 3' and 5' end (Figure 1-2). The 150nt 5' UTR region acts as an internal 
ribosomal entry site (1RES) for initiation of cap-independent translation of the large 
ORF that encodes a 3,900 amino acid polyprotein. This polyprotein is processed by 
virus-encoded proteins and host cell protease into 12 mature proteins comprising of 
four structural and eight non-structural proteins (Moennig & Plagemann, 1992). 
Towards the 5' end of the genome are genes encoding the structural proteins while 
those encoding non-structural proteins are located at the 3' end (Ruggli et al. 2003).
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Figure 1-2. A diagrammatic representation of the Classical swine fever viron structure and 
viral genome organisation.
The CSFV genome encodes a single polyprotein which is cleaved by proteases to produce 12 
proteins. The arrows indicate which viral and host proteases are used for cleavage in the 
polyprotein. The envelope proteins ERNS (low or no neutralising activity), E2 (major 
immunogene, with high neutralising activity), and the non-structural protein NS3 (no 
neutralising activity) are regions able to induce detectable antibodies shown as (Y). (Beer et 
al, 2007).
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The first of these encoded proteins is the Npro, a non-structural protein exhibiting 
an autoproteolytic activity responsible for the cleavage from the nucleocapsid core 
protein C (Ruggli et al, 2009; Stark et al, 1993). Recent studies have also shown that 
Npro interferes with innate immunity by preventing induction of type I Interferon in 
vitro, while in vivo, CSFV with a deletion in the Npro gene are attenuated in pigs. This 
protein prevents interferon induction by inducing the degradation of Interferon 
regulatory factors -3 (IRF-3), a transcription factor vital for IFN induction, by a 
proteasome dependent mechanism (Bauhofer et al, 2007). This evidence points to 
the possibility of Npro playing a key function in CSF pathogenesis (Ruggli et al. 2009).
The NS2-3 protein undergoes an incomplete cleavage by the NS2 autoprotease 
and in Bovine viral disease virus (BVDV); another pestivirus, this uncleaved form is 
important for the generation of infectious virions during viral replication (Agapov et 
al, 2004). As show in Figure 1-2, the other polyprotein cleavage by the NS3 serine 
proteinase generates the NS4A, NS4B, NS5A and NS5B (Tautz et al, 1997)
Among the CSFV structural proteins are the C-core proteins, the Erns, E l and E2 
glycoproteins (Risatti et al. 2005). The Erns glycoprotein is loosely attached to the viral 
envelope; it has a mass of 25.4kDa and is encoded by 226 amino acids and is also 
secreted from infected cells (Rumenapf et al, 1993; Weiland et al, 1999). This 
glycoprotein is an endoribonuclease possessing two regions expressing RNase 
activity, and this activity has been suggested to be associated with CSFV virulence 
(Meyers et al, 1999).
Another structural protein, the E2 glycoprotein has been defined as the most 
immunogenic protein as it induces a protective response in pigs. Although the E l and
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E2 proteins are anchored to the virion envelope by the carboxyl terminal, the E2 can 
also exist as a homodimer via disulfide likage with the Erns protein. It is also the major 
determinant of virulence in pigs as strains lacking or containing a partial regions of 
the gene have been found to be nonviable (van Gennip et al, 2002; van Gennip et al,
2005). Other studies have shown significant in vivo attenuation in the highly virulent 
Brescia strain when the E2 region was replaced with that from a vaccine strain 
(Risatti et al, 2005).
The E2, Erns and NS3 proteins are able to induce detectable antibodies and can 
thus be used as diagnostic markers (Floegel-Niesmann, 2001).
1.1.3 Immunology and Classical Swine Fever
CSFV is able to grow and cause persistent infection in vitro without causing any 
cytopathic changes. The virus targets mainly monocytes and at later stages of 
infection, lymphocytes and granulocytes, among the leukocyte population, B cells 
appear to be sensitive to this virus (Susa et al, 1992). It has been shown that this 
early lymphopenia is an indirect induction of apoptosis in uninfected cells; as the 
virus is notable non-cytopathic, it was concluded that the cells killed during 
leukopenia were uninfected cells (Sanchez-Cordon et al, 2003; Summerfield et al,
1998). Studies have linked this lymphocyte depletion to a virus induced cytokine 
imbalance or viral superantigen causing an upregulation of Fas, and downregulation 
of Bcl-2 in activated memory T cells and as a result an increased susceptibility to 
apoptosis (Summerfield et al, 1998; Susa et al, 1992; Van Oirschot, 1983).
Monocytes and macrophages play important roles in the innate and adaptive 
immune response to infection and produce prostaglandins E2 (PGE2) as an anti­
33
Chp 1. Introduction
inflammatory mediator. (Parihar et al, 2010). These cells upon infection with a 
pestivirus like BVDV, induce an elevation in the secretion of PGE2, where it plays a 
role as an immunosuppressant (Peterhans et al, 2003). Unlike BVDV, CSFV infection 
induces an enhanced lymphocyte proliferation, even in the presence of the elevated 
PGE2, this elevation has been associated with lympho-stimulatory factors like 
interleukin-1 (IL-1) which is seen in the serum of infected pigs. On the other hand, 
the upregulation of PGE2 and IL-1 in infected pigs has been related to the 
characteristic haemorrhagic disorder, fever and coagulation disorders in CSF (Knoetig 
et al, 1999).
As well as monocytes and macrophages another important cell of the immune 
system, the dendritic cell (DC), can serve as an efficient reservoir for the 
dissemination of the virus within the host (Carrasco et al. 2004). CSFV-DC interaction 
studies have shown efficient viral replication within DCs without the induction of 
any cytopathic effect. Despite this, the virus suppresses the maturation of monocyte 
derived dendritic cells (mo-DC), resulting in a change in cytokine and co-stimulatory 
molecule expression. Due to this suppression, IVIHC-II upregulation on mo-DCs is 
inhibited, nevertheless, these cells can still act as antigen presenting cells by 
presenting the E2 glycoprotein to T cells (Carrasco et al, 2004; Ceppi et al, 2005;
Chen et al, 2012).
NF-kB activation during viral infection is one of the host's protective immune 
mechanisms against viruses (Santoro et al, 2003). CSFV studies have shown that the 
inability of CSFV in activating this translational factor in infected DCs is another 
method used by CSFV to evade the host innate defense (Chen et al, 2012).
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The infection of endothelial cells by CSFV has also been suggested to play 
important roles in immunosuppression and virus dissemination (Bensaude et al, 
2004). In endothelial cells, infection by this virus induces the expression of IL -la  and 
IL-6 proinflamatory cytokines, these cytokines promote procoagulant activity that 
would help eliminate the virus (Mantovani et al, 1997). Although IL-1 is a potent 
autocrine activator of endothelial cell genes which are involved in vascular function, 
this cytokine was not seen secreted from endothelial cells (Bensaude et al, 2004). As 
discussed earlier, the secretion of IL-1 and PGE2 by macrophages plays important 
roles in mediating vascular tone and function (Knoetig et al, 1999) and suggests that 
it may be involved in the paracrine activation of vascular cells (Bensaude et al, 2004). 
The activation of these IL -la  and IL-6 proinflamatory cytokines is seen early at 2hrs 
post infection (p.i) and is followed by rapid intracellular cytokine mRNA degradation. 
Followed by this initial activation is a second increase in cytokine synthesis, this 
occurs at 18-72hrs p.i as a result of virus replication commencing between 12-18hrs 
p.i this second increase occurs along with an increase in molecules involved in 
coagulation and vascular permeability (Mittelholzer et al, 2000). All these secreted 
factors and cytokines disrupt the haemostatic balance resulting in thrombocytopenia 
and platelet aggregation followed by haemorrhagic fever seen during the 
pathogenesis of the infection (Bensaude et al, 2004; Knoetig et al, 1999).
1.1.4 Vaccination control
Due to the economic implications of CSF, alternative methods of control have 
been implemented or are under consideration. Amongst these, routine vaccination is
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the most common means used for prevention and control in high endemic areas 
(Suradhat et al, 2007).
Several types of vaccine have been developed towards CSFV control. Live 
attenuated vaccines, e.g lapinised Chinese 'C  strain, are safe and provide 
prophylactic protection against CSFV. The disadvantage of these vaccines is the 
inability to differentiate the antibody response in pigs produced by these vaccines 
from that produced after CSFV infection (van Oirschot, 2003). This led to the 
development of a vaccine able to differentiate antibody responses between 
vaccinated and infected pigs; the E2 subunit marker vaccine (Hulst et al, 1994). This 
vaccine induced good immunity against the clinical signs when used as a 
prophylactic, although transplacental transmission of CSF virus could not be 
prevented as sows had to receive a booster vaccination. Another disadvantage of 
this vaccine is its inability to induce rapid protection; two doses are required to 
induce reasonable immunity and prevent horizontal transmission. With the E2 
subunit vaccine, discrimination between infected and vaccinated pigs can be 
performed with an ELISA that detects antibodies against the Erns protein, although 
this assay isn't very sensitive in detecting infection with the field strain as compared 
with the vaccine strain (de Smit et al. 2001; Floegel-Niesmann 2001; Moennig et al.
2003).
Combination vaccines have also been developed but their outcomes may vary 
based on the particular vaccine in combination (van Oirschot 2003). For instance in a 
study where the protective effect of CSFV vaccine combined with Aujeszky's disease 
vaccine was compared with the CSFV vaccine alone, a CSFV-specific cellular and
36
Chp 1. Introduction
antibody response with a comparable neutralising antibody titre was observed in 
inoculated pigs. However, there was a greater protection in the pigs vaccinated with 
the CSFV vaccine after 140 days post vaccination when compared with the 
combination vaccine (Suradhat et al, 2001).
With all the variables faced with the current vaccines and while DNA and 
recombinant vaccines against CSFV are under development (Hammond et al, 2000) 
other studies are looking into the use of cytokines as an antiviral treatment strategy, 
such as seen in the use of IFNy against foot-and-mouth disease virus (FMDV) (Yao et 
al, 2008).
1.2 Interferons
Interferons were first discovered as an antiviral agent in 1957 during virus 
interference studies by Isaacs and Lindenmann (Isaacs & Lindenmann, 1957). These 
proteins are known as the first line of defence initiated by cells upon viral infection. 
They are a group of evolutionarily conserved cytokines with three main biological 
activities: antiviral activity, antitumour activity and immunomodulatory effect 
(Pestka et al, 2004; Pestka et al, 1987). These multifunctional properties are induced 
through the synthesis of various proteins. A general property of the IFNs is their 
ability to efficiently induce a transient resistance to a broad range of viruses, thereby 
creating an antiviral state in the specific cell (Bekisz et al, 2010; Goodbourn et al, 
2000; Randall & Goodbourn, 2008).
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1.3 Interferon Genes and Proteins
Initially, Interferons were classified based on their antigenic specificity and amino 
acid sequences into Leukocyte, fibroblast and immune cell Interferon (Pestka et al. 
1987). They were later grouped into two distinct types; I and II based on their ability 
to bind to common receptor types (as outlined in Table 1-1) which are made up of 
two heterologous subunits. The binding of these IFNs to their respective receptors 
activates a network of distinct but related signalling pathways; the JAK-STAT pathway 
along with additional signalling cascades. This signalling results in the transcriptional 
regulation of several genes that promotes the different pleiotropic responses elicited 
by IFN (Pestka et al, 1987; Platanias, 2005; Rawlings et al, 2004).
The Type I IFNs are also known as viral IFNs, due to their induction upon viral 
infection. They are produced by most cell types where they play important roles in 
innate immunity by the induction of both direct and indirect innate immune 
responses. Type I IFNs in humans consists of seven subclasses. Within these are the 
IFNa subtypes; which is a family of thirteen homologous genes; IFNal, a2, a4, a5, 
a6, a7, a8, alO , «13, «14, a l6 , a !7  and a21, that express 12 distinct proteins 
(Pestka et al, 2004; Rubinstein, 2007), one IFNp gene which is ubiquitously 
expressed, the IFN8 gene expressed mainly by trophoblast, IFNe expressed in the 
uterus and ovary, the IFNœ which is mainly synthesized by leukocytes, IFNk  which is 
selectively expressed in epidermal kératinocytes, IFNt gene family synthesized by 
Ovine trophoblasts and the IFNÇ gene which is expressed in the spleen, thymus and 
lymph node (Chen et al, 2004; Jonasch & Haluska, 2001; LaFleur et al, 2001; Sen & 
Lengyel, 1992). Among these types, IFNô are only expressed in pigs or in cattle, while
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IFNt and IFNÇ are expressed in ruminant and mice respectively (Samarajiwa et al,
2006). In humans and mice the genes encoding these type I IFNs are clustered on 
chromosome 9 and chromosome 4 respectively (Chen et al, 2004; van Pesch et al,
2004), while in pigs, they are clustered on chromosome 1 (Sang et al, 2010).
As part of their indirect roles in activating antiviral actions, IFNa/|3 can activate 
some effector cells that are essential in the innate immune response system; they 
include natural killer (NK) cells, macrophages and DC's. A particular subset of DCs; 
plasmacytoid dendritic cells (pDCs) appear to play important roles as the major IFNa 
producing cells (Fitzgerald-Bocarsly, 2002; McKenna et al, 2005). Following viral or 
microbial challenge pDC have been shown to produce up to 103 times more IFN in 
cell culture than other blood cells (McKenna et al, 2005; Siegal et al, 1999). The IFNa 
genes have also been grouped based on their response activity; the immediate early 
response which is induced early without the need of ongoing response and the late 
IFNa genes which are synthesized more slowly and require protein synthesis.
The Type II IFN, also known as immune IFN, consists solely of the IFNy gene 
product. This antiviral IFN binds to a distinct type II receptor and, in contrast to the 
type I IFNs which are activated directly in response to virus infection, IFNy is 
synthesized in response to the recognition of infected cells by activated T 
lymphocytes including CD4 T h l cells, CDS cytotoxic suppressor cells and NKcells. 
Structural homologies do not exist amongst the type I and II IFN, but the genes they 
induce share functional similarities. Although they can induce the transcription of a 
wide variety of genes, wide scale screening using oligo-nucleotide array has
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identified several IFN inducible genes that have been induced by either type I or, and 
type II IFNs (Goodbourn et al. 2000).
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More recently, a third group of Interferon was discovered: the type III IFNs 
(Platanias, 2005; Randall & Goodbourn, 2008). These are based on their IFN-like 
antiviral activity and their ability to induce typical IFN-inducible genes (Uze & 
Monneron, 2007). This group comprises of three homologous proteins; IFN X l, À2 
and X3, which are also referred to as IL-29, IL-28A and IL-28B, respectively (Ank et al, 
2006b). Like the type I Interferons, they are induced by viral infection and tend to 
use the same signalling pathway as the IFNa/|3 genes; the JAK-STAT pathway, 
thereby inducing genes that encode for proteins such as 2/5/-oligoadenylate 
synthetase (2/5,-OAS), RNA-dependent protein kinase (PKR) and myxovirus resistant 
protein-A (MxA) (Kotenko et al, 2003). As type III IFNs can signal through almost all 
STAT molecules, they are said to exhibit much wider functions when compared to 
type I IFNs. Unlike the type I and II Interferons, they bind to a different cell-surface 
receptor which consists of two chains IFNXR1 (also known as IL-28 receptor-oc/IL- 
28Roc) which is specific for IFNXs and IL-10Rp an accessory receptor (Kotenko et al. 
2003). Once secreted, they bind to receptors on cells and elicit an equivalent antiviral 
response to IFNoc/p. Although, like INFa/p, they are induced in many cells following 
virus infection. Peripheral blood mononuclear cells (PBMC), monocyte derived DCs 
appear to be the major producers (Kotenko et al, 2003) while pDCs are also seen to 
express high levels following viral infection (Coccia et al, 2004). In contrast to type I 
receptors, IFNXR1 expression is limited to primary epithelial-like tissues 
(Sommereyns et al, 2008).
IFNXs can be expressed by both immune and non immune cells. And interestingly 
can be induced by both type I and type III IFNs (Sirén et al, 2005), as such IFNXs have
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been classed among the group of cytokines belonging to the Interferon stimulated 
genes (ISG)(Ank et al, 2006a).
IFN-X's exert both antiviral and antiproliferative activities as well as 
immunomodulatory effects that are related to type I IFNs, these include increasing 
NK and T cell cytotoxicity, promoting T h l responses (Numasaki et al, 2007), 
mediating cell apoptosis as well as the up-regulation of MHC class I to promote 
antigen presentation (Kotenko et al, 2003; Sheppard et al, 2003). These 
immunoregulatory actions exerted by IFN-X are cell type-specific and are dependent 
on a few factors such as the distribution of IFN-XRs, the nature of the signal 
transduction, and the genes activated (Li et al, 2009).
The successful cloning of the human Interferon genes has also provided 
substantial information on the biological and physical characteristics of these 
proteins in relation to how they induce antiviral activities (Pestka, 1983). Over the 
years, a variety of IFNs have been discovered from a variety of species (Isaacs & 
Lindenmann, 1957) and made commercially available (Baron & Narula, 1990). These 
have been of significance to human health care, and IFNas have especially been 
shown to be effective in the control of hepatitis in some patients (Floofnagle et al, 
1986; McHutchison et al, 2009; Poynard et al, 2009).
1.3.1 Porcine Interferon
The nature and properties of the porcine IFNs (PolFNs) resemble those in humans 
and mice. The type I IFN represents a heterogeneous family of related proteins 
encoded by a family of closely related, clustered, intronless genes which are located
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on chromosome 1 and 10 of the porcine genome (La Bonnardière et al, 1994; Sang et 
al, 2010; Yerle et al, 1986). The type I PolFN consist of 39 functional genes and are 
classified into seven subclass; IFN-a, -(3, -8, -e, -k, -coand-aco, all interspaced and not 
clustered with members of different subtypes on chromosome 1 of the porcine 
genome, except for IFNk which is found on chromosome 10. Among the type I 
PolFNs, only PolFNcx, -8 and -CD contain multiple subtypes (Lefevre et al, 1998). The 
presence of multiple subtypes with highly conserved genes in the loci of some 
subclasses has pointed to gene duplication being responsible for the evolution of 
type I genes (Antonelli, 2008; Kaessmann et al, 2009). All type I IFN contain a 
functional IFNabd domain with putative binding sites for the IFNa receptor (IFNAR) 
subunit which suggests that the IFN-stimulated antiviral signalling is conserved 
among the IFNs; specifically the type I IFNs possess a diverse range of antiviral 
activity on different cell-virus systems. An example is seen in porcine reproductive 
and respiratory syndrome virus (PRRSV) and vesicular stomatitis virus (VSV) where 
the antiviral activity of type I IFNs range from 0 to >105U/ng. In a study by Sang e t  
al., although most type I IFNa subtypes retained the highest antiviral activity against 
both PRRSV and VSV, other subtypes like IFNp, -8, -to and -act), depending on the 
target cell-virus system, differed in antiviral activity (Sang et al, 2010).
Porcine Type II IFN is encoded by a single gene with introns and consists of only 
one single member IFN-y (Cheng et al. 2006). Like the human IFN-y, PolFN-y is 
synthesized by antigen-stimulated lymphocytes and NK cells thereby inducing a cell 
mediated response (CMI) against intracellular pathogens including viruses. The 
response leading to the production of PolFN-y has been a useful tool for detecting
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the presence of antigen-specific, immunological memory using lymphoproliferative 
assays in pigs. The presence of PolFN-y is also a good indication of anti-viral immunity 
in pigs (Suradhat et al. 2001) and it also plays an role in conferring long-term control 
of viral infections (Biron C A, 2001; Samuel, 2001).
1.4 Interferon gene expression pathway
Studies suggest that for cells to sense viruses and activate their type I IFN genes, 
they make use of two major but distinct cellular signal transduction pathways; (i) the 
classical and (ii) the Toll-like receptor pathway. These pathways play important roles 
during infection. Most cells including fibroblasts, hepatocytes and conventional 
dendritic cells (cDCs) use intracellular sensors to detect viral components in the 
cytoplasm to activate the main interferon regulatory transcription factors IRF and 
NF-kB which in turn transactivate IFN-p gene expression. As an initial response, these 
infected cells then secrete mainly IFNP and then switch to IFNa during the later 
amplification phase of the IFN response (Marie et al, 1998); this is known as the 
classical pathway. On the other hand, pDCs, which secrete high level of IFNs (Colonna 
et al, 2002) use Toll-like receptors (TLRs) expressed on the cell surface or in 
endosomes to sense extra-cellular or engulfed viral material. This signalling pathway 
involves the adaptor protein MyD88 and activates IRF-7 which is constitutively 
expressed in pDCs, and it serves as a main IFNa and -p gene expression regulator 
(Honda et al, 2005b).
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Figure 1-3. Type I interferon signalling, induction and action (Bowie & Unterholzner, 2008; 
Haller et al, 2006).
The Left panel: the release of dsRNA during virus replication, results in the activation of 
three transcriptional factors NF-kB, IRF-3 and AP-1 required for the full induction of IFNp. 
The RIG-1, MDA5 and IPS-1/MAVS activates TBK-l/IKKe kinases, these kinases then 
phosphorylate IRF-3.
The right panel: This synthesized IFNp binds to IFN type I receptors and activates signals 
through the JAK STAT pathway. This results in the expression of several IFN stimulated genes 
(ISG) like, myxovirus resistance (Mx) protein, 2'5'-oligoadenylate synthetase (OAS), IFN- 
inducible dsRNA-dependent protein kinase (PKR) and IFN-stimulated protein of 20 kDa 
(ISG20). IRF-7 induces the expression of more IFNp there by amplifying this response 
(paracrine response). Suppressor of cytokine signalling (SOCS) and protein inhibitor of 
activated STAT (PIAS) shown in the pink boxes are negative regulators of the JAK STAT 
pathway.
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1.4.1 Classical pathway
In infected cells, double-stranded RNA (dsRNA) molecules that act as viral 
transcription intermediates, activate a signalling cascade or chain. During this chain, 
two intracellular RNA helicases; RIG-1 (Yoneyama et al, 2004) and MDA5 (Andrejeva 
et a I, 2004) (which are ubiquitously expressed in most tissues and induced by IFNs) 
are known to recognise viral dsRNA, they allow autocrine and paracrine action of the 
signalling system. These two helicases each contain two N-terminal caspase- 
recruiting domain (CARD)-like regions and a C-terminal DExD/H box RNA helicase 
domain (Andrejeva et al, 2004; Yoneyama et al, 2004). The binding of dsRNA to this 
helicase domain induces a conformational change that allows the CARD domain to  
interact with other CARD-like domains from downstream signalling partners. 
Interferonp promoter stimulator (IPS) or Mitochondrial antiviral signalling molecule 
(MAVS) possess a CARD-like domain which binds to RIG-1 and MDA5 to mediate RIG-1 
and MDA5 signals to downstream factors (Kato et al, 2005; Yoneyama et al, 2004). 
They also contain a C-terminal region that interacts with FADD, and RIP1, which are 
both involved in NF-kB signalling. These activities link IFN production and innate 
immune responses to mitochondrial activity (Kawai et al, 2005; Seth et al, 2005 ). It is 
plausible that the localization of IPS-1/MAVS in the membrane is to help keep the 
interacting RNA-sensing helicases close to the viral replication factories which often 
arise in association with intracellullar membranes (Haller et al, 2006).
IPS/MAVS proteins indirectly lead to the activation of the IRF-3 kinases. These 
kinases are members of the IFN regulatory factor family and they play a central role
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in the activation of IFN-p promoter (Kawai et al, 2005; Seth et al, 2005). Upon 
phosphorylation, IRF-3 homodimerizes and moves into the nucleus where it recruits 
the transcriptional coactivatiors and CREB-binding protein (CBP) to initiate IFN-P 
mRNA synthesis (Fitzgerald et al, 2003; Suhara et al, 2002). Also, NF-kB and AP-1 are 
recruited in a dsRNA dependent way and all together these factors up-regulate the 
initial IFN-ccP gene expression that triggers the expression of IRF-7 which is normally 
absent or present in most cells at low amounts (Sato et al, 2000). IRF-7 is a good 
regulator of IFN gene expression and the full activity of IRF-3 requires co-operation 
with IRF-7 (Haller et al, 2006; Iwamura et al, 2001). The second-wave of IFNs are 
produced by a positive feedback loop which initiates the synthesis of several IFNa 
subtypes and is induced by IRF-7(Marie et al, 1998); which is activated in the same 
way as IRF-3 (Smith et al, 2001). Figure 1-3 is a representation of signalling events in 
some hematopoietic cells such as conventional dendritic cells (cDCs). Using 
expressed TLR3, these cells can sense viral and other dsRNA molecules in the 
endocytic compartment. Ligand-induced triggering of the TLR3 is then induced by 
dsRNA through the adaptor molecule TRIF which bypasses IPS-1/MAVS. This trigger 
directly activates the kinase TBK-1 and IKKe leading to phosphorylation and nuclear 
translocation of IRF-3 and IFN-P gene expression. It is important to note that in these 
TLR-3-expressing cells, infection is not required to induce type I IFN production. In 
contrast, their response to viral RNA is dependent on the uptake of activated virus 
particles or dead cells into the endosomal compartment (Schulz et al, 2005).
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1.4.2 TLR pathway
Toll-like receptors (TLRs) are a class of pattern recognising receptors (PRRs) that 
recognise pathogens or pathogen derived products thereby initiating signalling 
events that activate the innate host defence mechanisms such as phagocytosis and 
inflammation (Barton & Medzhitov, 2002; Hawlisch & Kohl, 2006; Werling & Jungi, 
2003). pDCs which are natural IFN producers recognise RNA or DNA viruses by TLRs 
expressed in endosomes. Upon activation, TLR 7, 8 and 9 signal via MyD88 (an 
adaptor molecule) which forms a complex with TRAP and IRF-7. Phosphorylation of 
IRF-7 allows it to transcriptionally activate multiple IFN-a genes (Iwasaki & 
Medzhitov, 2004). The ability of plasmacytoid dendritic cells (pDCs) to constitutively 
express IRF-7 differentiates them from other cell types (Asselin-Paturel & Trinchieri, 
2005; McKenna et al, 2005). In response to IFN, IRF-3 and IRF-7 are further up- 
regulated and together generate a positive feedback loop for high IFN-a and -(3 
production (Tsujimura et al, 2003).
Another difference is in other cell types, that the membrane-bound TLR-9 and 
probably the TLR-7/TLR8 are rapidly translocated to lysosomes and degraded, 
whereas in pDC, they remain active in the endosomal compartment for a long time 
period, (Honda et al, 2005a). This might be the reason why some viruses like measles 
virus and respiratory syncytial virus target pDCs thereby blocking IFN production as 
type I IFNs also play important roles in the adaptive immune response (Schlender et 
al, 2005). In these cells, the virus can inhibit the production of IFN by the TLRMyD88- 
IRF-7 pathway thereby causing an induced prolonged immunosuppression or 
immune imbalances (Le Bon & Tough, 2002).
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1.5 Interferon receptor Signaling via JAK-STAT pathway
IFN signaling involves an IFN-mediated heterodimerization of specific IFN cell 
surface receptor subunits with their respective IFN. Activation of the IFN and its 
respective receptor send signals to the nucleus via the JAK-STAT pathway (Haller et 
al. 2006) as summarized in Figure 1-4 below.
The type I IFN receptors consists of two subunits; IFNAR-1 and IFNAR-2 (Samuel 
2001) while the IFN-y receptor complex consists of IFNGR-1 and IFNGR-2 (Bach et al, 
1997; Pestka et al, 1997).
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Figure 1-4. Interferon receptors and activation of classical JAK-STAT pathways by type I and 
type II Interferons (Platanias, 2005).
The type I receptor (IFNAR) at cell surfaces to which all type I IFN bind is made up of two 
subunits; IFNAR1 and IFNAR2. These receptors; IFNAR1 and IFNAR2 associate with members 
of the Janus activated kinases (JAKs) called tyrosine kinase 2 (TYK2) and JAK1, respectively. In 
contrast, type II IFN which is composed solely of IFN-y, binds a distinct type II IFN receptor. 
Like the type I receptor, it is also composed of two subunits, IFNGR1 and IFNGR2 which 
interact with JAK1 and JAK2, respectively.
Upon activation of the JAKs associated with the type I receptor, the tyrosine 
phosphorylation of STAT2 (signal transducer and activator of transcription 2) and STAT1; 
results to the formation of STAT 1-STAT2-IRF9 (IFN-regulatory factor 9) complexes, also 
known as ISGF3 (IFN-stimulated gene factor 3) complexes. The ISGF3 is then translocated to 
the nucleus where they bind to IFN-stimulated response elements (ISREs) in the promoters 
of certain interferon stimulating genes (ISG) thereby initiating the transcription of IFN 
stimulated genes. The binding of IFNy to the type II receptor, activates JAK1 and JAK2 to 
regulate the phosphorylation of STAT1. This phosphorylation also results in the formation of 
STAT1-STAT1 homodimers (which can also be induced by type I IFN). the homodimers are 
translocated to the nucleus where they bind to GAS (IFN-y-activated site) elements present 
on the promoter of some ISGs to initiate transcription.
The signal transducer and activator of transcription (STAT) family of proteins are 
latent cytoplasmic transcription factors with seven known members; STAT-1, STAT-2,
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STAT-3, STAT-4, STAT-Sa, STAT-5b, and STAT-6. In response to cytokine stimulation, 
they become tyrosine phosphorylated by the Janus family of tyrosine kinase (JAK) 
enzymes; composed of Jak-1, Jak-2, Jak-3, and Tyk-2 (Schindler, 2002). These 
different JAK and STAT proteins are known to perform distinct functions in cytokine 
signaling, mediating IFN-dependent biological responses, and inducing an antiviral 
state.
Jak-1 and Tyk-2 kinases are involved in IFN-a/p signaling, while the Jak-1 and Jak- 
2 kinases function in IFN-y signaling. Activation of the receptor-associated JAKs 
results in subsequent phosphorylation of latent cytoplasmic STAT transcription 
factors (Lau et al, 2000).
As a rapid response to signaling by IFNs-a/p, IRF-9 associates with STAT-2 in the 
cytoplasm thereby preparing the complex for activation by dimerization with STAT-1 
to form the ISGF-3 complex. This ISGF-3 complex binds directly to the ISRE found in 
the promoters of some IFN-a/p-regulated genes and plays an important role in the 
antiviral actions of IFN (Haller et al. 2006).
The binding of the IFN-y receptor causes dimerization, which results in activation 
of Jak-1 and Jak-2 by trans-phosphorylation. The activated JAKS then phosphorylates 
and binds to STAT-1 protein, allowing its dissociation from the receptor to form a 
homodimer. It is then translocated into the nucleus where it binds to GAS element to 
activate transcription of IFN-y inducible genes (Goodbourn et al, 2000; Stark, 2007;
Stark et al, 1998; Tourkine et al, 1995).
Aside from the JAK-STAT signal transduction pathway, additional pathways of 
signal transduction possibly involving the RNA-dependent protein kinase (PKR)
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(Williams 1999), mitogen-activated protein kinase, and phosphatidylinositol 3-kinase 
may also occur under different conditions (Stark, 2007). IFN-a, -|3 and -y can regulate 
the expression of IFN-responsive genes by a STAT-1 and PKR-independent alternative 
signaling mechanism that requires both the IFN-y receptor and JAK-1 kinase (Ramana 
et al, 2001).
Suppressor of cytokine signaling proteins (SOCS) act as negative-feedback 
regulators of JAK-STAT signalling. They are induced by numerous cytokines including 
IFN-y. They suppress the activation of Jak by binding to the kinase domain on all the 
Jak kinases thereby inhibiting signalling (Naka et al, 1999). Subsequently, in response 
to IFNa and IFNy, SOCS-1 inhibits the tyrosine phosphorylation and nuclear 
translocation of STAT-1. This inhibition prevents the antiviral and antiproliferative 
activities of IFNs in cell lines stably expressing the SOCS proteins (Song & Shuai,
1998). Studies targeting the disruption of the SOCS-1 gene suggest that the most 
important physiological function of this signalling suppressor is the negative 
regulation of IFN-y signalling and STAT-1 function (Alexander et al, 1999; Yasukawa 
et al, 2000). The protein inhibitor of activated STAT (PIAS) family of cellular proteins, 
PIAS-1 and PIAS-3, which can bind to STAT-1 and STAT-3 are also negative regulators 
of STAT signaling (Ihle, 2001). Negative regulation of JAK-STAT signal transduction is 
also achieved by dephosphorylation catalyzed by the protein tyrosine phosphatase 
SHP-l which suppresses the signal transduction process of several cytokines, 
including IFN-a by catalyzing the dephosphorylation of JAKs (David et al, 1995; David 
et al, 1996).
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1.6 Viruses and Interferon response evasion
In order to establish infection and produce progeny viruses in infected host cells, 
viruses have evolved means to down-regulate IFN responses. This may involve 
interfering with the general host cell gene expression or protein synthesis. For 
instance FMDV produces L proteinase which is able to shut off host cell protein 
synthesis. Mutation of this protein resulted in an attenuated strain that induced 
elevated IFNcc/p levels (Chinsangaram et al, 1999). Although this process would 
prevent IFN production in the host cell, on the other hand, the host cell is more likely 
to die rapidly and the virus is less likely to establish latent or persistent infection as 
cellular protein synthesis is inhibited (Randall 2008).
In CSFV, type I response is inhibited in target cells via the degradation of IRF3. 
The CSFV Npro, targets and binds IRF-3 to mediate a ubiquitin-dependent 
proteasomal degradation (Seago et al, 2010). This IRF3 depletion allows the virus to 
establish host infection during the early stages of the disease (Bauhofer et al. 2007).
Several viruses can inhibit the antiviral actions of IFN via several means; (i) the 
viral protein or responses induced in infected cells are able to target the IFN 
response in these cells, (ii) A single viral protein can block several stages of the IFN 
induction and signalling cascade, (iii) A virus can induce several IFN-antagonistic 
activities targeting different pathways. For example the paramyxoviruses, some of 
which use the V protein to block induction of IFN by binding to the dsRNA-sensing 
helicase MDA5 (Andrejeva et al, 2004). They also induce the ubiquitinylation and 
subsequent degradation of STAT-1 in a complex reaction (Didcock et al, 1999; 
Precious et al, 2005).
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Herpes simplex virus-1 (HSV-1) core protein activates SOCS-3 thereby down- 
regulating STAT and JAK (Yokota et al, 2004), while the hepatitis C virus (HCV) 
NS3/4A protease has the ability to inhibit RIG-1 signalling and induce the cleavage of 
the adaptor protein TRIP thereby disrupting TLR3 signalling. The protease is essential 
to cleave the non-structure! proteins from the HCV polyprotein synthesized on 
intracellular membranes and may also lead to degradation of the membrane-bound 
cellular IPS1/MAVS complexes.(Breiman et al, 2005; Li et al, 2005).
In many negative-strand RNA viruses e.g Rabies virus, Ebola virus, an important 
viral polymerase complex the phosphoprotein P, is the main IFN antagonist. This 
protein is used to interfere with the activation of IRF-3 (Easier et al, 2003; Brzôzka et 
al, 2005). As discussed earlier, the anti-viral responses induced in cells occur in a 
cascade-like manner; for instance the JAK STAT pathway, any viral induced 
interference at any stage during the IFN-signalling would go on to disrupt the 
expression of several inducible proteins like MX, PKR, OAS and as a result reduce the 
production of the second wave of IFNs.
Inhibiting IFN signalling also causes the down regulation of MHC I molecules 
within infected cells thereby making them poorer targets for cytotoxic T-Lymphocyte 
attack (Randall & Goodbourn, 2008). Other viruses can also inhibit the induction of 
cellular antiviral mechanisms thereby inhibiting the action of IFN or develop a 
replication strategy that is not responsive to host IFN (Samuel, 2001).
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1.7 Interferons as antiviral treatment
The use of IFNs as potent antiviral agents has evolved rapidly over the years 
resulting, for example, with pegylated IFN-a2 and IFNa2b- being used as an 
approved HCV treatment (Shepherd et al, 2004; Souvignet et al, 2007; Yoshida et al,
2009).
FMDV like CSFV can also result in catastrophic cases, with several limitations 
involved in its control (Barteling & Vreeswijk, 1991). Although current vaccines used 
in cases of FMDV outbreaks can confer immunity within a week, there is a need to 
develop disease control strategies that more rapidly and effectively induce 
protection (Biront et al, 1987; Mason et al, 2003; Parida, 2009). Studies on the 
antiviral action of type I IFNs have demonstrated the effective inhibition of FMDV 
viral replication in porcine and bovine cells using recombinant porcine and bovine 
IFNa and IFN|3 (Chinsangaram et al. 2001). Similarly, several studies have 
investigated and shown the antiviral ability of IFNoc/p in inhibiting vesicular somatitis 
virus VSV (Horisberger 1992), transmissible gastroenteritis virus (TGEV) and PRRSV 
(Albina et al. 1998).
Studies have also demonstrated that constitutive expression of the MxA gene; an 
interferon stimulated gene, in IFN susceptible animals confers full protection against 
a number of viruses and conclusively establish this protein as an important 
intracellular mediator of the antiviral effects of IFN-a/(3 (Hefti et al, 1999).
Recent studies are now looking to improve the antiviral actions of these 
cytokines by investigating any evidence of synergism when used in combination. An 
example of one such study was reported in a Pseudorabies virus (PRV) infection
56
Chp 1. Introduction
when porcine IFNy acted synergistically with other porcine IFN a/(3 to potently inhibit 
PRV replication in vitro (Yao et al. 2007).
In CSF outbreaks cases, the live vaccine confers immunity within a week (unlike 
the E2/DIVA vaccine which takes longer than a week), but is limited in differentiating 
between field and vaccine strain (de Smit et al, 2001; Floegel-Niesmann, 2001; 
Moennig et al, 2003). This current success seen with IFNs as a potent antiviral 
treatment led to investigating its use as a possible control strategy against CSF.
1.8 Hypothesis, Aims and objectives
Among the type I IFN, PolFNas are key components of the innate immune system 
known to elicit a variety of antiviral effects. Although these cytokines are induced in 
response to CSFV infection, studies have confirmed this induction to be non- 
protective (Summerfield et al, 2006), despite this, a protective antiviral effect against 
CSFV by IFNa has been observed in vitro (Xia et al, 2005b). The focus of this study 
was to observe for any differential effect among the PolFNoc subtypes and identify 
the most likely highly active anti-CSFV IFNa subtype using porcine monocytes; as 
they are known to be one of the primary target cells of this virus (Knoetig et al,
1999). Although this information may not fully represent the action of porcine IFNa 
against CSFV in vivo, knowing the key candidate immunomodulatory IFNa molecules 
and understanding the differential expression pattern of PolFNa in vivo can inform 
on the relationship between the anti-CSFV activity of different IFNa subtypes and 
CSFV infection.
Chp 1. Introduction
There were three underlying hypothesis for this study; (i) that IFNa subtypes 
possess differential anti-CSFV effects (ii) that these subtypes could induce a 
synergistic effect when used in combination and (iii) that these subtypes are 
differentially expressed following CSFV infection.
The aims of this study are:
1. To characterize the efficacy of commercially available porcine 
immunomodulatory proteins for abrogation of CSFV infection on monocytes. 
We would therefore observe the effect of a commercially available porcine 
IFN-a on CSFV infection in vitro.
2. To produce preparations of standardized, active porcine Interferon alpha 
subtypes not available commercially, and use these preparations to identify 
and characterize those with the potent ability to abrogate CSFV in vitro.
3. To identify which of the different polFNa subtypes are expressed in vivo 
before and after CSFV infection via polymerase chain reaction (PCR) or 454 
deep sequencing analysis of samples from pigs experimentally infected with 
CSFV.
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Chp 2. Materials and Methods
2.1 Mammalian cell culture
2.1.1 Porcine Kidney cells
Monolayer cultures of Porcine kidney cells (PK15) are susceptible to CSFV and 
have been commonly used for the routine isolation and cultivation of CSFV (Ressang, 
1973).
PK15 cells were supplied as a confluent monolayer in a 75cm2 flask (cell and 
tissue culture unit, AHVLA, United Kingdom). Cells were disaggregated into individual 
cells by incubating with 0.5% Trypsin- Ethylenediaminetetraacetic acid (EDTA) (Life 
Technologies, UK) for Sminutes (mins) followed by washing with sterile IX - 
Phosphate buffered saline solution (PBS), before being passaged at a 1:2 ratio at a 
seeding density of Ix lO 6 cell/75cm2 flasks containing 20ml of Earle's Minimum  
Essential Medium (MEM) (Life Technologies-Gibco, UK) supplemented with 10% fetal 
calf serum (FCS) (Autogen Bioclear UK Limited, UK), O.lmg/mlpenicillin/streptomycin 
and 0.25% nystatin (Life Technologies,UK). Cultures were monitored daily under a 
light microscope and split every 2-3 days when they reached 80-90% confluency.
2.1.2 Chinese Hamster Ovary cells
The Chinese Hamster Ovary cell line (CHO-K1) is commonly used for large scale 
production of therapeutic proteins (Kim et al, 2012) and was also chosen for IFN 
production because of its rapid growth in cell culture. The cell line was supplied as a 
confluent monolayer in a 75cm2 flask (Cell and tissue culture unit, AHVLA,UK); 
disaggregated as above, split 1:3 at a seeding density of Ix lO 6 cells/75cm2 flasks
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containing 20ml of Dulbecco's Modified Eagle Medium (D-MEM) (Life Technologies- 
Gibco, UK) supplemented with 10% FCS, 1% penicillin/streptomycin and 0.25% 
nystatin. Cultures were monitored daily by a light microscope and passaged every 2- 
3 days until they reached 80-90% confluency.
2.1.3 African green monkey kidney cells
African green monkey kidney cells (Vero) are commonly used for the propagation 
of Vesicular Stomatitis Virus (VSV); a virus routinely used to assay for the antiviral 
activity of IFNs due to its high sensitivity to IFNs (Basu et al, 2006; Schlegel et al, 
1982).
Vero cells (cell and tissue culture unit, AHVLA, UK) were propagated in EMEM 
supplemented with 10% FCS, O.lmg/ml penicillin/streptomycin and 0.25% nystatin. 
Cells were supplied as a confluent monolayer in a 75cm2 flask. The confluent culture 
monolayer was disaggregated using 0.5% Trypsin-EDTA (Life Technologies, UK) into 
individual cells and split 1:3 to 1:6 at a seeding density of l-2 x l0 6/75cm 2 flasks 
containing 20ml of the appropriate culture media. Cultures were monitored daily and 
split every 2-4days when they reached 80-90% confluency.
2.1.4 Mardin Darby bovine kidney cells t2
Mardin Darby bovine kidney cells t2 (MDBK-t2) obtained from Dr. Bryan
Charlestone, (Pirbright laboratory, UK) were utilized for measuring IFN activity.
These cells are stably transfected with the interferon stimulated human MxA
promoter linked to a chloramphenicol acetyltransferase (CAT) reporter gene, and
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are also resistant to blasticidine (Francois et al, 2005; Fray et al, 2001). They were 
cultured in MEM supplemented with 10% FCS, O.lmg/ml penicillin/streptomycin, 
0.25% nystatin and lO^g/ml of blasticistidine. Confluent cell cultures were split at 
a ratio of 1:3 to 1:6, and seeded at 2-4 x 104cells/cm2 into sterile flasks. Cultures 
were monitored daily and split when they reached 80-90% confluency.
2.2 Viruses and virus propagation
All manipulations with live viruses were conducted in a microbial safety cabinet, 
class II (MSC II), under Specified Animal Pathogens Order(SAPO) III containment 
procedure.
2.2.1 Viruses
2.2.1.1 Vesicular stomatitis virus
Vesicular stomatitis virus (VSV) is a nonsegmented, negative-strand RNA virus 
which replicates efficiently in a variety of cells lines to a high titre and in most cases 
producing a cytopathic effect (Lichty et al, 2004; Rodriguez & Nichol, 1999).
VSV is highly sensitive to porcine IFNs in vitro (Derbyshire, 1989) and replication 
of this virus is inhibited by the 6 8 kDa IFN inducible dsRNA- activated protein kinase 
(protein (p6 8 ) kinase) PKR. As a result of this inhibition, VSV is commonly used for 
IFN detection and in antiviral activity assays to quantify the inhibitory activity of IFN 
on viral replication (Friedman, 1977; Lefevre & La Bonnardiere, 1986; Meager, 2002; 
Sang et al, 2010).
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2.2.1.2 CSFV Alfort 187 and Brescia
CSFV isolate Alfort 187 (Genotype 1.1) and Brescia (Genotype 1.2) were obtained 
from the mammalian Virus Investigation Unit (AHVLA-Weybridge, UK). CSFV Alfort 
187 strain was isolated from a pig infected with the highly virulent CSFV strain; 
Alfort (Dahle & Liess, 1995) while Brescia is a moderately virulent strain (Moormann 
et al, 1990; Risatti et al, 2005). Both are known to replicate in vitro in porcine cells 
(Kasza et al, 1972) without inducing any cytopathic effect (Manual, 2008).
2.2.2 Propagation of Vesicular stomatitis and Classical swine fever virus
Vero cells used in the propagation of VSV were seeded in 75cm2 tissue culture 
flasks cultured with 20ml Minimal Essential Medium (MEM) supplemented with 10% 
FCS and incubated for 24hrs at 37°C, 5% C02, in a humidified incubator until cells 
reached a confluency of 80-90%. Similarly, CSFV was propagated under the same 
conditions but using PK15 cells.
Subsequently, the cell sheet was washed with 10ml of MEM without serum and 
the cell monolayer was inoculated with 1ml of stock virus. Cell cultures were 
incubated for 2hrs to allow virus attachment after which 19mls of fresh 
supplemented MEM were added. Cell cultures were incubated for 2d ays and in the 
case of VSV infected cultures, until approximately 50% viral cytopathic effect (CPE) 
was observed after viewing under a light microscope. CPE consisted of the rounding 
of cells and detachment from the surface of the culture plate resulting in the 
disappearance of the cell sheet.
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The infected cell cultures were frozen overnight at -80°C and thawed to release 
virus particle from infected cells. Subsequently, under sterile aseptic conditions, 
ISmls of the virus-cell suspension was transferred into a sterile 50ml falcon tube and 
stored at room temperature (RT). The culture flask containing about 5mls of virus­
cell suspension was then subjected to two freeze-thaw cycles to release cell- 
associated virus; each freeze thaw cycle was at -80°C for 15mins. The 15ml 
suspension previously collected was then added back into the flask and mixed gently 
before being clarified by centrifugation at 2000g for lOmins at 4°C using an Allegra 
centrifuge. The virus supernatant was collected and stored at -80°C in 1ml aliquots.
For subsequent passage of virus cultures, the frozen 1ml viral aliquots were used 
to inoculate fresh vero cell cultures as described above.
2.2.3 Virus titration
The titre of the virus stocks was determined in vitro by inoculating serial dilutions 
of the virus material to a susceptible cell line. All viruses were serially titrated using 
the cell lines on which they were propagated.
Confluent monolayers of PK15 or Vero cells in 25 cm2 tissue culture flask were 
detached with 0.5% Trypsin-EDTA as above. Cell counts were obtained using a 
haemocytometer: cells were diluted 1 in 10 in a 0.45%v/v solution of the viability 
stain trypan blue and 1 0  pi of the cell-stain mixture loaded onto a new improved 
Neubauer haemocytometer. Trypan blue selectively traversed the non-intact 
membrane of dead cells and coloured them blue, live, non-coloured cells were
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counted with a Leica inverse microscope. Cells were resuspended in MEM with 10% 
FCS to give a final cell count of 2 x l0 5cells/ml.
Ten-fold serial dilutions of the virus sample to be titrated were prepared in bijoux 
bottles and added to 96-well microtitre plates, in which 50pl of MEM/FCS had been 
dispensed. A 50pl aliquot of each dilution was added to all 8  wells of a column 
starting with the most dilute in the first column. The 10th column was left empty 
while the 11th and 12th column served as no virus control columns and lOOpI of 
MEM/FCS was added. Finally 50pl of cell suspension was added to each well, starting 
with the control column.
The plates were sealed with a clear plastic seal and incubated at 37°C in 5% C02.
2.2.3.1 Detection of VSV infection in Vero cells and calculation of virus 
concentration
Plates infected with VSV were observed under the light microscope after 3 days 
and wells with cytopathic effects (CPE) were scored with a plus (+). The 50% end 
point dilution expressed as TCIDso/ml (50% Tissue Culture Infective Dose) was 
calculated using the Karber formula (Karber, 1931) shown below:
TCID50 = 10a
Where a= L+d[0.5-(x/y)] and:
L = highest dilution resulting in wells with CPE
d = difference between the log dilution steps: is 1  for a 1 0 -fold dilution, 
x = sum of the number of other wells showing no CPE 
y= number of wells per dilution
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The virus titre, equivalent to 10a was represented as (a) TCID5o/50^l of virus, 
which was converted to TCIDso/ml by calculating the log of [10a multiplied by 20].
The multiplicity of infection (MOI) is defined as the number of virus particles 
infecting each cell. This is calculated as:
I^IQI _  TCIDso/ml of virus inoculum x  volume of virus inoculum (ml)
number of infecting cells
2.2.3.2 Detection of CSFV infection with an Immunoperoxidase staining assay
As CSFV is a noncytopathic virus, identifying the presence of virus within cells is 
via detection of CSFV-antigen with an Immunoperoxidase staining test using anti- 
CSFV monoclonal antibodies and 3 ,3 -Diaminobenzidine tetrahydrochloride (DAB) as 
a substrate.
The infected cell cultures were observed under the inverted microscope to assess 
the condition of the cells. The cell layer should be intact and between 70-100%  
confluent. All reagents were prepared (as stated in Table 2-2) before the start of the 
assay.
In a class II microbiological safety cabinet, the culture media was removed and
the culture plates were washed three times with 200pl PBS-tween20 (PBSt). The
culture plates were blotted on an absorbent paper and cells were fixed by adding
lOOpI of 4% paraformaldehyde for GOmins at room temperature. The fixative was
discarded and the cells were washed three times with PBSt. To block endogenous
peroxidises, 50pl of H ^ /M e th a n o ! was added to each well and incubated for lOmins
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at room temperature. The H2O2 solution was then removed and wells were washed 
three times with PBSt. The Fc receptors on the infected cultures were blocked by the 
addition of 50pl 10% v/v goat serum (Life sciences) in PBSt, and plates incubated for 
1 0  mins at room temperature.
Following incubation, the goat serum was discarded and, without washing, cells 
were incubated for GOmins at RT with 50pl of 10pg/ml anti-CSFV monoclonal 
antibody WFI303 in PBSt. Antibody was removed and cells were washed three times 
with PBSt. Wells were blotted on an absorbent paper followed by incubation with 
SOpI of rabbit anti-mouse HRP polyclonal antibody (Dako, UK) in PBSt and incubated 
for 30 mins at room temperature. Cells were washed three times with PBSt and once 
with sterile water and blotted on an absorbent paper. Colour detection was by the 
addition of lOOpI of DAB into each well and incubating for lOmins at room 
temperature. Cells were then washed three times with sterile water. Under the 
inverted light microscope, cells which stained positive for CSFV appeared brown with 
a granular appearance, comparing infected cells wells with mock infected control 
wells aided in distinguishing between specific positive staining and non-specific 
background staining. The 50% end point dilution was expressed as TCIDso/ml (as 
explained in 2.2.3.1).
2.3 Preparation and cloning of Porcine IFNa genes into plasmid vectors
The pcDNA3.1/V5-His TOPO TA expression kit (Life Technologies, UK) was 
employed to clone porcine IFNa genes (PolFNa) (Figure 2-1). This vector was
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supplied linearized by cleavage between base pair 953 and 954 in the TOPO cloning 
site. The overhanging 3' deoxythymidine (T) residue and covalently bound 
Topoisomerase (TOPO) on the vector allowed the direct insertion and efficient 
ligation of the amplified PolFNa genes with the vector as well as the bacterial 
transformation of the recombinant vector into TOPIO E.coli cells (Life Technologies, 
UK).
Following cloning of the PolFNa genes and analysis for the correct transformants 
by restriction enzyme digest (2.3.4.2) and DNA sequencing (2.3.4.3), the plasmid was 
transfected into mammalian cells (2.4.1). The presence of the Human 
cytomegalovirus (CMV) immediate-early promoter in the vector permits the efficient 
high-level expression of the polFNa proteins. The protein was expressed in fusion 
with the V5 epitope and the polyhistidine tag which allows for detection (2.4.3) and 
purification (2.4.2).
PolFNa genes that were not cloned using the above cloning method were 
synthesized commercially (2.3.2).
2.3.1 Generation of plasmids expressing recombinant PolFNa genes
Genomic DNA was extracted from porcine tonsil tissue using the DNeasy blood 
and tissue kit (Qiagen, UK); according to manufacturer's instructions. As IFNa genes 
lack introns, coding regions of the PolFNa subtypes were amplified by PCR using a 
platinum Toq amplification kit (Life technologies, UK), and Ip l of genomic DNA as a 
template in a 50fil reaction volume containing lOOpM of each PolFNa forward and 
reverse primer and 0.5pl platinum Taq polymerase. Reactions were incubated at 
94°C for Im in; this initialization step was followed by a template denaturing step at
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94°C for ISsecs, an amplification gradient temperature range from 50-66°C for 
BOsecs and a final extension of 6 8 °C for BOsecs. PCR products were ligated into a 
pcDNAB.l TOPO TA HIS vector (Figure 2-1) such that they were in-frame with the C- 
terminal 6 x His tag according to the manufacturer's protocol, (Life technologies, UK). 
The ligated mixture was transformed into One Shot TOPIO Chemically Competent 
E.coli (Life technologies, UK) as described in 2.3.3.1. The transformed culture (20- 
50pl) was spread on Luria Bertani broth (LB) agar plates supplemented with 
100pg/ml ampicillin and incubated overnight at 37°C.
To identify constructs containing genes inserted in the right orientation such that 
the encoded ORF was in frame with the C-terminal VS epitope and 6 X-polyhistidine 
tag, isolated plasmids were digested using the A/col enzyme (2.3.4.2). The resulting 
fragment was analysed on a 1% agarose gel (2.3.4.1). Following gel analysis, plasmid 
clones with the expected restriction digest pattern were further analysed by DNA 
sequencing (2.3.4.3).
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PCR
Product
i^ïilïr ,i co V5 epitope
pcDNA3.1/
V5 -His-TOPO
5 5 2 3  bp
Figure 2 -1 A map of the pcDNA3.1/V5-His-TOPO vector used for the expression of polFNa 
recombinant genes. Features on the vector include;
CMV promoter; bases 209-863, T7 promoter/priming site: bases 863-882, Multiple cloning 
site: bases 902-1019, TOPO cloning site: 953-954, V5 epitope: bases 1020-1061, Polyhistidine 
tag: bases 1071-1088, BGH reverse priming site: bases 1111-1128, GBH polyadenylated 
signahbases 1110-1324, f l  origin of replication: bases 1387-1800, SV40 promoter and origin: 
bases 1865-2190, Neomycin resistance gene: bases 2226-3020, SV40 polyadenylation signal: 
bases 3039-3277, pUC origin: bases 3709-4382, Ampicillin resistance gene: bases 4527-5387.
70
Chp 2. Materials and Methods
2.3.2 Generation of plasmids expressing synthetic PolFNa genes
Subtypes that were not isolated after amplification from genomic DNA were 
synthesised commercially by Integrated DNA technologies (IDT, www.idtdna.com) or 
from GeneArt (Life technologies; UK).
2.3.2.1 Isolation of synthesised PolFNa genes supplied by Integrated DNA 
Technologies
PolFNa genes synthesised by IDT were supplied cloned into a pIDTSmart, 
Kanamycin resistance vector (pIDTSMART-KAN) Figure 2-2. This is a small high copy 
number vector, lacking common restriction sites and promoters found in traditional 
vectors and therefore not suitable for the required protein expression.
The lyophylised synthetic pIDTSMART-KAN IFNa DNA's obtained from IDT were 
re-suspended in 20pl; 10 mM Tris, 0.1 mM EDTA buffer (pH 8.0) to reach an 
approximate working concentration of 0.1 pg/pL; this buffer was to solubilise the 
DNA as well as protect it from degrading. A 2pl aliquot of each plasmid DNA was 
chemically transformed into E.coli Top 20 cells, as described in 2.3.3.1. Transformed 
cells were spread on LB agar plates supplemented with 100pg/ml kanamycin and 
incubated overnight at 37°C After incubation, a small scale preparation of 
pIDTSMART-KAN IFNa plasmid DNA was prepared from kanamycin resistant colonies 
as detailed in 2.3.3.2 and an aliquot was stored at -80°C.
The presence of PolFNa inserts in the recombinant plasmids was analysed by 
restriction enzyme digest using 5U of Kpn\ and fcoRV enzymes (2.3.4.2).
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To isolate the PolFNa insert, the restriction digest was repeated but scaled up to 
a total volume of 1 2 0 pl.
DNA fragments in a total volume of 120pl were separated by agarose gel 
electrophoresis on a 1% agarose gel (2.3.4.1) alongside a Ikb  DNA ladder. The 
fragment encoding the PolFNa gene was excised carefully and extracted from the 
agarose gel slice using the QIAquick Gel Extraction Kit (Cat. No. 28704; Qiagen, UK) 
according to the manufacturer's instructions
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Insertion Site 165
M l3 Forward-20
Oral 299
M l3 Reverse-27
Origin of Replication
pIDTSmart Kan 
1962bp
Clai 1379
Clal 564
Kanamycin Resistance
Puvi 893
Sequence surrounding the insertion site:
M l3 F o rw a rd  -2 0
GTAAAACGAC 3GCCAGT:TA IC-AGGCAGC TIG A TTC IA G  CTGATCGTGS ACCGGAAGGT GAGCCAGTGA
C Â Iir iG C rG  CCGGTCAM™ AGATCAG.CG AACTAAGAIC GACGAGCACC IGGCCTICCA CTCGGZCACT
71 G -TG A -IG C A  GTCCAG7TAC GCTGGAG7CT GAGGC:GG:G CTGAAIGAIA IGCGACCGCC GGAGGGIIGG
-CAACGAACGT CAGGICAATG CGACCTCAGA CTCCGAGCAG GAC-TACTA7 ACGCGGGCGG CCICCCAACG
141 GUTGAGACG GGCGACAGA" GE1JE A IC A C IA C IG  GACCGCGAGC IG IG C IG C G A  CCCGTGATCT
CAAACTCIGC CCGCTG-CIA GEHE TAG!GATSAC CTGGCGCTCG ACACGACGCT GGGCACTAGA
20 1  TACGGCAITA TACGTATGAT CG3TCCACGA TCAGCTAGAT TATCTAGTCA GCTTGATGTC ATAGCTGTTT
ATGCCGTAAI ATGCATACTA SCCÂGGTGCT AGTCGATCTA ATAGATCAGT CGAACTACAG TATCGACAAA
M l 3 G .everse - 2 7
25 1  CCTG 
GGAC
Figure 2-2 A map of the pIDTSmart Kanamycin vector in which PolFNa genes synthesised 
by Integrated DNA technologies were supplied.
The vector contains 1962base pair and a summary of the different features are: insertion 
site at bp 165, M13 forward and reverse region, four restriction enzyme site: Dral;299, Clal; 
584, Puvl;893, Clal;1379, and a Kanamycin resistance gene.
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2.3.2.2 Cloning of PolFNa genes into recombinant pcDNA3.1 vector
The pcDNA3.1/V5-His-TOPO expression vector required for cloning of synthetic 
genes from IDT was prepared by digesting a recombinant pcDNA3.1/polFNa plasmid 
(described in 2.3.1) with Kpn\ and EcoRV restriction enzymes (2.3.4.2). The DNA 
fragment was separated on a 1% agarose gel (as described in 2.3.4.1 ). The larger 
DNA fragment; pcDNA3.1/V5-His-TOPO vector was excised as before and gel purified 
using the QIAquick Gel Extraction Kit (Cat. No. 28704; Qiagen, UK).
A ligation reaction was prepared at different molar ratios of insertivector as 
shown in the equation below. The mastermix contained 100-200ng of the vector or 
insert, Ip l of lOx Ligase Buffer (300mM), lU n it of the T4 DNA ligase (Cat. No. M1801;
Promega, UK) and sterile deionised water was added to make up a final total volume 
of lOpl. The reaction was incubated at 16°C overnight, in a conventional table top 
PCR machine.
Concentration of Vector (ng) X Size of insert (kb) w Ratio of insert _ . .. ,  ^ %-----------------------  ------t— ■ y, , , ------------------— - x  — - —  ----- -—  =  Concentration of vector (ng)
Size of vector (kb) ratio of vector
The ligation mixture was transformed into One Shot TOPIO Chemically 
Competent E.coli (Life technologies, UK) as described in 2.3.3.1. The transformed 
culture (20-50pl) was spread on LB agar plates supplemented with 100pg/ml 
ampicillin and incubated overnight at 37°C.
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To identify correct constructs containing genes inserted in the right orientation, 
such that the encoded ORF were in frame with the C-terminal V5 epitope and 6 X- 
polyhistidine tag, isolated plasmids were digested using the enzyme A/col (2.3.4.2) 
and analysed on a 1% agarose gel (2.3.4.1). Following gel analysis, plasmid clones 
with the expected restriction digest pattern were further analysed by DNA 
sequencing (2.3.4.3).
2.3.2.3 Preparation of PolFNa genes supplied by Gene Art
PolFNa genes synthesised by Gene Art were cloned into pcDNA3.1/V5-His B 
(Figure 2-3). This vector is similar to the pcDNA3.1/V5-His-TOPO expression vector 
but with a different reading frame to facilitate the in-frame cloning of the polFNa 
gene.
The synthetic PolFNa genes were flanked by Kpn\ and EcoRV sites and subcloned 
in frame with the C-terminal HIS tag in the vector pcDNA3.1/V5-His B (Figure 2-3).
Supplied lyophilized synthetic genes were re-suspended in lOOpI; lOmM Tris, 
O.lm M EDTA buffer (pH 8.0). A 2pl aliquot of DNA was transformed into One Shot 
TOPIO Chemically Competent E.coli (Life technologies, UK) as described in 2.3.3.1. 
Large scale plasmid preparations (2.3.3.2) were prepared from selected colonies and 
the correct plasmid construct was confirmed via sequencing (2 .3 .4 .3 ).
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T7 promoter, priming site //md III Kim II------------------------------------ 1 I 1
6 6 1  ATTAATACGA CTCAC7ATAG GGAGACCCAA GCTGGCTAGT TA ACC 7T G  GTA C v r  '7
S e r  L e u  V a l  P ro  S e r
/AïwH I /kfX I* AfoR I Ar»R V  A.crX I*
I   I I I I
9 1 8  TC   • fA ” CC AGC ACA G7G
■ A . r  j . t.e  . w  (-1 : G /.-  in  y G", y : *■ ; G in  l e  S e r  S e r  T h r  V a l
Sot I Xho 1 Hut?. II SJu 1   VS epitope_______
9 6 9  GÇG GCC GOT CCA GE T  CAC C C A jTTC  GAA GGT AAG CCT ATC CCT AAC C C T CTC
A l a  A la  A la  A r g  G l y  H is  P ro  P h e  G lu  G l y  L y s  P ro  l i e  P ro  A sr. P ro  Leu
   ^ 1 Poîyhistidinc lag
1020 CTC GGT CTC GAT T C I  ACC CGT ACC GGT CAT C A T CAC CAT CAC C A T TGA GTT
L e u  G l y  l e u  A sp  S e r  T h r  A r g  T h r  G ly  H is  H i s  H is  H is  H is  H is  * 4 *
Pme I BOH Reverse priming site
1071 7AAACCCGC7 GATCAGCCTC GACTGTGCCT TCTAGTTGCC ÂGCCATCTGT
V5 epitope Cn 6xHis
-  T -  —  >— — x — f r , ^ —
C3 Q ‘i s l l i s ^ o . _____iCiticoaQUjUjcQ^xx^toi f  40 Q f A J
pcDNAS.I/ 
V5 -H isB
5.5 kb
Figure 2-3 Vector map of pcDNA3.1/V5-His B expression vector used for expression of gene 
synthesised by GENE ART technologies.
Above is the polylinker map of pcDNAB.l V5-His B vector. PolFNa gene is inserted into the 
highlighted region.
Below is a map of the pcDNA3.1/V5-His-B vector (5506 bases) with a summary of the 
different features on the vector. CMV promoter: bases 209-863, T7 promoter/priming site: 
bases 863-882, Multiple cloning site: bases 902-999, V5 epitope: bases 1000-1041, 
Polyhistidine (6xHis) tag: bases 1051-1068, BGH reverse priming site: bases 1091-1108, BGH 
polyadenylation signal: bases 1090-1304, f l  origin of replication: bases 1357-1780, SV40 
promoter and origin: bases 1845-2169, Neomycin resistance gene: bases 2205-2999, SV40 
polyadenylation signal: bases 3018-3256, pUC origin: bases 3688-4361 (C), Ampicillin 
resistance gene: bases 4506-5366 (C); (C- complementary strand). There is a unique Soc II 
site between the Apa I site and the Sfu I site.
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2.3.3 Cloning and isolation of plasmids in E.coli
2.3.3.1 Chemical transformation
A 2pi aliquot of plasmid DNA was added to 50 pi of One shot Top 10 E.colf cells 
(Life technologies, UK) and incubated on ice for 30 minutes. The cells were then heat 
shocked for exactly 30secs at 42°C in a water bath and then incubated on ice for 
2mins after which 250pl of pre-warmed super optimal broth with catabolite 
repression (S.O.C) medium were added and the cells incubated at 37°C for 1 hour at 
225rpm in a shaking incubator. Finally the transformed culture (20-50pl) was spread 
on LB agar plates supplemented with 50-100pg/ml of either ampicillin or kanamycin 
antibiotic and incubated overnight at 37°C.
2.3.3.2 Isolation of plasmid DNA
For the bacterial culture of colonies generated following a chemical 
transformation, antibiotic resistant colonies were selected and added to 3ml LB 
medium supplemented with 50-100pg/ml of either ampicillin or kanamycin and 
incubated overnight at 37°C 225rpm in a shaking incubator.
Subsequently, plasmids were isolated from the bacterial culture using a Qiagen 
mini-prep plasmid purification kit (Cat. No. 27405; Qiagen, UK) according to the 
manufacturer's instructions.
Following the identification of the colony of choice, selected colonies were 
streaked on to LB agar with 50-100pg/ml of the appropriate antibiotic and incubated 
overnight at 37°C. A single colony was isolated and inoculated into l-2m l of LB broth 
supplemented with 50-100pg/ml of the appropriate antibiotic. The culture was
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incubated at 37°C overnight. In a sterile cryovial, 850pil of the culture was mixed with 
150|il of sterile glycerol and stored at -80°C.
For the large scale preparation of plasmid DNA, lOpil of the bacteria glycerol 
stock was added to 100ml LB broth supplemented with lOOpig/ml of the appropriate 
antibiotic. The bacterial culture was incubated overnight at 37°C 225rpm in a shaking 
incubator. The plasmid was isolated from the bacterial culture using the QIAGEN 
plasmid midi-prep isolation kit (Qiagen,UK) according to the manufacturer's 
instructions and purified DNA obtained from the reaction was analysed by restriction 
enzyme analysis (2.3.4.2).
2.3.4 Plasmid DNA analysis
2.3.4.1 Agarose gel electrophoresis
DNA was analysed on 1% Agarose gels prepared by dissolving l.Og Agar in 100ml 
lx  Tris-borate-EDTA buffer (89 mM Tris-borate and 2mM EDTA, pH 8.3) and adding 
10,000X SYBR Safe DNA Gel stain (Life technologies, UK) to a dilution of 1/20,000. 
The mixture was melted by boiling.
Samples for analysis were mixed with sample buffer as described in appendix 1 
and loaded in appropriate wells alongside a Ikb  DNA ladder (Promega, UK) to 
determine the size of the separated fragments. The gel was electrophoresed in lx  
TBE buffer at 126volts for Ihour and the DNA was visualised using a UV 
transilluminator.
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2.3.4.2 Restriction enzyme digest of DNA
Restriction enzyme digest of DNA samples was performed in a 20^1 master mix 
containing lug  of DNA sample, 2\x\ of lOx restriction enzyme buffer, 0.2pl of Bovine 
serum albumin (BSA) to a final concentration of O.lmg/ml; this helped improve the 
efficiency of the digest and a total of 10U of restriction enzyme, the mixture was 
made up to 20|il with sterile deionized water and incubated for 2 hour at 37°C. 
Digested DNA were analysed on a 1% agarose gel (2.3.4.1).
2.3.4.3 DNA sequencing
The nucleotide sequences of recombinant plasmids were determined using ABI 
prism Big-Dye terminator 3.1 cycle sequencing ready reaction kits (Applied 
biosystems, UK) in a lOul reaction containing 1.6pmol/fa,l of T7 forward 
(TA ATACG ACTCACTATAG G G ) or BGH reverse (TAGAAGGCACAGTCGAGG) sequence 
primer (Life technologies, UK), with the appropriate concentration of DNA based on 
the DNA template size and reaction buffer. The sequencing reaction was cycled at 
96°C for Im in, followed by 25 cycles of 96°C for lOsecs, 50°C for 5secs and 60°C for 
4min. The sequencing products were precipitated, purified and analysed on an ABI 
Prism TM310 genetic analyser. Sequence data were assembled using the SeqMan 
program on the DNASTAR, Lasergene software package. The assembled sequences 
were analysed with BLASTP and TBLASTN programs (Altschul et al, 1990), using the 
National Center for Biotechnology Information (NCBI) website tools 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and compared with the Sus Scrofa database 
to identify which PolFNa subtype was cloned.
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2.4 Expression of rPolFNot protein in mammalian cells
2.4.1 Transient expression of PolFNa protein
CHO-K1 cells were transfected with PolFNa plasmids in 6 -well plates using a DNA 
transfection reagent lipofectamine 2000 (Life technologies, UK) as directed by the 
manufacturer. A day before transfection, CHO-K1 Cell monolayers were trypsinised 
and added to wells of a 6 -well plate at a density of 6.25x10s cells/well in 2ml of 
complete growth medium. On the day of transfection, the growth medium was 
removed and replaced with D-MEM without PCS. At the time of transfection, the 
culture medium was removed and cells were incubated for 4hours at 37°C in 5% C02 
with SOOpI of Opti-MEM* (a reduced serum medium) containing 4pg of plasmid DNA 
and lOpil of lipofectamine 2000 reagent. After 4hours incubation, the transfection 
mixture was replaced with 2ml of D-MEM growth media. Supernatant containing the 
expressed IFNa protein was collected after 24hours incubation at 37°C and 5% C02 
and stored at -20°C.
2.4.2 Purification of expressed rPolFNa protein
Expressed rPolFNa proteins were concentrated by centrifugation through a V- 
15ml 10k centricon column (Millipore, UK) at 4000g for 30mins at 4°C. These 
columns allowed the concentration of proteins above lOkDa. The concentrated 
protein was diluted 2 fold in 2x HIS bind buffer (lOOmM Sodium-Phosphate, pH 8.0, 
600mM NaCl, 0.02% Tween-20) and purified using the DYNA-bead HIS-tagged protein
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isolation kit (Life technologies). Purification was performed according to the 
manufacturer's instructions. His-tagged protein was eluted from the cobalt magnetic 
beads in 100^1 His elution buffer (300mM Imidazole, 50mM Na-Phosphate pH 8.0, 
300mM NaCl, 0.01% Tween-20).
To reduce the concentration of imidazole and salts in the purified protein 
preparations, eluted protein was diluted five fold in PBS and the buffer was then 
exchanged in PBS using a 0.5ml 10k centricon column. Buffer exchange was 
performed according to manufacturer's instructions by centrifugation at 1400g for 
lSmins at 4°C and each 500^1 aliquot of protein was eluted in 50^1 PBS at 1000g for 
2 mins.
To prevent loss of protein activity, proteins were aliquoted in 2.5^1 aliquots and 
stored at -20°C.
2.4.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
western blotting
For the analysis of expressed proteins, 50pl aliquots of purified recombinant 
proteins were resuspended in 25pl of 3X Reducing Blue Loading Buffer (Biolabs, UK). 
The 3x Reducing buffer was prepared by adding Ip l 1.25M dithiothreitol (Reducing 
Agent) to 10|il 3X Blue Loading Buffer (New England Biolabs, UK). Protein samples 
were heated at 95°C for 5mins and separated on a 12% SDS-PAGE gel alongside a 
molecular weight marker (Life technologies, UK). After electrophoresis, the protein 
was blotted onto a nitrocellulose membrane (Amersham, UK). Membranes were 
blocked in PBS-buffered saline 0.05% (v/v) Tween 20 (PBS-T) containing 5% (w/v)
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milk powder (blocking buffer) and then incubated for Ih r  with a mouse anti-His (C- 
term) antibody ( Life technologies, UK) diluted 1:5000 (0.2pl/ml) in blocking buffer. 
The membranes were washed with PBS-T and incubated for Ih r  with a rat anti­
mouse IgG conjugated with horse radish peroxidase (Promega, UK) diluted 1/5000 in 
blocking buffer. After further washing in PBS-T, the peroxidase activity was detected 
using a chemiluminescent substrate (ECL Plus detecting reagent, GE health care, UK) 
followed by exposure to X-ray film (Kodak, UK). The X-ray film was then developed 
on a kodak x-ray film developing machine.
2.4.4 Quantification of PolFNa by Enzyme-linked immunosorbent assay
Expressed PolFNa was quantified by enzyme-linked immunosorbent assay 
(ELISA). A PolFNa ELISA was designed and optimised using two different mouse anti­
pig monoclonal anti-IFNa antibodies (mAb) purchased from PBL, UK; clones F17 and 
k9. The k9 mAb was biotinylated using the EZ-Link Sulfo-NHS-Biotinylation Kit 
(Thermoscientific, UK) performed according to the manufacturer's instructions.
Luminunc® maxisorp protein ELISA plates (Nunc, Fisher Scientific, UK) were 
coated with 100 pl/well F17 anti-IFNa mAb at lpg /m l in carbonate/bicarbonate 
buffer 0.1 M, pH 9.6 and incubated overnight at room temperature. Plates were 
washed twice with PBS supplemented with 0.05% Tween 20 (wash buffer). Plates 
were blocked with 300p!/well PBS Calcium (Ca) and Magnesium (M g ), 0.05% Tween, 
4% BSA; pH 7.2 (blocking Buffer) and incubated for 1 hr at room temperature.
Blocking buffer was removed and 50pl/well commercial PolFNal standards (PBL, 
UK); starting at 6 ng/ml and serially diluted 1/2 in 1% BSA (w/v) in PBS (reagent
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buffer) to a final concentration of 0.023ng/ml, alongside 50[il/well of rPolFNa 
protein diluted in reagent buffer was added. Plates were incubated for 1 hr at room 
temperature and then washed five times in washing buffer. Subsequently 100^il/well 
biotinylated mouse anti-IFNa K9 mab diluted to 0.15ng/ml in reagent buffer was 
added to all the wells and plates incubated for 1 hr at 26°C. Wells were then washed 
three times with Wash Buffer.
Streptavidin conjugated with horse radish peroxidise (MRP) (GE Healthcare, UK) 
diluted 1 / 1 0 0 0  in blocking buffer was added (1 0 0 |il/well) and the plate was 
incubated for 45mins at 26°C. Wells were washed five times with wash buffer before 
adding 100nl/well of 3,3',5,5'-Tetramethylbenzidine (TMB) substrate. Plates were 
incubated for lSmins in the dark at room temperature and the reaction was stopped 
by adding 100pil/well of sulphuric acid (2N) and the absorbance was read at 450 nm 
on a Perkin Elmer plate reader. Relative antibody titre values were extrapolated from 
the linear portion of the PolFNal standard curve on each plate.
2.4.5 Biological reporter gene assay for the quantification of Porcine type IIFN
To confirm the induction of biologically active PolFNa following CSFV infection, a 
commercial type I IFN sandwich chloramphenicol acetyltransferase (CAT) ELISA 
(Roche, UK) was used.
The ELISA is used for the quantitative measurement of CAT expression in MDBK- 
t2 cells. As described earlier, these cells (2.1.4) were transfected with a human MxA 
promoter linked to a CAT reporter gene. Upon induction by IFN, this promoter drives 
the expression of CAT protein which is then measured by the CAT ELISA.
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A 50|il aliquot of MDBK-t2 cells maintained under blasticidin selection were 
seeded into 96-well microtitre plates at a density of 2 .5 x l(f  cells/well while a three­
fold serial dilution of the commercial recombinant polFNa (PBL, UK) in E-MEM, 
starting at 800U/ml to l . lU /m l served as the standard. A 50^1 aliquot of the samples 
to be tested and the prepared polFNa standard were then added to cells in 
designated wells, cultures were incubated for 24hours at 37°C 5% C02.
Lysates were prepared from the stimulated MDBK-t2 cultures as described by the 
manufacturer and the amount of CAT expression induced by the samples was 
quantified using an enhanced substrate. Briefly, the extracted cells containing the 
CAT enzyme were added to polyclonal antibody specific for CAT (anti-CAT) precoated 
wells on a microtitre plate. Following binding, a digoxigenin-labeled antibody specific 
for CAT (anti-CAT-DIG) which binds to the CAT was added. A third peroxidise 
conjugated polyclonal antibody specific for digoxigenin was added and lastly the 
peroxidase substrate. A yellow colour was observed in CAT positive wells as a result 
of the catalytic reaction produced upon cleavage of the substrate by the peroxidase 
enzyme. The absorbance, which is directly correlated to the level of CAT expressed in 
the cell extract, was read at 405nm using a FLUOstart OPTIMA microplate reader 
(BMG Labtech, Aylesbury, UK).
2.5 Measuring the biological activity and antiviral effect of purified rPolFNa 
protein on mammalian cells
Antiviral assays are the most common and widely accepted method of 
assessing/quantifing the potency of IFN proteins, and according to the WHO the 
results should be expressed as international units (IU) (Meager, 2002). Although the
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biological activity of recombinant IFNs can be assessed using a wide range of cell 
PK15 were our preferred cell type as I was quantifying protein from a similar specie 
type. VSV was also chosen as it has significant sensitivity to IFNa (Derbyshire, 1989; 
Marcus & Sekellick, 1978).
2.5.1 Assessing the cytopathic effect induced by VSV in PK15 cells
To quantify the inhibitory activity of PolFNa on VSV replication in PK15 cells, it 
was important to determine the amount of virus required to give the highest CPE; so 
as to achieve nearly complete killing of unprotected cells following IFN treatment.
Before viral infection lOOpI aliquots of PK15 cells, seeded at a density of 2.0 x 
105cells/ml, were added into wells on a 96-well plate. Cells were cultured in 
EMEM/FBS and incubated for 24hrs at 37°C 5% C02.
VSV at a TCIDso/ml of 108'88 was used in preparing a 10-fold dilution series of 
virus. Fifty microlitres of each dilution was then added to each column on the plate in 
duplicates, while 50pl of culture media was added to the no-virus control wells. Cells 
were incubated for a further 24hrs at 37°C 5% C02 and the amount of viable cells 
was determined by staining cells with 50pl crystal violet (CV) staining solution 
(Sigma-Aldrich, UK) diluted to 0.05% v/v in 20% ethanol, for lOmins at room 
temperature.
The cell monolayer was carefully washed twice with PBS and fixed with 50pl/well 
4% paraformaldehyde for 30mins at room temp. Fixed/stained plates were washed 
with water three times and dried on a bench. The CV stain was eluted by the addition 
of 1 2 0 |il methanol and 1 0 0 (il of eluted stain was transferred into a new tissue
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culture plate. The dye eluted from viable cells was quantified at 540nm on the Perkin 
Elmer plate reader, this resultant optical density is directly correlated to the 
biological activity of each sample. Using the known activity of the PolFNal standard 
and the equivalent O.D value, a standard curve was created and the activity of the 
unknown samples was extrapolated from the standard curve.
2.5.2 Measuring the anti-VSV activity induced by PolFNa subtypes
PK15 cells at a density of 2x l0 5cells/ml were plated in 96 well tissue culture 
plates with modified EMEM/FCS, each well contained lOOpI of cell suspension. 
50pl/well of the polFNal standard (200IU-7.78IU) diluted in EMEM/FCS was added 
to the first four columns on the 96-well plate. A 50pl aliquot of expressed polFNa 
diluted in EMEM/FCS was added alongside the PolFNa standards. Cells were 
incubated overnight for 24hrs at 37°C 5% C02.
A lOOpI aliquot of VSV at a predetermined multiplicity of infection (MOI) 
obtained in 2.5.1 was added to each column on the plate. Cells were then incubated 
for a further 24hrs at 37°C 5% C02 and stained using crystal violet dye. The dye 
eluted from viable cells was quantified at 540nm on the Perkin Elmer plate reader, 
this resultant optical density is directly correlated to the biological activity of each 
sample. Using the known activity of the PolFNal standard and the equivalent O.D 
value, a standard curve was created and the activity of the unknown samples was 
extrapolated from the standard curve.
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2.6 Assessing the antiviral effect of purified rPolFNa protein in primary 
porcine cells
Primary cells were obtained from blood taken from White/Landrace cross-breed 
pigs obtained from a local commercial supplier. Animals were kept on straw bedding 
in a covered housing in small groups of 3-4 pigs. These experimental pigs were 
clinically healthy, free of antibodies against pestiviruses and generally around 2 years 
of age. All procedures were conducted under the UK Home Office license PPL 
70/7057 and in accordance with the UK Animals (Scientific Procedures) Act 1986.
2.6.1 Isolation of Porcine monocytes
PBMC's were isolated from heparinised venous pig blood (30ml) using Ficoll 
(1.077g/ml Autogen Bioclear, UK) density gradient centrifugation. Briefly 30ml blood 
were layered onto 20ml Ficoll and centrifuged at 1455xg with the brakes off for 
30mins at room temperature. The visible zbuffy layer7 material containing PBMC was 
aspirated and contaminating erythrocytes were lysed by the addition of lOmls of 
Pharmlyse buffer (BD Biosciences, UK) and incubation for lOmins at room 
temperature (RT). Cells were then washed three times in phosphate buffered 
solution supplemented with 2%FCS v/v (Sigma-Aldrich, UK) (PBS/FCS) by 
centrifugation at 931xg for 5mins at RT. Subsequently cells were resuspended and 
pooled in PBS/FCS.
PBMC were counted by analysing 25pl of cell suspension on a volumetric flow  
cytometer (MACSQuant, Miltenyi Biotec, UK). PBMC were gated according to typical 
forward and side scatter characteristics. Magnetic microBeads conjugated to
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monoclonal anti-human CD14 antibody (Miltenyi Biotec, UK) were added to PBMC at 
a ratio of 20|il of beads to 107 cells and incubated for 30 minutes at 4°C.
The cells were washed twice in PBS/2%FBS and re-suspended in 500^1 
PBS/2%FBS; 5mM EDTA (Sigma) (MACs buffer). Monocytes were separated into the 
CD14 expressing (CD14+) fraction using a MACS LS column (Miltenyi Biotec, UK) 
according to manufacturer's instructions. The magnetically bound CD14+ cells were 
eluted by flushing the column with 6 mls RPMI supplemented with 10%FBS 
(RPMI/FBS). Monocyte cell density was determined by analysing 50pl of cell 
suspension using a MACSQuant flow cyto meter as above.
2.6.2 Infection of porcine monocytes with different CSFV strains
Two CSFV strains; Alfort 187(Ruggli et al, 1996) and Brescia were used to infect 
porcine monocytes to identify which of the two CSFV strains would produce the 
highest amount of viral E2 glycoprotein protein and which would result in the highest 
percentage of CSFV infected monocyte cells.
Monocytes were added to wells in a 24-well plate at a density of Ix lO 6 
monocytes/ml in a total of 2ml/well and cultured for 24hrs in RPMI/10% FBS. Cells 
were then infected with the two virus strains at an MOI of 7 for 24hrs at 37°C in a 
humidified 5% C02 incubator.
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2.6.3 Interferon treatment of monocyte cells
To investigate the effect of cytokine treatment on porcine primary cells, assays 
involving the pre- and post -treatment of porcine monocytes with commercially 
obtained PolFNa (20U) (PBL interferon source, USA) were performed.
2.6.3.1 Interferon pre-treatment assay on monocytes
To investigate the effects of cytokine pre-treatment on virus infection, 24-well 
plates containing 2ml of Ix lO 6 monocytes/ml were either untreated or treated with 
commercially available PolFNa (20U) and incubated at 37°C 5% C02 for 24hrs. The 
treated monocytes were then infected with CSFV Alfort 187 at an MOI of 7, 
incubated at 37°C 5% C02 for 4hrs, after which the virus supernatant was replaced 
with fresh RPMI.
After a further 24hours in culture, the amount of CSFV infected cells was 
determined as described in 2.6.4. The culture supernatant was harvested and the 
amount of viral RNA was assessed by quantitative RT-PCR.
2.6.3.2 Interferon post-treatment assay on monocytes
For the post-treatment assay, monocytes were seeded into 24-well plates as 
before and infected with CSFV Alfort 187 at an MOI of 7. Cells were incubated at 
37°C 5% C02 for 4hours. After the 4hr incubation, supernatant was removed and 
cells were washed with growth media to remove excess virus. Cells were then 
treated with the commercial PolFNa (20U) (PBL,USA) and incubated at 37°C 5% C02 
for 24hours
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2.6.4 Quantification of CSFV infected cells
The amount of CSFV infected cells were either accessed via staining for the viral 
E2 protein expressed intracellulary or by quantifying the amount of CSF viral-RNA 
released into cell supernatant via polymerase chain reaction (PCR).
2.6.4.1 Cell viability and CSFV viral E2 envelop protein staining
To quantify the level of expression of viral E2 glycoprotein, monocytes were 
harvested and cell viability was evaluated with the live/dead fixable violet dead cell 
stains kits (Life Technologies, UK) with adjustments to the manufacturer's protocol. 
The principle of the live/dead assay is based on the reaction of a fluorescent reactive 
dye with cellular amines. The dye can penetrate the compromised membranes of 
dead or dying cells and react with free amines in the interior and on the cell surface, 
resulting in intense fluorescent staining. For viable cells, only the cell surface amines 
react with the dye resulting in very weak staining and usually a 50-fold difference in 
intensity between the live and dead cell populations. This difference is preserved 
following fixation of cells. The violet dyes are detected only in the violet (405 nm 
emission) channels of the flow cyto meter.
Fluorescent reactive dyes were reconstituted with 50 pi of DMSO. Cells were 
washed twice with 200pl PBS by centrifugation at 500 x g for 2 minutes and 0.25 pi of 
the reconstituted fluorescent reactive dye was added to each cell suspension, mixed 
well and incubated at 4°C for 30 minutes, in the dark. Cells were washed twice with 
200 pi of cold PBS and permabilised by treatment with the Cytofix/Cytoperm kit (BD 
Bioscience, UK), according to the manufacturer's instructions. Cells were stained
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intracytoplasmically with a mouse anti-CSFV monoclonal antibody (mAb) (WH303; 
(Edwards, 2000)) specific for the CSFV glycoprotein E2, followed by an 
allophycocyanin (ARC) conjugated anti-mouse IgGl secondary antibody (BD 
Biosciences, UK).
The percentage of infected cells was determined by gating on the cell population 
that stained positive with the E2 antibody. The amount of expressed intracellular 
CSFV E2 protein was then quantified on the flow cyto meter by assessing the mean 
fluorescence intensity (MFI) of the E2 positively stained infected cells.
For all flow cytometry analysis, two methods were employed;
(i) For analysis, the target cell population; monocytes was gated on the side 
scatter area (SSC-A) versus forward side scatter area (FSC-A) plot and the 
debris was excluded from this population. Using viability dyes, live cells were 
distinguished from the dead cell population. Gates were drawn around the 
live cell population acquired on the logarithmic scale of the violet live-dead 
fluorescent dye signal versus the linear scale of the forward side scatter area 
(FSC-A). This live monocyte population of interest was used for further 
analysis of all fluorescent antibodies on a logarithmic scale. This population of 
interest was used to analyse the percentage of E2 positively stained cells
(ii) While in other cases, monocytes were first gated on the side scatter area 
(SSC-A) versus forward scatter area (FSC-A) plot to remove duplex cells 
followed by the strategy described in (i) above.
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2.6.4.2 CSFV Quantitative Polymerase Chain Reaction
Viral RNA was extracted from 140jil of cell culture supernatant using the QIAamp 
Viral RNA Mini Kit (Qiagen, UK) according to manufacturer's instructions and the viral 
copy number was quantified by Real Time RT PCR using Superscript III (SSIII) 
platinum Taq (Life Technologies, UK). The 25^1 PCR reaction mix contained 12.5jjJ 
super script 2x reaction buffer, lun it of SSIII Taq polymerase enzyme, a final 
concentration of 5mM MgS04, 0.2ml RNAsin, 50nM ROX, 600nM of CSFV primers: 
CSF100F and CSF192-R, 200nM of CSFV FAM probe (Hoffmann et al, 2005), which 
was modified with BHQ1 quencher, and 3pJ of RNA. The PCR was run on a Stratagene 
Mx3005P machine with the following thermal profile; reverse transcription at 50°C 
for 15min, initial dénaturation at 95°C for 2min, followed by 45 cycles of 
dénaturation at 95°C for 15secs and annealing at 59°C for 30secs, and extension at 
68°C for BOsecs.
A ten-fold serial dilution of RNA standard included in each PCR was used in 
determining the viral genome copy number. This RNA standard was made from an in 
vitro transcribed plasmid; PCRXLV324-6 which contains the 5'UTR region of CSFV 
strain Alfort 187 flanked by V324 and V326 primers (Vilcek et al, 1994).
2.6.5 Viral RNA extractions from pig blood
Extractions of viral RNA from porcine samples were performed using the QIAmp 
Viral RNA Mini Kit (Qiagen, UK) which combined the selective binding properties of a 
silica gel-based membrane with the microspin speed. The membrane ensured high 
recovery of pure, intact RNA. This involved thoroughly mixing 140pl of sample with
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lysis buffer containing carrier RNA. The lysis buffer, containing guanidine 
thiocyanate, inactivated ribonucleases (RNases; catalyzes the degradation of RNA 
into smaller components) and ensured isolation of intact viral RNA, whereas carrier 
RNA increased the viral RNA recovery by improved binding of viral RNA to the 
membrane and limited degradation of the RNA by RNase activity. The mixture was 
incubated at room temperature for lOmins, followed by the addition of 560|il 
ethanol. The mixture was then applied to the column and centrifuged at 6000g for 
Im in. The ethanol adjusted buffering conditions provided optimum binding 
conditions of the RNA to the silica gel-based membrane in the column. The 
membrane bound RNA was then washed in two steps using two different buffers to 
remove any contaminants. The first washing step was centrifuged at 6000g for Im in  
and the second at 20,000g for 3min. RNA was eluted in 60pil of RNase-free water by 
centrifugation at 6000g for Im in. Elutes were stored immediately at -80°C.
2.7 Identifying the ex vivo expression levels of different polFNa subtypes 
before and after CSFV infection
To understand the antiviral potency of IFNas against CSFV it is important to 
analyze the individual antiviral activity within the different subtypes, as well as which 
and when these subtypes may be induced during infection. With this information, 
the identity of the subtype/(s) that could be considered for therapeutic protection 
against CSFV would be deciphered.
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2.7.1 Experimental animals
Three, ten weeks old White/Landrace cross male pigs were intranasal infected 
with the highly virulent CSFV strain Brescia at a viral dose of 106TCID5o, all pigs were 
housed together on straw bedding in containment.
To reduce animal suffering, all pigs were monitored regularly and clinical score 
sheets were carefully completed. The animals in these experiments did not 
experience any clinical signs necessitating euthanasia. The signs are based on a 
predetermined humane endpoint, which were either a temperature above 41°C or 
total clinical score above 15 and more than 2 individual clinical scores reaching a 
value of 3. Animals were euthanized on preset days by intramuscular administration 
of Ketamine/Rompun sedative followed by intravenous administration of 20% 
sodium pentobarbitone solution.
All procedures were conducted under the UK Home Office license PPL 70/7403  
and in accordance with the UK Animals (Scientific Procedures) Act 1986.
2.7.2 Sample Collection from experimental animals
Blood samples were collected into serum collection vacutainers from three pigs 
at different time point; 3days prior to challenge (dpc) and at different days post 
infection (dpi); 2, 4, 7, 9 ,1 1 ,1 4 . After collection, blood samples were allowed to clot 
before being centrifuged at 1455g for lOmins; the serum supernatant was collected 
for IFN bioassay (2.4.5).Heparin blood was collected at different times (dpi) for 
isolation of PBMC cells (2.6.1) while EDTA blood was also collected for viral RNA 
extraction (2.6.5).
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2.7.3 Total RNA extraction from PBMC cells
RNA extraction from cells was performed using the RNeasy Plus Mini Kit (Qiagen, 
West Sussex, UK) which removed any genomic DNA contamination using a gDNA 
eliminator spin column. An aliquot containing 107PBMC was first disrupted by the 
addition of the 350^1 of lysis buffer per 5 x 106 cells. The lysis buffer contained 
guanidine-isothiocyanate to which lOpil of 2-mercaptoethanol (2-ME) (Sigma- 
Aldrich,UK) was added for every 1ml of buffer. 2-ME was used to eliminate 
ribonucleases released during cell lysis. The homogenized lysate was added to the 
gDNA eliminator column and centrifuged for BOsecs at 8000g. The column, in 
combination with the high-salt buffer, allowed the efficient removal of genomic DNA. 
To the flow through, 350pl of 70% ethanol (which provides appropriate binding 
conditions for RNA) was added, mixed by pipetting and transferred to the spin 
column. Centrifugation was performed at 8000g for ISsecs which allowed the 
binding of total RNA to the membrane.
The membrane bound RNA was then washed in three steps using two different 
buffers to remove any contaminants. The first and second washing steps were 
centrifuged at 8000g for ISsecs and the third at 8000g for 2mins. RNA was eluted in 
40pl of RNase-free water by centrifugation at 8000g for Im in. Elutes were quantified 
and stored at -80°C. This procedure selectively excluded RNA molecules smaller than 
200 nucleotides, which include 5.8S or 5S rRNA (ribosomal RNA) and tRNA (transfer 
RNA).
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2.7.3.1 Testing of RNA quality and quantity
RNA was quantified using the Nanodrop 2000 Spectrophotometer (Thermo 
Scientific, UK). RNA quality was assessed using the RNA Nano Labchip kit with a 
detection range of 5-500ng/nl and the Agilent 2100 Bioanalyzer (Agilent 
TechnologiesUSA).
The chip contained wells for the gel, samples and an external standard or ladder. 
The wells are interconnected by micro-channels which were filled with a gel (sieving 
polymer) and fluorescence dye. The gel was prepared by pipetting 550^1 of the gel 
matrix into the spin column provided and centrifuged at 1500g for 10 minutes at 
room temperature. To 65|il of the filtered gel, 1 1^ of dye concentrate was added and 
centrifuged at 13,000g for lOmins at room temperature. The chip was placed on the 
chip priming station, to which 9^1 of gel-dye mix was added to an already assigned 
well. The plunger was positioned at the 1ml mark, the chip priming station closed 
and the plunger pressed until held by the chip. After 30secs the chip was released 
and the plunger slowly pulled back to the 1ml position. The chip priming station was 
opened and 9pil of gel-dye mix added to the remaining gel wells. The marker was 
added to all sample wells and the ladder well at 5pil each. This marker was used to 
compensate for drift effects that may occur during the course of a chip run. To the 
well assigned for the ladder, Ipil of heat denatured RNA ladder was added along with 
l\x\ of the samples in each of the sample wells. Once the wells and channels were 
filled, the chip became an integrated electrical circuit. The chip was placed in the 
adapter of the IKA vortexer (IKA GmbH and Company, Germany) for 1 minute and 
then run in the Agilent 2100 bioanalyser (Agilent Technologies, USA). The cartridge
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had 16-pin electrodes, each connected to an individual power supply, which fitted 
into the wells of the chip.
The charged RNA was electrophoretically driven by a voltage gradient. The 
constant mass to charge ratio and the presence of a sieving polymer matrix 
separated the molecules by size, where the smaller fragments migrated faster than 
the larger ones. The Dye molecules intercalated into RNA strands and these 
complexes were detected by a laser-induced fluorescence at different speeds. The 
RNA 6000 Nano ladder (with a total concentration of 150ng/|il) loaded on each chip 
was used as a reference for data analysis. The ladder contained six RNA fragments 
ranging in size from 0.2 to 6 kb (0.2kb, O.Skb, l.Okb, 2.0kb, 4.0Kb and 6.0Kb).
The concentration of unknown samples and the identification of rRNA peaks 
were determined by the software which automatically compared the unknown 
samples to the ladder fragments. All samples were graded with RIN (RNA Integrity 
Number) values which indicated the quality of the RNA. RNA with RIN values in the 
range of 8-10 were used in further assays.
2.7.4 Complementary DNA (cDNA) production
The extracted RNA was reverse transcribed into complementary DNA (cDNA) 
using the ROCHE transcriptor high fidelity cDNA synthesis kit (Roche, UK).
Transcription was performed according to the manufacturer's instructions.
Briefly about 200ng of total extracted RNA was added to 2.5pM of anchored- 
oligo(dT)i8 primer; for transcription of the poly(A)+ RNA in the whole RNA pool. The 
template and primer master mix was made up to 13pl with PCR grade water and the
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mixture was heated for lOmins at 65°C in a block cycler; to denature the RNA 
secondary structure with a heated lid so as to minimize evaporation. To the 
denatured mix, a master mix containing 4^1 of the high fidelity reverse transcriptase 
reaction buffer to a final concentration of 8mM MgCI2, 20U of RNase inhibitor, 
deoxynucleotide mix at a final concentration of Im M  each, and 2.5U of transcriptor 
high fidelity reverse transcriptase were added. The total mixture was then incubated 
on a heated block at 55°C for 30mins after which the reverse transcriptase enzyme 
was inactivated at 95°C for 2mins. Transcribed cDNA samples were store at -80°C. 
Quantification of the cDNA was performed using the Nanodrop 2000 
Spectrophotometer (Thermo Scientific, Surrey, UK) and stored at -20°C.
2.7.5 PolFNa differential polymerase chain reaction primer design
To differentiate between the different PolFNa subtypes expressed within a 
sample, subtype specific primers to the different PolFNa subtypes were designed.
Using the confirmed plasmid DNA of each IFNa subtype as a positive control 
template, the primers and PCR conditions were optimized and validated.
2.7.5.1 Optimising the magnesium concentration and annealing temperature of the 
PolFNa subtype specific PCR reaction
In order to obtain a stringent PCR condition, the amount of magnesium sulphate 
(MgS04) in the reaction was first optimised.
A SOpI sample of master mix containing lOxPCR mix, 0.2mM of each dNTP, 1U of 
Taq DNA polymerase, 0.2pM of each forward and reverse primer, and varying
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concentration of MgS04 was prepared. For the PCR reaction, a no template control 
was included as a negative control and the plasmid DNA of each polFNa subtype was 
used as a template for the positive control.
PCR was performed following initial denaturing at 95°C for 2mins followed by a 
subsequent denaturing at 95°C for SOmins, an annealing gradient temperature range 
from 55°C to 77°C, and an extension at 72°C for Im in. The PCR cycle was repeated 35 
times followed by a final extension at 72°C for 5mins.
A 10|il aliquot of the amplified DNA product was separated on a 1% agarose gel 
alongside a Ikb  DNA ladder.
2.7.6 Differential IFN expression via high-throughput sequencing
PolFNa genes are expressed upon viral infection, but this expression has also 
been suggested to differ with respect to the stimulant as well as across different cell 
or tissue type (Sang et al, 2010).
2.7.6.1 Ultra deep sequencing PCR primer preparation
The Ultra deep sequencing of a target region within the IFN ORF/sequence will 
allow the detection, identification and quantification of low-level DNA variants in a 
population. Using this unique technology of DNA sequencing, prepared amplicon 
libraries can be used to obtain sequences of single DNA molecules from a sample 
mixture.
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The preparation of amplicon libraries uses the emulsion-based clonal 
amplification feature of the system which allows for the sequencing of a single 
molecule without having to clone the target sequence into bacteria.
A PCR amplification step is required for preparing a DNA sample for Amplicon 
sequencing and this PCR requires the design of one or two special fusion primers 
(Figure 2-4). For the purpose of obtaining a full coverage and fully over lapping reads, 
two forward and reverse primers were designed. Each primer must contain a 21 base 
GS FIX Titanium Primer A or Primer B which includes a 4-base library key at the end 
of the primer of the titanium primer, and a template specific sequence at the 3' end. 
A 10-mer multiplex identifier (MID) sequence was also included in the different 
primer sequences; this allows for automated software identification of a PCR 
product/sequence after sample pooling. These MID and titanium primer keys 
sequences were obtained from the standard 454 set table in the ROCHE 454 
sequencing technical bulletin No. 013-2009.
Using the sequence consensus from the polFNa 1-17 sequence alignment, 
template specific reverse and forward primer were designed such that they anneal to 
conserved target sequences and amplify a non-conserved region within the different 
subtypes to allow discrimination of the different subtypes.
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Figure 2-4 Schematic representation of the PCR reaction component and the generated 
amplicon library product.
The DNA amplicon required for the ultra deep sequencing of the target region is generated 
by a PCR amplification step. The PCR reaction involves the binding of the template specific 
region on the specific fusion primers to complementary sequences on the DNA template 
(A*). The deep sequencing fusion primers PCR primer used in this reaction contains a 21 
base GS FLX Titanium Primer A or Primer B, a 4-base library key at the end of the titanium 
primer, followed by a 10-mer multiplex identifier (MID) which allows for identification of 
samples and a template specific sequence at the 3' end of the fusion primer (B*). The 
generated amplicon consists of the whole fusion primer and the amplified product (C*).
2.7.6.2 PolFNa deep sequencing PCR optimisation and amplicon library generation
The deep sequencing fusion primers were optimised using a High fidelity 
platinum taq polymerase kit (Life Technologies, UK) along with the designed MID 
fusion primers.
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A 50|il sample of master mix containing lOxPCR mix, 0.2mM of each dNTP, 1U of 
Taq DNA polymerase, 0.2|iM  of each fusion forward and reverse primer, and 50mM  
MgS04 was prepared. For the PCR reaction, PCR grade water was included as a no 
template control and lOng of a prPoFINcx plasmid DNA as the positive control.
The PolFNa deep sequencing PCR was performed following initial denaturing at 
94°C for Imins followed by a subsequent denaturing at 94°C for BOsecs, an optimised 
annealing temperature, and an extension at 68°C for BOsecs. The PCR cycle was 
repeated 35 times. A lOpI aliquot of the amplified DNA product was separated on a 
1% agarose gel alongside a Ikb  DNA ladder.
Following this primer optimisation, the amplicon libraries required for deep 
sequencing were generated using the ROCHE fast start fidelity kit (Roche, UK) 
according to manufacturer's instruction.
2.8 Analysis of generated 454 sequence data
A BLAST+ alignment software programme was used for the analysis of the 
sequence data (Camacho et al, 2009). This software is a stand-alone version of the 
Basic Local Alignment Search Tool (BLAST) introduced by The National Center For 
Biotechnology Information (NCBI). The command-line application software uses a 
query to perform a sequence similarity search of nucleotide sequences against a 
nucleotide database. The output result from the search contains the sequence ID, 
the corresponding target, the percentage identity, the length of the alignment, the 
number of mismatches and the number of gaps.
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2.9 Statistical Analysis
Statistical analysis was performed using GraphPad Prism 6 software. The average 
mean of independent experiments were represented as ±  mean with standard 
deviation (SD). For all comparisons, a two-way analysis of variance (ANOVA) test was 
used to determine significant differences except where alternative methods were 
used.
2.10 Sequence Analysis
Sequences were compiled and analyzed using the Lasergene software suite 
(Version 10.0.0; DNASTAR). Multiple nucleotide and amino acid sequence alignments 
were performed using Clustal-W method in MegAlign. Protein pair wise alignments 
were performed with the Lipman-Pearson method in MegAlign (Lasergene). 
Predicted protein molecular weights were calculated using the SIB Bioinformatics 
resource portal; ExPASY (http://web.expasv.org/compute p i/). Phylogenetic trees 
were constructed using the maximum-likelihood method and tested with 1000 
bootstrap replicates in MEGA version 5.03.
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2.11 Chemicals, media and buffers
Table 2-1 Chemicals, media and buffers
Chemical Manufacturer
3-amino-9-ethyl carbazole; Sigma-Aldrich, UK
Bovine serum albumin (BSA) Sigma-Aldrich, UK
lOx Cell fix (4% paraformaldehyde 
solution in PBS)
Sigma-Aldrich, United Kingdom
3,3'-Diaminobenzidine 
tetrahydrochloride (DAB)
Sigma-Aldrich, UK
CD14 Microbeads Miltenyi, UK
Dimethyl sulphoxide (DMSO) Life Technologies, United Kingdom
Ethanol (absolute) Sigma-Aldrich, United Kingdom
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, United Kingdom
Fetal calf serum (PCS) Autogen Bioclear UK Limited, Witshire, 
United Kingdom
Fiocoll separating solution, density 
1.077 g/ml
Source BioScience LifeSciences, 
Nottingham, United Kingdom
Goat Serum Life Technologies, United Kingdom
Hydrogen peroxide Sigma-Aldrich, United Kingdom
MACS (magnetic cell sorting) buffer 
(500 ml of PBS, 2% PCS and 5 mM 
sodium EDTA)
Animal Health and Veterinary 
Laboratory Agency, Weybridge, United 
Kingdom
MACSQuant running buffer (PBS, EDTA 
and sodium-azide)
Miltenyi Biotec, Germany
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MACSQuant storage solution (sodium- 
azide)
Miltenyi Biotec, Germany
MACSQuant washing solution 
(detergents and a stabilizer)
Miltenyi Biotec, Germany
Minimal Essential Medium (MEM) Life Technologies-Gibco, United 
Kingdom
(3-Mercaptoethanol ((3-ME) Sigma-Aldrich, Dorset, United Kingdom
NjN-dimethyl-formamide Sigma-Aldrich, Dorset, United Kingdom
Penicillin/streptomycin Life Technologies, United Kingdom
IX-Phosphate buffered saline solution 
(PBS)
Life Technologies-Gibco, United 
Kingdom
RNAse-free water Oiagen, West Sussex, United kingdom
RPMI (Roswell Park Memorial Institue)- 
1640
Life Technologies-Gibco, United 
Kingdom
Sodium acetate Sigma-Aldrich, Dorset, United Kingdom
2% Trypsin Life Technology, United Kingdom
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Table 2-2 Reagents required for the staining of CSFV infected cells using 3,3'- 
Diaminobenzidine tetrahydrochloride (DAB).
Reagent Concentration
PBSt: Tween 20 was diluted to a final concentration 
of 0.2%v/v in 0.01MPBS
Hydrogen peroxide-Methanol 
(H202/Methanol)
Hydrogen peroxide was added to methanol to a 
final concentration of 3%v/v
3,3'-Diaminobenzidine 
tetrahydrochloride (DAB)
Two buffers were first prepared 
Buffer A Stock:
200mM Disodium Hydrogen Orthophosphate 
containing 0.05% Tween 20.
Buffer B Stock:
105mM citric acid containing 0.05% Tween 20
14ml of Buffer A was added to 6 ml of Buffer B 
and pH was adjusted to 6.4
One tablet of DAB was dissolved in 20ml of the 
Buffer A/B mixture dispensed into a universal. 
The mixture was passed through a O.45|^m filter 
into a sterile universal and 10|il of hydrogen 
peroxide was added. This mixture was used 
immediately
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2.11.1 Antibodies
Table 2-3 Primary and secondary antibodies
Antibody Origin Clone Manufacturer
ARC conjugated Anti-mouse IgGl Rat X56 BD Bioscience, United 
Kingdom
Anti-His (C-term) antibody Mouse 3D5 Life technologies, UK
Anti-mouse IgG HRP Rat - Promega, UK
Anti-mouse IgGl Isotype control Rat - AbD
Anti-mouse polyclonal antibody Rabbit Da ko, UK
Anti-Pig monoclonal Interferon 
Alpha antibody
Mouse K9 PBL, UK
Anti-Pig monoclonal Interferon 
Alpha antibody
Mouse F17 PBL, UK
CSFV-E2 monoclonal IgGl antibody Rat WH303 cell and tissue culture 
unit, AHVLA, United 
Kingdom
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Chp 3. Cloning and expressing PolFNa
3.1 Rationale
Based on examination of the current porcine genomic sequence for polFNa, 
seventeen different PolFNa genes have been identified (Cheng et al, 2006; Sang et al, 
2010), of which only PolFNal has been cloned, expressed and is currently 
commercially available (PBL,UK). The other 16 PolFNa subtypes, although 
characterized (Sang et al, 2010), are not commercially available. The anti-viral 
activities of these subtypes against some viral infections have been confirmed, but 
these activities vary in different cell lines (Sang et al, 2010; Xia et al, 2005a).
The ability of one porcine IFNa; PolFNal subtype to control CSFV infection has 
been demonstrated in vitro (Xia et al, 2005a). However, no studies have compared 
the activity of the seventeen different IFNa subtypes against CSFV. Therefore, in 
order to confirm the individual antiviral activity, and specifically anti-CSFV activity of 
the seventeen different PolFNa subtypes, we cloned, expressed and then tested 
their individual antiviral activity against Vesicular Stomatitis Virus and PK15 cells; to 
obtain protein preparations with standardised activity, prior to comparing the 
proteins activity against CSFV.
3.2 Characterization and amplification of PolFNa genes
To clone the PolFNa genes used in this study, the Web based algorithm biostn 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) was used to correlate the porcine interferon 
IFNa subtypes sequences in GenBank as described by Sang and colleagues (Cheng et 
al, 2006; Sang et al, 2010) (Table 3-1) with the Sscrofal0.2 genome assembly of the
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Swine Genome Sequencing Project with NCBI Reference Sequence: NC_010443.4 
(www.ensembl.org). Current analysis revealed that they were all located on 14 
different loci on chromosome 1 of Sscrofal0.2 genome.
Table 3-1 Different porcine interferon alpha subtypes and their respective Genbank 
accession number and location nucleotide on S.Scrofa 10.2
PolFNa subtype GenBank Accession No. Annotated Loci in Sus scrota 10.2 
Reference assembly NC_010443.4.
PolFNal GQ415055 224610947-224611491
PolFNa2 GQ415056 224467646-224468191
PolFNaS GQ415057 Annotated to alpha 2 locus
PolFNa4 GQ415058 224984019-224984588
PolFNaS GQ415059 225045743-225046312
PolFNaG GQ415060 225181045-225181687
PolFNa? GQ415061 Annotated to alpha 11 locus
PolFNaS GQ415062 224778822-224779391
PolFNa9 GQ415063 224762619-224763188
PolFNalO GQ415064 224549629-224550174
PolFNall GQ415065 224693606-224694151
PolFNal2 GQ415066 Not annotated on current assembly
PolFNal3 GQ415067 225215348-225215917
PolFNal4 GQ415068 225194046-225194615
PolFNalS GQ415069 225138616-225139182
PolFNalG GQ415070 225122722-225123291
PolFNal? GQ415071 224848396-224848941
Using the Clustal W option on the MegAlign programme on the DNAstar
Lasergene software, nucleic acid sequences obtained from the Sscrofal0.2 database
were aligned. The aligned sequences had an overall conservation of between 94.5%
(PolFNal4 & PolFNal?) to 99.8% (PolFNa? & P o lFN all) identity at the nucleotide
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level and 90% (PolFNaM & PolFNalG) to 99.5% (PolFNa? & P olFN all; PolFNaS & 
PolFNalS) at the amino acid level. The alignment also revealed a COOH-terminal 
deletion in seven (PolFNal, a2, a3, a?, alO , a l l ,  a l? ) out of the 17 subtypes (Figure 
3-1). The shorter genes encode for 181 amino acid (AA) pre-proteins while the longer 
genes encode for 189AA pre-proteins. Both short and long forms contain a 23AA 
putative signal peptide at the N-terminal region and, therefore, encode for 158AA 
and 166AA mature proteins respectively. Using this alignment, primers were 
designed to conserved regions at the start and end of the reading frame in order to 
clone the 17 PolFNa subtypes.
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Chp 3. Cloning and expressing PolFNa
3.2.1 Cloning of PolFNa genes using PolFNa degenerate primers
The seventeen PolFNa subtypes share a high sequence homology, therefore the 
first attempt at cloning the subtypes involved the design of three degenerate PCR 
primers; one forward and two reverse primers that would amplify all the short and 
long PolFNa subtypes (Figure 3-1 and Table 3-2). The forward primers were all 
designed to contain a Kozak sequence (GNN ATG) at the start of the initiating codon 
so as to enhance the expression in mammalian cells.
Table 3-2 Degenerate PCR primers for amplification of PolFNa genes
Primer Name: Sequence (S' to 3'): Melting
temperature
IFN-Fwd GNN ATG GCC CCA WCC TCA RC 57°C
IFN-Rev long CTC CTT CYT CCT GAG TCT G 63.4°C
IFN-Rev short CAG GTK TST GGA GGA AGA G 58.9°C
N=A/T/G/C, W=A/T, R=A/G, K=T/G, S=C/G.
The PolFNa genes were amplified using the method described in 2.3.1 and the 
above degenerate primers. After optimisation of PCR conditions with a gradient of 
annealing temperatures, 56°C was chosen as optimal for the PCR reaction. For each 
primer pair set; (IFN-Fwd + IFN-Rev short and IFN-Fwd + IFN-Rev long), lOpI of 
PolFNa amplified PCR products were separated on a 1% agarose gel (as described in 
2.3.4.1). DNA fragments consistent with the expected sizes of 543bp and 567bp, 
representing the short and the long polFNa subtypes respectively, were observed on 
the agarose gel (Figure 3-2). These DNA fragments were excised from the gel and 
purified.
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The purified polFNa PCR products were ligated into the pcDNA3.1/V5-HIS-TOPO 
expression vector such that expression was under the control of the cytomegalovirus 
immediate-early promoter.
Ladder 1 2
10 0 0  bp  
750  bp
500 bp
Figure 3-2 Agarose gel analysis of PolFNa PCR products amplified from porcine genomic 
DNA using PolFNa PCR primers (IFN-Fwd + IFN-Rev short and IFN-Fwd + IFN-Rev long).
The fragments were separated by electrophoresis alongside a Ikb DNA ladder (promega, 
UK). Ladder: 1Kb DNA ladder Lane 1: PCR amplicon using IFN-Fwd and Rev short primer. Lane 
2: PCR amplicon using IFN-Fwd and Rev long primer.
Several recombinant clones were analysed by sequencing using the T7 forward or 
BGH reverse primer (as described in 2.3.4.3) and the generated sequences were 
aligned w ith sequences obtained from Genbank.
Following sequence analysis, all selected clones were found to possess numerous 
mismatches, with the primers designed to amplify short polFNa subtypes mainly 
generating clones closely similar to long subtypes at the 3' end and thus represented 
truncated long subtypes. Also the presence of the degenerate nucleotides in the 
primer resulted in clones with the incorrect nucleotide for the particular subtype 
incorporated at the degenerate position.
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3.2.2 Amplification and cloning of PolFNa genes using subtype-specific primers 
and sequence analysis of generated recombinant PolFNa plasmids
Due to the failure of the degenerate primers in generating constructs encoding 
the expected subtypes or subtypes with high nucleotide similarity to the sequence of 
the polFNa subtypes from the Sus Scrofa 10.2 genome, alternative subtype specific 
PCR primers were designed. The forward and reverse primers were designed such 
that they anneal to regions at the start and end of the ORF's of the different 
subtypes (Table 3-3). As these subtypes also share a high sequence homology at the 
start and end regions, the primers were paired such that some pairs would amplify 
more than one subtype (Table 3-4).
Table 3-3 Sequences of polFNa subtype specific PCR primers and melting temperatures
Primer Name: Alternative
name
Sequence (S' to 3'):
Melting
temperature
IFN alpha FP1 FP1 GNN ATG GCC CCA TCC TCA GC 65.6°C
IFN alpha FP2 FP2 GNN ATG GCC CCA ACC TCA GC 65.600C
IFN alpha RLP3 RLP3 ‘ CTC CTT CCT CCT GAG TCT G 59.1°C
IFN alpha RLP4 RLP4 CTC CTT CTT CCT GAG TCT G 56.5°C
IFN alpha RLP5 RLP5 CTC CTT CTT CCT GAA TCT G 56.4°C
IFN alpha RSP6 RSP6 CAG GTT TCT GGA GGA AGA G 59°C
IFN alpha RSP7 RSP7 CAG GTG TGT GGA GGA AGA G 61°C
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Table 3-4 Different PCR primer combinations and the polFNa subtype they were expected 
to amplify
Primer Pair Alternative Name Target amplicon
FP1 and RLP3 Set 1 IFN alpha 13
FP2 and RLP4 Set 2 IFN alpha 9, 5 ,1 4
FP2 and RLP5 Set 3 IFN alpha 4
FP2 and RLP3 Set 4 IFN alpha 16,15
FP2 and RLP6 SetS IFN alpha 2 ,1 7 ,1 0
FP2 and RLP7 Set 6 IFN alpha 11
Using the thermal profile described in 2.3.1, PCR conditions for each primer set 
were optimized with a gradient of annealing temperatures, the optimal annealing 
temperature chosen for each primer set was then used for amplification of PolFNa 
genes as shown in Table 3-5.
Table 3-5 Different PCR primer combinations, the chosen optimal annealing temperature 
and the target PolFNa amplicon
Primer Pair
Alternative primer 
name
Annealing 
Temperature (T°) Target amplicon
FP1 and RLP3 Set 1 60 PolFNalS
FP2 and RLP4 Set 2 53 PolFNa9, 5 ,1 4
FP2 and RLP5 Set 3 55 PolFNa4
FP2 and RLP3 Set 4 55 P o lF N a l6 ,15
FP2 and RLP6 SetS 55 PolFNa2,17,10
FP2 and RLP7 Set 6 66 P o lF N a ll
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A 10|al aliquot of the amplified product from each primer pair set was separated 
on a 1% agarose gel. DNA fragments consistent with the expected sizes of 543bp and 
567bp, representing the short and long polFNa subtypes respectively, were observed 
on the gel (Figure 3-3). Following gel analysis, polFNa DNA fragments were excised 
from the gel and purified using the Qiagen gel purification extraction.
A  b
Ladder 1 2  3 Ladder 1 2 3
1000bp 
750b p 
500b p -
Figure 3-3 Agarose gel analysis of PolFNa PCR products amplified from porcine genomic 
DNA using PolFNa subtype specific PCR primers. (IFN alpha- FP1 and -FP2 and IFN alpha 
RLP3, -RLP4, RLP5, -RSP6 and -RSP7).
The amplified products were separated by electrophoresis alongside a Ikb DNA ladder 
(promega, UK) (A). Lanes designated as 1, 2 and 3 shows PCR amplicons from: IFN-FP1 and 
RLP3 (Set 1), IFN-FP2 and RLP4 (set 2), IFN- FP2 and RLP7 (set 6) respectively. Amplified 
products were separated by electrophoresis alongside a lOObp DNA ladder (promega, UK) 
(B). Lanes designated as 1, 2 and 3 shows PCR amplicons from: IFN-FP2 and RLP5 (Set 3), 
IFN-FP2 and RLP3 (set 4), IFN- FP2 and RLP6 (set 5) respectively.
The purified products were cloned into the pcDNA3.1-Topo-HIS-V5 vector and 
the generated clones analysed by A/col restriction enzyme digest. Clones w ith the 
polFNa gene in the right orientation were then selected for sequence analysis.
Sequencing confirmed the constructs had the coding region of the polFNa gene 
in the right orientation and also in-frame with the 6x polyhistidine tag at the C-
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terminal end of the pcDNA3.1-Topo-HIS-V5 vector (an example of such analysis is 
shown in Figure 3-4). Sequences from clones bearing these properties were aligned 
with polFNa sequences obtained from Genbank so as to identify the corresponding 
IFNa subtype (Table 3-1).
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Chp 3. Cloning and expressing PolFNa
Following a series of gene amplification reactions and cloning of amplified 
products, constructs encoding five of the seventeen different PolFNa subtypes were 
identified; these recombinant plasmids were designated as clone 2e, 3, 5, 8d, and 6 
(Table 3-6). The cloned sequences were similar to PolFNa genes; PolFNaZ, a l6 , a l3 ,  
a8 and a l2  respectively, of the Sscrofal0.2 genome assembly; with 98-100% identity 
at the nucleotide level. A summary of the nucleotide differences in the recombinant 
clones compared to the sequences from the S.scrofa 10.2 genome is described in 
Table 3-7.
Clone 2e
Sequence analysis of clone 2e indicated it encoded a gene with only one 
nucleotide difference, at position 366 (change from thymidine (T) to cytidine (C)) to 
the S.Scrofa 10.2 polFNa2 gene. This difference did not introduce any change in the 
amino-acid sequence of prPolFNa2.
Clone 3
Clone 3, which was amplified using primer set 1 contained a gene which was 
highly similar to polFNa!6. This subtype was expected to have been amplified by 
primer set 4 rather than primer set 1. As a result a nucleotide change at position 10; 
which is in the primer region, was introduced in this plasmid. This adenosine (A) to a 
thymidine (T) change results in an amino acid change from a Threonine to a Serine. 
Other nucleotide changes in the plasmid sequence were at position 182 (change 
from a T to an A; causing an amino-acid change from Phenylalanine to Tyrosine) and
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a nucleotide change at position 413; (change from a guanine (G) to an A; resulting in 
an amino-acid change from a Glycine to an Aspartate). A lipman-Pearson protein 
alignment on the Megalign programme (Lipman & Pearson, 1985) revealed that 
these amino-acid changes were favourable i.e conservative/ and may not affect the 
protein function (Betts & Russell, 2003).
Clone 5
Clone 5 was amplified using primer Set 1 as expected, this clone encoded a gene 
with similarity to polFNoclB but with 10 nucleotide differences some of which 
introduce amino-acid sequence changes. These differences in rpolFNalS were at 
position 174 (a nucleotide change from C to T introducing no amino-acid change), at 
position 186 (a nucleotide change from T to C introducing no amino-acid change), at 
position 189 (a nucleotide change from T to A causing an amino-acid change from 
Histidine to Glutamine), at position 198 (a nucleotide change from T to G ; causing an 
amino-acid change from a Phenylalanine to a Leucine ), at position 393 (a nucleotide 
change from C to G introducing no amino-acid change), at position 396 (a nucleotide 
change from C to G introducing no amino-acid change), and at position 499 (a 
nucleotide change from G to A ; creating an amino acid change from Valine to 
Isoleucine). Pairwise alignment revealed that all these changes were conservative 
except for changes at position 380 (a nucleotide change from C to T causing an 
amino acid change from Alanine to Valine ), and at position 539 (a nucleotide change 
from A to G ; creating an amino acid change from Asparagine to Threonine). These 
two amino-acid changes are less well conserved while at position 182 an amino-acid
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change from a serine to a phenylalanine (introduced by a nucleotide change from C 
to T) was non-favourable and more likely to affect the protein function.
Clone 6 and Clone 8d
Clone 6 and 8d which bore high similarity to PolFNaS and P o lFN all respectively 
were generated by primers set 2 and set 4 respectively, which were designed for 
other polFNa subtypes. This unexpected amplification might be as a result of high 
sequence similarity between subtypes. For clone 6, there were changes at position 
22 (nucleotide change from C to T; causing an amino acid change from Leucine to 
Phenylalanine), at position 39(nucleotide change from G to A), at position 144 
(nucleotide change from C to T), and at position 560 (nucleotide change from G to A; 
causing an amino acid change from Arginine to Lysine). These two amino acid 
changes were favourable. While the two nucleotide changes in clone 8d at position 
553; from C to T and at position 536; from a C to G, resulted in a conserved amino 
acid change from Leucine to Phenylalanine but a non-favourable change from  
Threonine to Arginine respectively.
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Chp 3. Cloning and expressing PolFNa
Alignment of the protein sequences also showed that all contain a 23AA putative 
signal sequence that would result in mature proteins comprising of 166amino-acids 
and 158amino-acids. They also had five conserved cysteine (Cys) residues at 
positions Cys24, Cys52, Cys109, Cys122 and Cys162 suggested to play a role in disulfide 
bond formation (Figure 3-5) (Sang et al, 2010; van Pesch et al, 2004). Despite these 
minor changes, these cloned polFNcx subtypes; clone 2e, clone3, clone 5, clone 6 and 
clone 8d, were used for the production of prPolFNa2, prPolFNalG, prPolFNal3, 
prPolFNaS and prPolFNal2 plasmids respectively. An alternative strategy was used 
for the cloning of the other 12 PolFNa subtypes.
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Chp 3. Cloning and expressing PolFNa
3.2.3 Amplification and cloning of synthesized PolFNa genes
After a series of attempts at generating plasmids bearing inserts with close 
similarity to the other 12 defined PolFNa subtypes by PCR amplification, the 
remaining PolFNa genes were generated synthetically.
Synthetic genes encoding the PolFNaS, a4, a7, a l4  and a l7  subtypes were 
supplied by IDT-DNA in an intermediate vector; pIDTSMART-KAN with flanking 
restriction enzyme sites; 5'Kpn I and 3' EcoR V which allowed transfer of the 
synthetic gene into the expression plasmid pcDNA3.1/V5-HisB (as described in 
2.3.2.1). The polFNa genes were extracted from the intermediate vector (Figure 2.2) 
and ligated into the pcDNA3.1/V5-His TOPO TA expression plasmid and transformed 
into an E.coli cloning host. Ampicillin resistant clones were selected and plasmid DNA 
purified and analysed by sequencing. The sequences of the synthetic plasmids were 
compared with porcine genomic sequences obtained from GENBANK (Table 3-1) and 
confirmed to have inserts with a 100% similarity with polFNa genome sequences of 
S.scrofal0.2 at both nucleotide and amino-acid level. The five genes were also found 
to be in frame with the 5' ATG and 3' poly histidine tag of the expression vector.
A different method of gene synthesis was applied for the amplification of the 
remaining polFNa genes which avoided this subcloning step. Genes encoding the 
PolFNal, a5, a6, a9, alO , a l l  and a !5  subtypes were synthesized by Gene Art 
technologies and provided already subcloned into a pcDNA3.1/V5-His B expression 
vector. Restriction sites Kpn I and EcoR V were included in the synthesis design to 
allow for subcloning in frame to C-terminal His tag in the vector. Following
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transformation of the provided plasmids, numerous clones were generated as 
described in 2.3.2.3, and a few selected for plasmid purification and further analysis.
Plasmids isolated from synthesised genes were analysed by sequencing as before 
and compared with genome sequences of S.scrofal0.2. Clones analysed showed a 
100% similarity at both nucleotide and amino acid level and were in frame with the 
5' ATG and 3' poly histidine tag. This method successfully generated PolFNal, a5, a6, 
a9, alO, a l l  and a !5  subtypes.
A summary of all the seventeen cloned prPolFNa plasmids is summarised in 
(Table 3-8).
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3.2.4 Identifying regions of the polFNa subtypes that may influence biological 
activity
A protein alignment of the cloned prPolFNas and the PolFNa GenBank sequence 
was created to identify amino-acid residues that might influence the biological 
activity of the polFNa subtypes. For the alignment, sequences of the recombinant 
polFNa plasmids; prPolFNa2, a8, a l2 , a l3  and a l6  were aligned with the seventeen 
polFNa GenBank sequences, the other twelve synthetic polFNa plasmids sequences 
were represented by GenBank polFNa sequences as they bear a 100% similarity. 
These subtypes were aligned with human IFNa2 using the Clustal W  option on the 
Megalign programme (Laser gene).
All the seventeen proteins bear a conserved 23 amino-acid NH2- terminal signal 
peptide and four conserved cysteine residues (Cys24, Cys52, Cys^z and Cysiez) which 
probably form two disulphide bonds (Cys24 - Cysi22 and Cys52- Cysi62) as described in 
human and also mouse IFNa (Hardy et al, 2004; van Pesch et al, 2004; van Pesch & 
Michiels, 2003b). Seven of the rpolFNa (short subtypes) lacked the COOH-terminal 8 
amino-acid hydrophobic tail which has been suggested to improve the antiviral 
activity in the long subtypes. The alignment also revealed the presence of putative N- 
glycosylation site (Asn-X-Ser/Thr) at position 101 in four of the subtypes; polFNa?, 
a9, a lO  and a l l .  The predicted peptides were examined against the conserved 
domain database (CDD; http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi 
(Marchler-Bauer et al, 2011)), and the results indicated that they all posses a 
functional IFNabd domain which is common to type I IFN, as well as a putative type I 
receptor binding sites (IFNAR-1 and IFNAR-2).
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Human IFNa typically possesses five putative a helices; A, B, C, D and E, linked by 
a long connecting AB loop and three short BC, CD and DE loops in between the five 
helices (Radhakrishnan et al, 1996). Within these helices are residues which have 
been suggested to influence the receptor binding and biological activity of human 
IFNa2b. These residues include: Arg22, Leu26, Phe27, LeuBO, LysBl, ArgBB and His34 
located on the AB loop, Ser68 located on the bend in helix B, Thr79, LysSB, Tyr85, 
and Tyr89, located on the bend in helices C, Argl20, Lysl21, Gin 124, LyslBl, and 
Glul32 located on helix D and Argl44, and G lul46 located on helix E (Radhakrishnan 
et al, 1996). An amino-acid sequence alignment of humanlFNa2b and all the 
seventeen prPolFNa subtypes (Figure 3-6) revealed the presence of these five helices 
on the cloned prPolFNa subtypes, and highlighted resides that might be involved in 
influencing the biological activity of rPolFNa. The alignment also revealed that these 
residues are not all conserved between the humanlFNa2b and porcine IFNa 
subtypes, but they are conserved among the seventeen prPolFNa subtypes. This 
analysis may predict residues and regions involved in the biological activity of the 
prPolFNa subtypes.
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Figure 3-6 Multiple sequence alignment of porcine interferon alpha 1-17 mature proteins
Alignments show the sequences of the PolFNa recombinant plasmids, prPolFNal-17 
GenBank sequences and human IFNal and human IFNa2b GenBank sequences; the other 
twelve recombinant synthetic plasmids not shown were represented by GenBank sequences 
as they bear a 100% similarity. The COOH-terminal hydrophobic tail of the IFNa subtypes is 
boxed. Blue highlighted regions represent conserved cysteine residues among all the aligned 
IFN types. Residues that differ from other residues are boxed. Labelled braces designated A- 
E; represent the 5 a-helical regions and 1 AB connecting loop as predicted from human 
IFNa2b. Residues implicated for biological activity are highlighted in red. Reference 
sequences of Human IFNa2b:NM_000605.3 was obtained from Genbank. Please note that 
HulFNa2b has a deletion at position 46 in comparison to the other polFNa sequences.
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3.3 Expression and purification of PolFNa protein
Commercial preparations of clinical IFNa are usually obtained from recombinant 
proteins expressed in E.coli, or from virus stimulated transformed cell culture and 
primary human blood leucocytes (Lefevre & La Bonnardiere, 1986; Viscomi et al, 
1995), the pcDNA3.1 vector used in this study allowed for expression in mammalian 
cell lines. CHO cells, which are commonly used as hosts for production of 
recombinant protein were chosen due to the cells characteristic ability to perform 
correct post-translational modifications (Lim et al, 2010; Wurm, 2004).
The five plasmids isolated encoding the PCR amplified recombinant PolFNas were 
transfected into CHO cells in order to produce biologically active proteins (as 
described in 2.4.1). Initially, the cellular location of the expressed proteins generated 
was analysed by SDS-PAGE and western analysis of cell culture supernatant and 
cytoplasmic fractions. Western analysis of the cytoplasmic fractions with an anti-His 
C-terminus HRP monoclonal antibody did not reveal any protein (data not shown) 
while analysis of the harvested culture supernatants identified His-tagged proteins 
which migrated slightly faster than the 25kDa marker (Figure 3-7). This suggested 
that the rPolFNa proteins were being secreted into the cell culture supernatant. Also 
amongst the five expressed proteins, clone2e-rPolFNa2 appeared to have a lower 
molecular weight when compared to the others which is due to the lack of the eight 
C-terminal amino acids in the protein structure. Similar results were obtained from 
supernatant of cells transfected with the synthetically produced plasmid (results not 
shown).
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Figure 3-7 Western analysis of different expressed polFN-a sub-types run alongside a 
protein ladder (Precision Plus Protein Kaleidoscope Standards; Biorad, UK), stained with 
anti-His(C-term) HRP antibody.
Lane 1: Clone 8d (rPolFN-al2) Lane 2: Clone 2e (rPolFN-a2) Lane 3: Clone 3 (rPolFN-al6) 
Lane 4: Clone 5 (rPolFN-al3) Lane 5: Clone 6 (rPolFN-a8). The exposed x-ray film was aligned 
with the nitrocellulose membrane in other to confirm the regions of the protein markers.
Following confirmation of the presence of the His-tag rPolFNa protein in the cell 
culture supernatant, all seventeen expressed rPolFNa proteins were concentrated 
and the concentrated protein preparations were purified by DYNA-bead-affinity 
chromatography (as described in 2.4.2). The Isolated histidine-tagged proteins were 
then eluted from the beads, and the eluted protein buffer was exchanged w ith PBS 
to reduce the concentration of salts.
To assess the level of purity of these rPolFNa proteins, an aliquot of each PolFNa 
preparation was analysed on a 12% SDS-PAGE gel stained by Coomassie blue. After 
several attempts, however, no distinct protein band was observed on the gel (data 
not shown), but western blot analysis using the mouse anti-His monoclonal antibody.
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identified proteins that migrated slightly faster than the 25kDa marker in all the 17 
his-tagged purified rPolFNa preparations.
Differences in the migration levels of the seven protein subtypes with shorter 
length (rPolFNal, a2, a3, a7, alO, a l l  and a l7 ) when compared to the other ten 
rPolFNa subtypes w ith longer lengths were observed, as shorter length types 
appeared to migrated faster than the longer length subtypes. It was also observed 
that rPolFNaE); a long subtype migrated slower when compared to other longer 
subtypes (Figure 3-8).
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Figure 3-8 Western blot analysis of recombinant rPolFN-a2-17 His-tagged proteins 
(~25kDa), stained with anti-His(C-term) HRP antibody.
The exposed x-ray film was aligned with the nitrocellulose membrane in other to confirm the 
regions of the protein markers for each of the subtypes as indicated.
Using the sequence analysis data generated and the SIB Bioinformatics resource 
portal (ExPASY, http://web.expasv.org/compute p i/), the predicted molecular 
weight of each protein was calculated and the protein short subtypes were found to 
range from 22.3kDa to 22.4 kDa while the long subtypes ranged from 23.3kDa to 
23.4kDa. The only exceptions were seen with subtypes isolated from the porcine
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DNA; prPolFNa2/ prPolFNaS, prPolFNal2, prPolFNalB and prPolFNalG which were 
larger than other subtypes.
The concentrations of these purified recombinant proteins were then quantified 
using an optimised polFNa ELISA with the commercially available rPolFNal (PBL, UK) 
serving as a standard (Table 3-9). The result showed that the protein preparation 
resulted in sufficient quantities except for rPolFNaS, a7, alO, a l l  and a !5  which had 
low amount of protein. This low concentration of protein may not necessarily 
influence the activity of the protein
Table 3-9 Quantification of purified recombinant PolFNa protein preparations. Purified 
proteins were quantified by ELISA using a commercial polFNal as standard.
Data shows an average of three independent experiments performed in triplicates.
rPolFNa
Predicted protein 
molecular weight (kDa)
Protein
concentration
(Hg/ml)
1 22.4 30.8
2 23 27.2
3 22.4 27.9
4 23.4 45.5
5 23.4 3.92
6 23.4 29.8
7 22.3 4.49
8 24 54.8
9 23.4 40.5
10 22.4 0.02
11 22.3 1.06
12 24 52
13 24 21.5
14 23.4 13.2
15 23.3 4.36
16 24 17.3
17 22.4 20
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3.4 Optimization of a biological assay, based on VSV infection of PK15 cells, 
to standardize the activity of the recombinant PolFNa protein 
preparations
The relative biological activity of expressed proteins was determined by assessing 
the antiviral activity of the proteins against VSV on the mammalian cell line; PK15 
cells. Several virus and cell line combinations have been used in detecting the 
antiviral activity of IFNs, however some combinations are better suited than others 
(Meager, 2002). As these IFNs were from pigs, it was important to choose a cell line 
that closely reflected the intended therapeutic use. Previous studies have confirmed 
the broad host range and high susceptibility to IFN of VSV hence its application in this 
bioactivity study (Joo & Su, 1987).
3.4.1 Assessing the cytopathic effect of VSV on PKlScells
Firstly, the MOI of virus required to infect PK15 cells and cause optimum levels of 
cell death was determined. This was defined as the least amount of virus required to 
cause the most cytopathic effect on PKlScells after 24 hours of infection. A range of 
VSV dilutions were added to PK15 cells and the level of cell death was assessed by 
Crystal Violet staining of cells as compared to uninfected controls; which were 
considered to have 0% cell death. The O.D values obtained from the virus titration 
were used to determine the percentage of cell death. The results showed that 
although a 1:10 dilution gave the highest percentage of cell death at 60.4%; using
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less virus; 1:100 did not produce considerably less. Therefore, a 1:100 dilution (MOI 
of 1.9) was chosen as dilution for infecting PKlScells Table 3-10 .
Table 3-10 The percentage of cell death induced upon infection of PK15 cells with serial 
dilutions of Vesicular Stomatitis virus.
Data shows an average of three independent experiments performed in triplicates.
Virus
dilution
Virus MOI
Average 
% Cell 
death
1:10 18.9 60.4
1:100 1.89 55.7
1:1000 0.189 52.3
1.00E+04 0.018 37.3
1.00E+05 0.001 15.6
1.00E+06 1.00E-04 4.6
1.00E+07 1.00E-05 5.1
1.00E+08 1.00E-06 6.8
1.00E+09 1.00E-07 9.1
1.00E+10 1.00E-08 8
uninfected - 0
3.4.2 Optimisation of PolFNal bioactivity assay
The aim of the VSV/PK15 bioassay was to measure inhibition of VSV in the 
presence of a protein preparation compared to the inhibition in the presence of a 
known standard (Food and Drug Administration, June 2006; Meager, 2002).
The linear range of the bioactivity assay was determined by assessing the anti- 
VSV activity of a series of purified commercial PolFNal dilutions. An initial range of 
1.25U - 400U indicated that ~5 - 150U/ml would result in a linear curve which was 
subsequently confirmed; by testing further concentrations of the standard, to be 
linear between the range 7.78 -133U/ml (Figure 3-9).
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Figure 3-9 Linear range of the VSV/PK15 bioassay.
PolFNal standards ranging from 400U to 1.25U (A) or 133U to 7.78U (B) were used to treat 
PK15 cells in a dose response test assay. The level of viable cells was quantified via 
colorimetric analysis of eluted crystal violet stain from viable cells read at 540 nm. Data is a 
representation of values obtained from five different wells. Error bars represent standard 
error of mean values.
To determine the repeatability of the VSV/PK15 assay, a 1:1.5 serial dilution of
PolFNal standards was used to treat cells on three different plates for 24hours
before infecting with VSV for a further 24hours. The corresponding activity of the
samples was extrapolated from the standard curve and the coefficient of variation on
each plate was used to determine the intra- and inter-plate variation. The intra plate
139
Chp 3. Cloning and expressing PolFNa
coefficient of variation of the tested standards ranged from 16.93-19.98% while the 
inter-plate coefficient of variation of the assay was 18.86%.
3.4.3 Anti-VSV activity of expressed PolFNa on PKlScells
With a defined infectious virus concentration and a defined PolFNal standard, 
the antiviral activity of the purified expressed recombinant rPolFNa subtype was 
evaluated using a two-step approach. We applied this strategy because the large 
number of samples would not permit a titration of all recombinant proteins on one 
plate and therefore limited the number of biological repeats that could be performed 
in parallel on a 96 well-plate.
Initially 2-fold serial dilutions of all recombinant proteins were prepared in 
MEM/FBS starting at a 1:750 dilution up to a 1:960000. Each dilution was then tested 
on a VSV/PK15 biological activity assay (as described in 2.5.2) alongside the PolFNal 
standard (200-11.706U); prepared in quadruplets, across two 96-well plates.
140
Chp 3. Cloning and expressing PolFNa
PolFNal Standard
0.6
y = 0.0014x + 0.2196
► Upper lim it
► Lower lim it
0.2
0.1
0.0
0 50 100 150 200 250
IFN U/ml
Figure 3-10 A PolFNal standard curve from the anti-VSV bioactivity of 17 recombinant 
rPolFNa proteins
Data provided is an average of four repeat wells.
The OD readings were plotted against concentration of the PolFNal standard 
and a linear regression on the standard curve revealed the lower and upper lim it of 
the assay (Figure 3-10); therefore the detection O.D. range of the assay was 
considered as 0.49- 0.25.
The O.D values of the individual rPolFNa sample dilutions that fell w ith in this 
detection range were therefore considered, and used in preparing dilutions to 
further evaluate the bioactivity of each rPolFNa protein sample, a summary of these 
dilutions is shown in Table 3-11 with the equivalent O.D value.
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Table 3-11 Summary of rPolFNa subtype dilutions suitable for VSV bioactivity 
quantification.
The table show the minimum dilution that resulted in a OD within the linear range of the 
VSV/PK15 assay and the O.D value obtained by dilution. N/A referred to values that were 
outside of the linear range of the assay.
rPolFNa Minimum Dilution within 
detection range of bioassay
O.D value
2 >96000 N/A
3 12000 0.495
4 48000 0.464
6 >96000 N/A
8 96000 0.373
9 24000 0.499
10 24000 0.425
12 >96000 N/A
13 48000 0.371
14 48000 0.377
15 750 N/A
16 48000 0.447
17 96000 0.424
Further dilutions of protein were then prepared, using the dilution values 
identified in Table 3-11 as a guide to estimate dilutions that would fall within the 
range of the assay. These dilutions were then tested to determine the bioactivity 
with a greater degree of certainty (Table 3-12).
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Table 3-12 Anti-VSV bioactivity assay of PolFNa subtypes.
Table shows the estimated dilution tested to quantify the bioactivity of polFNa subtypes, the 
O.D values were obtained after colorimetric analysis of eluted crystal violet stain from viable 
cells and the corresponding anti-VSV activity determined by interpolation from the polFNal 
standard curve
Dilution factor rPolFNa O.D Replicates Av. IFN U/ml
125000 2 0.4273 0.4505 0.4791 1.93E+07
250000 2 0.4412 0.4304 0.4338 3.57E+07
2500000 2 0.2436 0.25 0.2466 4.34E+07
15000 3 0.3443 0.2999 0.2811 8.77E+05
100000 4 0.3169 0.3172 0.2993 7.00E+06
28 5 0.2592 0.2484 0.2349 7.64E+02
125000 6 0.5074 0.4604 0.4907 2.21E+07
250000 6 0.4508 0.4798 0.4661 4.08E+07
2500000 6 0.238 0.2269 0.2403 2.39E+07
24 7 0.2519 0.2627 0.245 7.26E+02
100000 8 0.4077 0.3219 0.3255 8.73E+06
25000 9 0.3749 0.3653 0.3572 2.42E+06
50000 10 0.2916 0.2764 0.2898 2.17E+06
24 11 0.2537 0.2719 0.2631 8.42E+02
125000 12 0.4582 0.4269 0.4236 1.80E+07
250000 12 0.3845 0.3506 0.3285 2.23E+O7
2500000 12 0.21 0.229 0.203 1.12E+07
50000 13 0.4233 0.4229 0.409 6.59E+06
50000 14 0.437 0.3979 0.394 5.43E+06
400 15 0.3594 0.3426 0.3596 3.24E+04
800 15 0.2826 0.2883 0.2788 3.65E+O4
2500 15 0.2341 0.2482 0.2403 3.36E+O4
70000 16 0.3767 0.2991 0.307 4.74E+O6
125000 17 0.4192 0.3128 0.3449 1.04E+07
250000 17 0.3393 0.2898 0.244 1.23E+07
Each prepared dilution was then used to estimate the biological activity of the 
rPolFNa subtypes. Dilutions were assayed in triplicate alongside PolFNal standard 
(200U - 11.7U; prepared in quadruplets). The assay was performed across two 
different plates with a set of standards on each plate to give a more accurate and
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repeatable estimate of the antiviral activity. The anti-VSV bioactivity was then 
calculated for each protein by computing from the standard using the equation 
y=mx+C where
y represents the equivalent O.D value for unknown rPolFNa concentration 
m the gradient of the PolFNal standard linear regression, 
c the y intercept of the linear regression and 
x the unknown equivalent U/ml
The corresponding antiviral activity of each rPolFNa protein was interpolated 
from the standard curve.
All PolFNa proteins were active against VSV on PKlScells with preparations of 
rPolFNaS, rPolFNa 7, rPolFNa 11 and rPolFNa 15 having the least activity/ml (Figure 
3-11). The intra-plate variation of all tested rPolFNa samples was quite low; with a 
coefficient of variation of 8.66%, while the inter-plate variation tested on an aliquot 
of rPolFNalS across three different plates gave a coefficient of variation of 8.36%, 
this low variation provided confidence in the validity of the result obtained for the 
assay.
Due to some technical setback, the activity of the expressed rPolFNal was tested 
at a later day. The protein was found to be biologically active against VSV, with a 
value of 1.31E+07 U/ml.
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Using the biological activity and concentration of each protein as determined by 
PolFNal ELISA (Table 3-9), the specific activity in U/ng was determined (Table 3-13). 
This specific activity is the biological/anti-VSV activity of one nanogram of the 
protein.
Specific activity (U/ng) =  Biological activity (u/ml)
Protein concentration(ng/ml)
From this it appears that amongst all 17 rPolFNa proteins, rPolFNa2, a6 and alO  
proteins have the highest anti-VSV activity per protein molecule while rPolFNaS, a7, 
a l l  and a l5  exhibited lower anti-VSV activity per molecule of protein.
Table 3-13 Summary of biological and specific activity of rPolFNa 1-17
Short rPolFNa subtypes are highlighted
rPolFNa Gene
length
Anti-VSV
bioactivity
(U/ml)
protein
concentration
(Hg/ml)
Specific
activity
(U/ng)
Amount of protein 
required for 200U 
(ng/200U)
1 Short 1.31E+07 30.80 425.0 0.47
2 Short 2.74E+07 27.20 1010.0 0.20
3 Short 6.67E+05 27.90 23.9 8.37
4 Long 5.21E+06 45.50 115.0 1.74
5 Long 1.56E+03 3.92 0.4 502.51
6 Long 3.04E+07 29.80 1020.0 0.20
7 Short 6.30E+02 4.49 0.1 1428.57
8 Long 7.20E+06 54.80 131.0 1.53
9 Long 1.90E+06 40.50 46.9 4.26
10 Short 1.04E+06 0.02 43700.0 0.00
11 Short 1.38E+04 1.06 13.0 15.38
12 Long 1.71E+07 52.00 329.0 0.61
13 Long 4.57E+06 21.50 213.0 0.94
14 Long 4.64E+06 13.20 352.0 0.57
15 Long 3.05E+04 4.36 7.0 28.57
16 Long 2.00E+06 17.30 116.0 1.72
17 Short 8.19E+06 20.00 410.0 0.49
146
Chp 3. Cloning and expressing PolFNa
3.5 Discussion
In this chapter, five of the seventeen prPolFNa; clone 2e, clones, clone 5, clone 6 
and clone 8d, subtypes were successfully cloned by amplification from porcine DNA, 
the other twelve subtype were generated synthetically. These recombinant subtypes 
were expressed in mammalian cells, and, they were found to be biologically active 
when tested on a PK15/VSV antiviral activity assay.
3.5.1 Cloning of seventeen polFNa subtypes
These five cloned genes representing prPolFNal, prPolFNalG, prPolFNalB, 
prPolFNaS and prPolFNal! respectively, bore 98-100% identity with currently 
available sequences on GenBank. Nucleotide analysis of these cloned subtypes 
revealed that these changes were not all derived from the primers used, except for 
prPolFNalG which had one change at the primer site. This therefore pointed to the 
possibility of PCR introduced errors. Alternatively this result could be due to 
differences in the gene sequences in the genomic DNA of the large white/landrace 
cross breed of pig compared to the Duroc breed that was used to generate the 
S.scrofa 10.2 genome sequence. The differences potentially introduced during 
cloning; that may influence the antiviral and specific activities of the cloned 
subtypes, resulted in the commercial synthesis of the remaining twelve prPolFNa 
subtypes. Sequence analysis of these subtypes with the S.scrofa 10.2 genome 
showed a 100% similarity at both nucleotide and amino acid level confirming the 
successful cloning of these seventeen subtypes.
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Amino-acid alignment of the seventeen subtypes also revealed that four of the 
subtypes; prPolFNa?, a9, a lO  and a l l ,  possess a putative /V-glycosylation site (Asn- 
X-Ser/Thr) at position 101 which correlates to one of the N-glycosylation sites in 
murinelFNalS. In mice, this glycosylation has been suggested to enhance protein 
stability in vivo and is less likely to influence the IFN-receptor binding affinity or 
correlate with biological activity (van Pesch et al, 2004; van Pesch & Michiels, 2003a). 
This region might not, therefore, influence the biological activity in pigs either, 
although further studies would be needed to confirm this.
The results from the western blot data of these expressed proteins also showed 
that rPolFNa9 (a long subtype) migrated more slowly when compared to other 
longer subtypes (Figure 3-8). This slower migration might be due to the presence of 
N-linked sugars as its calculated molecular mass did not differ significantly to other 
long subtypes (Table 3-9) (Garfin, 2003). Three other subtypes rPolFNa?, a lO  and 
a l l  (with short gene length), were also seen to possess these N-linked sugars, but 
there was no clear evidence of this in their migration on the western blot. From the 
calculated molecular weight of the subtypes, rPolFNa2, rPolFNalG, rPolFNalS, 
rPolFNaS and rPolFNa!2 appeared to be much bigger than the other subtypes with 
similar gene lengths. This was due to the extra nucleotide bases introduced at the 3' 
end of the subtypes during cloning into the pcDNA3.1/V5-His TOPO TA vector, these 
nucleotides resulted in a six amino acid protein; KGNSA with a predicted molecular 
weight of 0.48kDa.
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3.5.2 Characterization of the seventeen polFNa subtypes
To further characterise these subtypes in relation to the observed anti-viral 
activity, sequence data obtained from all seventeen rpolFNa subtypes were 
compared with the data obtained for human IFNa2b (hulFNaZb) from other studies. 
Structural analysis of the hulFNa2 mature peptide (ref|NIVI_000605.3), revealed 
that, mutation in amino acid residues; Leu30, Lys31, Arg33, His34, Phe36, Argl20, 
Lysl21, G lnl24, Tyrl22, Tyrl29, Lysl31, and G lul32 tend to change the biological 
activity of the protein (Radhakrishnan et al, 1996). It has also been shown by Gamble 
et al that a change in Arg33 to Lys or Ala reduces the activity by 500 and 2500 fold 
respectively (Gamble et al, 1986). In another study, a hu lFN al/a2 hybrid molecule 
which differs from hulFNa2b at positions Arg22 to Ser, Leu26 to Pro, and Phe27 to 
Ser had a 50-fold reduction in biological activity (Weber et al, 1987). Also in human 
cells, studies showed that hulFN-a2b had a reduced activity when compared to IFNal 
as a result of changes in residues at Ser68, Thr79, and Tyr85 of hulFN-a2b, although 
these changes also increased the activity in murine cells (Rehberg et al, 1982). In this 
study, when compared to the seventeen prPolFNa subtypes (Figure 3-6), not all 
these regions were found to be conserved, but they might inform on possible 
mutational sites for further studies on improving the antiviral activities of polFNa 
subtypes.
As shown on the alignment, five putative alpha helices have been identified, of 
which the AB1 loop (residues 22 to 33) was suggested as the region most sensitive to 
amino-acid changes and helix C is suggested to be involved in binding to IFNAR-1 
(Valenzuela et al, 1985). These residues identified as involved in receptor binding
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and biological activity are Arg22, Leu26, Phe27, Leu30, Lys31, Arg33 and His34 
located on the AB loop, Ser68 located on the bend in helix B, Thr79, Lys83, Tyr85, 
and Tyr89, located on the bend in helices C, Argl20, Lysl21, Gin 124, Lysl31, and 
Glul32 located on helix D and Argl44, and G lul46 located on helix E (Radhakrishnan 
et al, 1996).
From the alignment done in this study, it was shown that some of these hulFNa 
residues differ from those in the polFNa subtypes. As there has been evidence of 
cross species activity of IFN; making IFNs less restrictive in species specificity (Carter 
et al, 1979; Gresser et al, 1974), the observed residue difference may suggest that 
these rpolFNa types may differ in antiviral activities from the human IFNa types. The 
alignment also revealed that some of these mentioned residues although differ to 
the HulFNcx2b, they are conserved among the seventeen polFNa subtypes; hence 
they most likely do not contribute to any polFNa differential anti-VSV activity 
observed. Further work on site directed mutagenesis of these polFNa subtypes can 
identify other residues involved in influencing the biological activity of these 
proteins.
3.5.3 Biological activity and protein concentration of expressed polFNa subtypes
The VSV/PK15 bioassay also revealed that these rPolFNa subtypes possess a wide 
variation in terms of their anti-viral activity but with no clear evidence of a 
relationship between biological assay and protein concentration. For instance, 
rPolFNalO, which was highly active against VSV had a very low protein 
concentration; almost not detected using the polFNa ELISA. This may suggest that
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the polFNa monoclonal antibodies used in this ELISA did not recognise some of the 
epitopes on these purified protein subtypes. These mAbs were designed by Lefevre 
et. al. against the complete rpolFNal (Lefevre et al, 1990) and used by Diaz de Arce 
and colleagues for the quantification of serum samples (Diaz de Arce et al, 1992). In 
his study, not all the polFNa positive samples were detected by the ELISA, raising the 
possibility that some subtypes were not detected. Future work on the design of 
subtype specific mAbs would help towards the proper quantification of these 
different polFNa protein subtypes by ELISA.
The intra plate coefficient of variance from the VSV/PK15 bioassay initially ranged 
from 16.93-19.98% (of highly concentrated samples and samples of low 
concentration respectively), while the inter-plate coefficient of variance was 18.86%. 
However, as this is a biological assay, it should be pointed out that several variables, 
ranging from the non-uniformity of the plates, pippetting error, to the cell staining 
procedure could have influenced this. However, after further repeats, the intra-plate 
variation of the tested rPolFNa samples was 8.66%, while the inter-plate variation 
tested on one of the subtypes; rPolFNalS was 8.36%. This low variation provided 
confidence in the validity of the results obtained from the assay, and similar levels 
have been recorded in other type I bioassays (Canosi et al, 1996; François et al,
2005).
Some studies have also shown that deletion of residues 1-4 , 102-111, or 156 - 
165 or substitution of residues Phe47, Gln48, or Gln61 does not affect the biological 
activity of hulFNa2b (Levy et al, 1981; Valenzuela et al, 1985). This doesn't support 
suggestions by Cheng et. al. 2006 who related antiviral activities with the C-terminal
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COOH residues at regions 159-166 (Cheng et al, 2006) and may, therefore, imply that 
this region is not a defining property for antiviral activity. For instance rPolFNalO; a 
short subtype displayed a 43 fold difference in specific activity in comparison to 
rpolFNa6 a long type. Similar results have also been seen with humlFNa2b, where 
deletion of this region showed no effect on antiviral activity (Radhakrishnan et al, 
1996).
3.6 Conclusion
Following the successful expression of these 17 rpolFNa types, in silico analysis of 
the predicted rpolFNa and humlFNa2b amino acid sequences revealed regions that 
might influence protein stability, receptor binding and biological activity. The analysis 
revealed that the rpolFNa subtypes are conserved in these regions and may not 
influence these properties, but the fact that IFNa subtypes tend to bind with varying 
affinity to the IFNAR (Kumaran et al, 2007a) might suggest that other residues in the 
receptor binding region might influence and result in varying antiviral activity.
Type I IFNs in general have been expressed in different expression systems, but 
to ensure proper folding, correct post-translational modification as well as efficient 
protein secretion, CHO-mammalian cells were chosen as the preferred expression 
system(Hossler et al, 2009). The disadvantage to this as seen following expression 
was the low protein yield observed in most of the subtypes. This limited 
experimental analysis due to insufficient amounts.
According to studies by Cheng et al, short polFNa subtypes are suggested to have 
higher antiviral activity; in this chapter it was shown that the eight amino acid COOH
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hydrophobic tail has no correlation with activity as measured by the VSV/PK15 
bioassay. (Cheng et al, 2006; Slutzki et al, 2006). The antiviral activities of rpolFNa 
subtypes when tested against VSV on a PK15 showed varying specific and antiviral 
activities, this clearly supports the differential activities of polFNa subtypes as 
suggested in other studies (Sang et al, 2010). Finally from the bioassay, rPolFNalO 
appears to be the most active protein against VSV.
Now that these subtypes were confirmed to be biologically active, they were 
tested against CSFV to determine any in vitro antiviral effect.
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CHAPTER 4
PROTECTIVE EFFECT OF rPolFNa PRE-TREATMENT ON 
CSFV INFECTED MONOCYTES
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4.1 Rationale
Monocytes play important roles in both the innate and adaptive immune 
responses to viruses such as CSFV, a virus which modulates the immune system of 
the infected host. This virus establishes a productive infection by primarily targeting 
myeloid dendritic cells, endothelial cells, epithelial cells, and monocytic cells, where 
it replicates efficiently causing persistent viral infection (Knoetig et al, 1999; 
Trautwein, 1988). Within these cells, CSFV manipulates the host-cell immune 
defence resulting in efficient non-cytopathic viral replication without inducing IFN 
secretion (Bensaude et al, 2004; Carrasco et al, 2001; Ruggli et al, 2003).
Despite this, a high IFNa level is detected in the serum of infected animals 
following CSFV infection (Husser et al, 2012) which may be due to the stimulation of 
natural interferon producing cells also called plasmacytoid dendritic cells, within the 
infected pig (Balmelli et al, 2005). This IFNa production is suggested to be elevated in 
more virulent CSFV strains and provides no apparent protection against infection by 
virulent strains (Ruggli et al, 2009; Summerfield et al, 2006)
PolFNa is known to possess protective activities against viruses which has been 
studied for several viruses including vesicular stomatitis virus (VSV) (Horisberger, 
1992), porcine reproductive and respiratory syndrome virus (PRRSV) (Albina et al, 
1998), FMDV (Chinsangaram et al, 2001) as well as in CSFV (where one recombinant 
PolFNal was tested on PKlScells) (Xia et al, 2005b). In this chapter, the differential 
antiviral activity of the different individual rPolFNa subtypes (cloned/expressed as 
described in chapter 3) were further examined, in order to determine subtypes 
which provided the best protection against CSFV infection in vitro. Porcine
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monocytes were chosen, as these cells, upon CSFV infection do not produce any IFNa 
(Ruggli et al, 2003), hence the effect of the exogenous rPolFNa could be investigated.
4.2 Infectivity of CSFV strains in porcine monocytes
Strains of CSFV vary in virulence with no well-defined genetic element identified 
responsible. These strains also vary in the ability to infect different cell populations 
(Mittelholzer et al, 2000; Van Gennip et al, 2004). We therefore examined the 
infectivity of two virulent CSFV strains; Alfort 187 and Brescia on freshly isolated 
porcine monocytes.
Porcine monocytes were cultured for 24hrs at a density of lx l0 6cells/ml. 
Cultured monocytes were either left uninfected or infected with either CSFV 
Alfortl87 or Brescia at an MOI of 7 for a further 24hrs. The percentage of CSFV virus 
infected cells was assayed using flow cytometry by gating on the population of viable 
cells that stained positive with the 22 antibody (as described in 2.6.4.1, Figure 4-1).
The mean percentage of infected cells from three independent experiments as 
displayed in Figure 4-2 revealed that infection with CSFV Alfort 187 produced a 
significantly higher infection (P < 0.0001)when compared to Brescia incubated cells. 
Hence, CSFV Alfort 187 was chosen as the strain for further assays.
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Figure 4-1 CSFV infection of purified CD14+ porcine monocytes.
Magnetically isolated CD14+ porcine Mo cultured for 24hrs were either left uninfected; 
incubated with culture media alone or infected with CSFV strain; Alfort 187 or Brescia for 
24hrs. (A) Plot of forward side scatter height FSC-H versus forward side scatter area FSC-A 
which was used to gate the duplex cells from the target monocyte population. (B) Plot of 
forward side scatter area/FSC-A (cell size) versus side scatter area/SSC-A (cell granularity) 
which was used to exclude debris from the Mo population. (C) Mo were then stained with 
fixable violet live-dead stain to exclude the live from the dead monocyte population. 
Monocytes infected with (D) CSFV Alfort 187 , (E) CSFV Brescia or (F) left uninfected were 
stained with a primary antibody; WH303 mAb specific for the CSFV glycoprotein E2 followed 
by a secondary antibody; APC conjugated anti-mouse IgGl secondary antibody. The 
percentage of positively stained infected cells (#) is shown in each gate.
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Figure 4-2 CSFV Alfort 187 has a higher virulence on porcine monocytes when compared 
with CSFV Brescia.
Porcine monocytes were either left uninfected or infected with CSFV Alfort 187 or Brescia 
for 24hrs, harvested and stained with WH303; an antibody specific for CSFV viral E2 protein. 
The infected cells were analysed on a FCM by gating on the viable population that stains 
positive for E2 antibody. The data are representative of three independent experiments. 
****(P < 0.0001), represents the level of significance between both CSFV strains, error bars 
represent the standard deviation of mean values.
4.3 Effect of polFNa treatment of monocytes preceding or following on 
CSFV infection in vitro.
Porcine IFNa has been identified as a major systemic cytokine induced during the 
acute stages of CSFV infection. This cytokine can be detected in the serum of 
infected pigs even before the onset of viremia (Jamin et al, 2008; Summerfield et al,
2006).
In order to understand the in vitro antiviral effect of the different expressed 
PolFNa's, a preliminary study using an in vitro infection of monocytes as a model was
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designed to assess the antiviral effect of the commercially available porcine IFNa 
before and after CSFV infection.
A protective effect has also been observed with West Nile virus with as little as 
10U/ml of IFN (Keller et al, 2006). Therefore for this study, monocytes isolated from 
three different pigs were treated with commercial PolFNa (20U/ml) for 24hrs 
followed by infection with CSFV at an MOI of 5 for 2hrs before replacing the media 
with fresh culture media. After a further 24hr in culture, the anti-viral effect of 
polFNa treatment on the infected monocytes was assessed. Using flow cytometry 
the percent infected cells and the amount of 22 protein expressed within infected 
cells was assessed, and by RT-PCR the amount of CSFV viral RNA secreted into the 
culture supernatant following infection was measured. For the post-treatment study, 
monocytes were infected for 2hrs before replacing the infected media with media 
containing commercial PolFNa (20U/ml) for a further 24hrs in culture.
The percentage of infected cells was determined on the flow cytometer by 
drawing a tight gate around the cell population that stained positive with the 22 
antibody.
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Figure 4-3 Dot plot of pre and post-treatment assay on monocytes with 20U of commercial 
PolFNa.
Magnetically isolated CD14+ porcine Mo were either pre-treated for 24hrs and infected with 
CSFV Alfort 187 or post-treated with 20U/ml IFNa following infection with CSFV Alfort 187 
for 24hrs. Monocytes were harvested and stained with fixable violet live-dead stain to 
exclude the live from the dead monocyte population before being stained with a primary 
antibody; WH303 mAb specific for the CSFV glycoprotein E2 followed by a secondary 
antibody; APC conjugated anti-mouse IgGl secondary antibody (BD Biosciences). Profiles 
show representative WH303-APC versus forward scatter; gated population indicate the 
proportion of CSFV infected cells.
Treatment of monocytes w ith PolFNa for 24hrs prior to CSFV infection resulted in 
a statistically significant reduction in the percentage of CSFV infected cells (p=0.0384) 
as well as a reduction in the levels of CSFV RNA in the cell culture supernatants 
(p=0.0149). Although not statistically significant (p>0.05) there was an observed 
reduction in the amount of viral E2 protein expressed within infected cells as 
measured by the mean fluorescence intensity of the infected cells (Figure 4-4) 
compared to the untreated control.
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Figure 4-4 Reduction of CSFV infected cells pre-treated with PolFNa
Treatment of monocytes with 20U/ml IFNa prior to CSFV infection resulted in a reduction in 
the percentage of CSFV infected cells (A) and a reduction in the levels of CSFV viral RNA in 
the culture supernatant (B), as well as a reduction in the level of E2 protein (measured as the 
mean fluorescence intensity) (C) in the cytosol after 24hr culture. N=3 for separate 
experiments. The P-value represents the level of significance compared to the untreated 
control, error bars representing the standard deviation of mean values.
When cells were treated following infection with CSFV (post-treatment), a 
significant reduction in the percentage of infected cells (P=0.0021) and in the levels 
of CSFV RNA in culture (p=0.0485) was observed with 20U/ml of PolFNa when 
compared to untreated controls. However, this post-treatment did not result in a
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statistically significant reduction in the level of viral E2 protein in the cytosol, 
probably due to variations between experiments.
Figure 4-5 Reduction of CSFV infected cells post-treated with IFNa.
Post-treatment of monocytes with 20U/ml IFNa resulted in a significant reduction in the 
percent of CSFV infected cells (A), reduction in the levels of CSFV viral RNA in culture 
supernatant (B), and a non significant reduction in the level of 22 protein (measured as the 
mean fluorescence intensity) in the cytosol (C)after 24hr culture. N=3 for separate 
experiments. P-value represents the level of significance compared to the untreated control, 
error bars representing the standard deviation of mean values.
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Although both pre and post-treatment of monocytes with the commercial 
polFNa conferred protection against CSFV, when comparing the level of E2 
expression between both assays, pre-treatment with PolFNa appeared to confer 
better protection against CSFV in vitro. Since the aim of this study was to assess the 
protective/antiviral effect conferred by PolFNa subtypes before the onset of CSFV 
infection, we proceeded with further study on the dose effect of pre-treating 
monocytes with commercial PolFNa protein.
Monocytes were isolated from three different pigs and pre-treated for 24hrs with 
four different concentrations of PolFNa; 200U/ml, 100U/ml, 50U/ml and 25U/ml 
followed by infection for a further 24hrs with CSFV Alfort 187 at a much higher MOI 
of 7 to achieve a higher and much better level of infection. The percentage of CSFV 
infected cells were assayed by flow cytometry.
As different levels of infection were attained across experiments, variation was 
corrected by setting a baseline level of infection with the untreated infected control 
and calculating the increase in protection following treatment (as shown below).
„ . Infection in untreated control -Infection in treated sample
% Protection = ------------------------------------------------------------------------------------ —  x 100%
Infection in untreated control
Results from these experiments showed a gradual increase in protection with an 
increase in amount of PolFNa. This reduction was significant at 100U/ml and 
200U/ml of PolFNa, unlike previous treatment assays with significant protection 
observed at 20U/ml.
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Figure 4-6 Increase in protection of infected monocytes following pre-treatment with 
PolFNa.
A 24hr pre-treatment of monocytes with 25U/ml, 50U/ml, 100U/ml and 200U/ml of PolFNa 
resulted in a reduction in the proportion of CSFV infected cells after a 24hr infection. N=3 
(individual pigs plotted), an average of 85% infection was observed in the untreated controls 
across the three experiments. P-value represents the level of significance between 
treatment and untreated infected where **= P<0.01, ****=p<0.0001, error bars 
representing the standard deviation of mean values.
4.4  The anti-CSFV effect o f seventeen rPolFNa subtypes on m onocytes
Phylogenetic analysis of the seventeen PolFNa subtypes revealed some 
variations among the different subtypes, with suggestions that the subtypes bearing 
the C-terminal deletion may be less active than the long subtype. The potential 
antiviral activities of the expressed and quantified 17rPolFNa's generated in this 
study against CSFV infection was determined.
Since treatm ent of porcine monocytes with 200U/ml of a commercial PolFNa 
conferred protection against CSFV infection in vitro, the anti-CSFV effect conferred
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by the expressed rPolFNa subtypes was investigated by pre-treating monocytes with 
200U/ml of each cytokine for 24hrs. The effect of each rPolFNa treatment on 
infected monocytes was assessed from analyzing the percentage of infected cells 
within the gated E2 positively stained monocytes (CSFV-infected cells) using flow 
cytometry (FCM) with a gating strategy as displayed in Figure 4-7 and Figure 4-8. The 
percentage of CSFV infected cells and the percentage of protection was determined 
as described in section 4.3.
Results from the pre-treatment assay revealed that the different rPolFNa 
conferred different levels of protection against CSFV with rPolFNal, -2, -3, -13 and - 
16 showing the least protection; less than 20% of cells were protected (Figure 4-8 
and Figure 4-9), while rPolFNcxS, -cx9 and -a !2  conferred the most protection against 
CSFV. Recombinant rPolFNa? was not included in this assay due to poor expression 
and therefore insufficient quantities of protein. As a preliminary study, only one pig 
was used for this analysis and statistical analysis was performed on technical 
replicates.
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Figure 4-7 Gating strategy for assessing the protective effect of the different rPolFNa 
subtypes on CSFV infection.
Porcine monocytes were harvested and stained with fixable violet live-dead stain to exclude 
the live from the dead monocyte population. Forward side scatter area FSC-A versus forward 
side scatter height FSC-H was used to gate the duplex cells from the target monocyte 
population (A). Side scatter area/SSC-A (cell granularity) versus forward side scatter 
area/FSC-A (cell size) was used to exclude the debris from the Mo population (B) while the 
fixable violet live-dead stain was used to exclude the live from the dead monocytes (C). 
Monocytes were either uninfected and cultured for 48hrs and stained with primary 
antibodies (D), untreated for 24hrs and infected with CSFV Alfort 187 at an MOI of 7 for 
24hours and then stained with Anti-Mouse IgGl Isotype control mAb (E) or WH303 mAb 
specific for the CSFV glycoprotein E2 (F). Representative dot plots from one pig are 
displayed.
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Figure 4-8. Different rPolFNa subtypes confer varying levels of protection against CSFV
Purified CD14+monocytes were pre-treated for 24hrs with 200U/ml of specific rPolFNa 
subtype and infected for 24hrs with CSFV Alfortl87 at an MOI of 7. Monocytes were 
harvested and stained with fixable violet live-dead stain to exclude the live from the dead 
monocyte population before being stained with a primary antibody; WH303 mAb specific for 
the CSFV glycoprotein E2, followed by a secondary antibody; APC (Allophycocyanin) 
conjugated anti-mouse IgGl secondary antibody (BD Biosciences).Profiles show 
representative FSC-A versus WH303-APC while the gated population indicate the percentage 
of CSFV infected cells which varied with the different polFNa subtypes. Gates drawn were 
based on unstained cells and isotype IgGl control samples (as shown in Fig 4-7).
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The anti-CSFV effect conferred by pre-treatment with 200U/ml of each subtype is 
shown in Table 4-1. The percentage of protection obtained from each rPolFNa 
subtype treatment was grouped into three categories for this experiment.
I. Protection above 40% was considered as highly active against CSFV
II. A range between 20% and 39% protection was considered as medium  
activity against CSFV
III. While protection below 20% was considered as having a low activity 
against CSFV
The data also revealed that at 200U/m l/ most of the subtypes with shorter gene 
length; C-terminal deletion appeared to have a low or medium anti-CSFV activity 
when compared to the untreated control.
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Table 4-1 Analysis of the anti-CSFV effect conferred following pre-treatment of porcine 
monocytes with 200U/ml of rpolFNa.
Subtypes with short gene lengths are highlighted red.
Subtype
Gene
length
Average
percentage
protection
Level of activity 
against CSFV at 
200U/m l
rPolFNal Short 17 Low activity
rPolFNa2 Short 16 Low activity
rPolFNa3 Short 16 Low activity
rPolFNa4 Long 30 Medium activity
rPolFNaS Long 39 Medium activity
rPolFNaG Long 32 Medium activity
rPolFNaS Long 35 Medium activity
rPolFNa9 Long 56 High activity
rPolFNalO Short 25 Medium activity
rP o lFN all Short 21 Medium activity
rPolFNal2 Long 54 High activity
rPolFNalS Long 17 Low activity
rPolFNaM Long 26 Medium activity
rPolFNalS Long 30 Medium activity
rPolFNalG Long 18 Low activity
rPolFNal7 Short 29 Medium activity
As shown in this experiment, rPolFNa9 and a !2  conferred the greatest antiviral 
activity, with a medium level of protection provided by rPolFNcx4, a5, a6, a8, alO, 
a l l ,  a l4 , a l5  and a !7  while a low level of activity was conferred by rPolFNal, a2, 
a3, a !3  and a l6 . To confirm the anti-CSFV activity of the rPolFNa subtypes, six 
representative rPolFNa types were selected; rPolFNal, a2, a4, a l4 , a9 and a l2 , to 
include the subtypes with high, medium and low anti-CSFV activity. Concentrations 
of 200U/ml and 400U/m l of the selected subtypes were used in a 24hr pre-treatment
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assay on CSFV infected porcine monocytes. The level of CSFV infected cells was 
assayed on a FCM by gating the population of viable E2 positive stained cells.
After pre-treatment with 200U/ml of the different subtypes, rPolFNal and a2  
(with C-terminal deletions) conferred the least antiviral effect amongst the six 
PolFNa subtypes tested (Figure 4-10). An increase in the amount of CSFV protected 
cells was also observed with an increase in the concentration of rPolFNa from  
200U/ml to 400U/ml. At this concentration; 40011/ml, the level of protection 
conferred by all subtypes was significant when compared to the untreated infected 
cells. One pig was used for this assay and the statistical analysis was performed on 
technical replicates.
□  200U/ml
400U/ml100n
c 80- o ****
60-
* * * *
* * * *
40- 
w o
as 20-
**
0>
PolFNa subtype
Figure 4-10 Differential effect of selected high medium and low activity rpolFNa subtypes 
against CSFV infection
Cells that were either untreated-uninfected or untreated-infected served as controls. The 
percentage of CSFV infected monocytes was assayed for by FCM by gating on the population 
of viable E2 positively stained monocytes.. N=1 experiment performed in triplicates. P-value 
represents the level of significance between the subtypes and untreated control, *=P<0.05, 
**=P<0.01, ****=p<0.0001 One-way ANOVA.
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4.4.1 Quality control testing of selected PolFNa subtypes
To confirm that the higher anti-CSFV activity observed for porcine monocytes with 
PolFNaS and a l2  is consistent across different PolFNa protein batches and therefore 
reduce the probability of errors due to incorrect standardization of protein samples, new 
protein preparations of six selected PolFNa subtypes were prepared.
The polFNa subtype panel was selected based on three identified criteria (1) the 
subtype gene length (2) the subtype anti-CSFV activity, and (3) phylogenetic relatedness.
A phylogenetic relationship between the coding region of the previously expressed 
seventeen PolFNa subtypes was inferred by means of the maximum likelihood method 
using MEGA 5 sequence analysis software (Tamura et al, 2011). The analysis was based 
on the JTT (Jones, Taylor, Thornton) model and also employed a discrete Gamma 
distribution to model evolutionary rate differences among sites (+G, five categories). 
Subtypes with C-terminal deletions are marked with ,* ,in the tree (Figure 4-11). Human 
IFNalpha orthologs (IFNal; NM_024013.2, IFNa2; NM_000605.3, IFNaG; NM_021002.2, 
IFNal3; NM_006900.3) were also included while rabbit IFN-omega (IFNs (0, S68999.1) 
and bovine-IFNco (AF238610.1) were all selected as outliers.
The results showed that all the polFNa subtypes are more closely related to each 
other and also lie within the same cluster than the human IFNa subtypes (Fig 4-11). The 
bovine and the rabbit IFNco cluster together separately from the IFNa subtypes. Within 
the PolFNa, two groups were identified (Group I and II), with PolFNalS and PolFNa9 
lying outside of these two main groups.
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As a result of this more distant relatedness, PolFNa9 was selected as one of the 
subtypes for further analysis. The other five subtypes were chosen from group I and II. 
Within group I, three subtypes without the C-terminal deletion; PolFNalZ, a l4  and otl6 
were chosen to represent subtypes with high, medium and low anti-CSFV activity, 
respectively. In group II subtypes with the C-terminal deletion; PolFNa2 and a l7 ,  
representing low and medium anti-CSFV activity types, respectively were selected.
173
Chp 4. Anti-CSFV effect of rPolFNcx
33
51
100
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29
63
45
92
99
36
37
47
100
100
rPolFNs-12.seq High activity
rPolFNa-14.seq Medium activity
rPo!FNa-6.seq
rPolFNa-7.seq*
rPolFNa-H.seq*
rPolFNa4.seq
rPolFNa-8,seq
rPolFNa-13.seq
rPolFNa-16 seg Low activity
rPolFNa-3.secf
rPolFNa-2.seq* Low activity
rPolFNa-lseq*
rPolFNa-S.seq
rPolFNa-10.seq*
rPolFNa-17,seq* Medium activity 
rPolFNa-15.seq — — — — ■
I
Group I
I
Group II
I
- rPolFNa-9.seq 
-Human IFNaS 
•Human IFNct2 
-Human IFNal 
■Human IFNa13 
■Bovine IFNw 
-Rabbit IFNw
High activity
Figure 4-11 PolFNa subtypes show close phylogenetic relatedness to some identified human 
orthologs than rabbit and bovine IFN-omega.
Phylogeny showing the inferred evolutionary history of the PolFNa family. The majority-rule 
consensus tree was inferred using topological model averaging, which is based on the most likely 
tree and the 4370 near-optimal trees found during the maximum-likelihood analysis (tested with 
1000 bootstrap replicates) in the MEGA5 sequence analysis software. The relative-likelihood 
scores (0 - 100%), on each branch, represent the level of confidence that one can have in these 
edges. represent subtypes with a C-terminal deletion. While selected subtypes for further 
analysis are underlined. The phylogenetic analysis is based on predicted amino acid sequences. 
GenBank accession numbers of PolFNs are listed in Table 2.8 of chapter 2. While the Genbank 
accession number for the outliners are: Human IFNalpha orthologs (IFNal; NM_024013.2, 
IFNa2; NM_000605.3, IFNa6; NM_021002.2, IFNal3; NM_006900.3), rabbit IFN-omega (IFNs to, 
S68999.1) and bovine-IFNco (AF238610.1).
174
Chp 4. Anti-CSFV effect of rPolFNa
The selected subtypes were expressed in CHO-kl cells, purified using the I MAC HIS 
magnetic column and quantified with the optimized PolFNcxl ELISA (2.2.4). Then, using 
the VSV/PK15 bioassay, the individual biological activities were determined as described 
in 2.5.2 (Table 4-2). The specific activity of the individual subtypes (i.e. the activity per 
nanogram of protein) was then determined from the PolFNcxl quantitative ELISA and the 
VSV/PK15 bioactivity assay.
Table 4-2 The biological activity, protein concentration and specific activity of selected 
rPolFNaZ, a9, a l2 , a l4 , a l6 , and <xl7 protein subtypes.
PK15 cells were treated with purified rPolFNal-17 proteins alongside PolFNal standards for 
24hrs and infected with VSV for a further 24hrs. The biological activity of each subtype was 
determined using the commercial PolFNal standard included in the assay. Protein 
concentrations of selected porcine IFNa subtypes were quantified by an optimised PolFNal 
ELISA as described in 2.4.4. Results shown is an average of three independent experiments.
PolFNa
Biological 
activity (U /m l)
Protein concentration 
Hg/ml
Specific activity 
U/ng
2 2.28E+06 21.4 1.07E+02
9 0.57E+06 6.24 9.20E+01
12 2.28E+06 10.40 2.18E+02
14 1.13E+06 4.76 2.37E+O2
16 0.87E+06 9.23 9.46E+01
17 0.86E+06 4.08 2.11E+02
The newly expressed and quantified proteins; rPolFNa2, a9, a l2 , a l4 , a !6 , and a l7
were tested on monocytes to confirm their anti-CSFV activity. As in previous assays,
200U/ml of each PolFNa protein was used to pre-treat monocytes. For comparison, cells
were treated alongside 200U/ml of the recombinant protein subtypes from the original
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batch. The 24hr treated cells were infected with CSFV Alfort 187 at an MOI of 7 for 
24hrs, after which the monocytes were harvested and analyzed by FCM. The effect of 
treatment with 200U/ml of the cytokine on infected monocytes was assessed from the 
percentage of infected cells determined by gating on monocytes that stained positive for 
22. The percentage of protection was determined as described in section 4.3.
Batch variation in the anti-CSFV activity exerted by the PolFNa proteins was 
observed, this was most evident with rPolFNa2 (Figure 4-12). There were also observed 
significant differences between the old and new protein batch of rPolFNa9; p=0.0088 
and rPolFNal2; p=0.0002 while the difference between the protein batches of rPolFNa2 
and rPolFNaM were more significant; pO.OOOl. Due to insufficient number of repeats, 
no statistical analysis was performed on data obtained from the old batch of rPolFNalG 
and rPolFNa!7 subtypes.
Within the old PolFNa protein batch, rPolFNaS and a l2  conferred the highest 
protection against CSFV of above 50% respectively while rPolFNaM, a !7 , a !6  and a2  
conferred lower protection (below 50%). In comparison to the un-treated control, two- 
way AN OVA data revealed that the anti-CSFV activity of rPolFNa9, a !2 , a l4  was highly 
statistically significant; pcO.OOOl, while data from rPolFNa2 showed a slight significant 
difference in protection when compared to the untreated control; p<0.05.
In contrast, the anti-CSFV activity observed following treatment with the new protein 
preparations revealed that; in order of best protection, rPolFNal2, a2 and a l4  offered
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the most protection of above 50%, while ctl7, a9 and cxl6 conferred protection of below 
50%. In comparison to the untreated control, the protective effect of all tested 
recombinant rPolFNa proteins was highly significant; p<0.0001. Comparing between 
subtypes, two-way ANOVA analysis revealed that most subtypes appeared to  be highly 
statistically significant from each other; p<0.0001 except for difference in anti-CSFV 
activity between rPolFNa: 2&14, 9&17, 16&17 with p values less than 0.01 and rPolFNa: 
2&12 with p values <0.001. The only non-significant difference in anti-CSFV activity was 
between rPolFNa9 and a !6 .
co
"43
O
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2
a.
* * * *100-1
•  Old Batch of polFNa 
■ New Batch of polFNa
* * * *
* * * *
60-
40-
20 -
Figure 4-12 Pre-treatment of porcine monocytes with 200U/ml of standardized rPolFNa2, a9, 
a l2 , a l4 , a l6 , and a l7  confers differential protection against CSFV infection.
Porcine monocytes were pre-treated with 200U/ml of standardized rPolFNa2, a9, a!2, a l4 , a!6 
and a!7 proteins for 24hrs and infected with CSFV Alfort at n MOI of 7 TCID50/cell. The level of 
protection was assayed for by FCM. N=3 for separate experiments. P-value represents the level 
of significance between the subtypes and untreated control, **=P<0.01, ***=P<0.001, 
* * * * =p<o oooi Two-way ANOVA.
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4.5 Assessing the activity of rPolFNa subtypes against CSFV over time
To assess the protective effect of rPolFNa at different times post-infection, three 
rPolFNa proteins (rPolFNal2, a l4  and a l7 )  were selected for analysis on the basis 
that they produced consistent high or medium levels of protection against CSFV 
(Figure 4-12).
To observe differences in the anti-CSFV protection conferred over time, 
monocytes were pre-treated with 200U/ml of rPolFNal2, a l4  and a l7  for Ohrs, 
18hrs, 24hrs and 48hrs. The cells were then infected with CSFV Alfort 187 at an MOI 
of 5 (to see what effect a lower level of virulence would have on protection over 
time). To compare the effect at different levels of infection and over a longer time 
frame, monocytes were also treated with 200U/ml of the same IFNa subtypes for 
Ohrs, 24hrs, 48hrs and 72hrs and then infected with CSFV at an MOI of 7. Cells were 
harvested as before and the percentage of monocytes protected from infection was 
determined by FCM analysis.
For cells infected with CSFV A lfortl87 at an MOI of 5, on average only 40% of 
cells were infected in the untreated controls. As a result, a high level of protection, 
>60%, was observed following pre-treatment with 200U/ml of these three IFN 
subtypes at all time points.
At time Ohrs there was no significant difference between the subtypes (Figure 4- 
13A), while at 18hrs, 24hrs and 48hrs (Figure 4-13B, C and D), the anti-CSFV activity 
offered by rPolFNal7 in comparison to rPolFNal2 gradually reduced (p<0.05, 
p<0.0001, pcO.OOOl). At 24hrs, this effect significantly increased with rPolFNaM  
being less protective in comparison to rPolFNa!2 (Figure 4-13C), while at 48hrs the
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largest significant difference was observed between all the three subtypes with 
rPolFNotl2 being the most active and rPolFNal? the least protective (Figure 4-13D) 
(p<0.0001). When comparing all the subtypes, it can be concluded that with the 
exception of rPolFNal2, the protection conferred by the subtypes gradually reduced 
overtime.
Also comparing between the different time points, there was no significant 
difference in protection from time Ohrs to 18hrs. A gradual decline at 24hrs was 
observed (p<0.05) while at 48hrs, a pronounced decrease in protection was observed 
(pcO.OOOl) (Figure 4-13E).
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In contrast, infection of monocytes with CSFV Alfort at an MOI of 7 resulted in a 
much higher level of infection with an average of 75% of cells becoming infected in 
the untreated controls. As a result of this better infection, an average of 50.6% 
protection was conferred by the three subtypes at Ohrs treatment (Figure 4-14A). 
The level of protection increased and peaked after 24hrs treatment, with a 
protection of 87%, 74% and 63% observed with rPolFNal2 , a l4  and a l l ,  
respectively (Figure 4-14B), this same pattern of protection was observed at 48hrs 
(Figure 4-14C) and 72hrs (Figure 4-14D). Although there was a significant difference 
in the protection conferred between the subtypes at all observed time points, 
unexpectedly between 24hrs and 72hrs, there was no significant protection 
conferred (Figure 4-14E).
Despite this non-significant effect between 24hrs and 72hrs, dot-plot results from  
the FCM analysis at 72hrs (data not shown) revealed a reduced amount of viable 
monocytes even in the untreated controls. This could therefore account for the 
successful protection conferred by the rPolFNa treatment.
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4.6 Additive effect of selected rPolFNa subtypes
To determine if the anti-CSFV effect conferred by PolFNa subtypes was improved 
when in combination with another rPolFNa subtype, six rPolFNa subtypes selected 
from the three groups of rPolFNa subtypes with low, medium or high anti-CSFV 
activity (Table 4-1) were used in combination in the treatment of porcine monocytes 
prior to infection with CSFV virus at an MOI of 7. A 200U/ml concentration of each of 
two subtypes with similar activity was used in combination (i.e. the combination 
contained a total IFN concentration of 400U/ml). Combinations of two IFN subtypes 
with low activity (rPolFNal + a2), medium activity (rPolFNa4 + a !4 ) and high activity 
(rPolFNaS + a !2 ) were tested and each combination was compared to 400U/m l of 
each subtype within the combination.
Pre-treatment of monocytes with 200U/ml of either rPolFNal or rPolFNa2 
protected about 21.07% and 16.43% of the monocytes from CSFV infection 
respectively (Table 4-3). A significant additive effect (p<0.05) was observed when 
the two subtypes (at 200U/ml) were used in combination, as compared to 200U/ml 
of each subtype. This combined effect was not significantly different from the 
protection conferred with 400U/ml of either rPolFNal or a2 subtype (Figure 4-15A).
The rPolFNa4 and a !4  tested individually at 200U/ml protected more 
monocytes; 40.94% and 44.88% respectively (Table 4-3). The effect observed from  
treatment with the two subtypes in combination was only significantly different to 
treatment with rPolFNa4 at 200U/ml (p<0.05) but not rPolFNaM at 200U/ml. 
Similarly, this combined effect was not significantly different from the protection 
conferred with 400U/ml of either rPolFNa4 or a !4  (Figure 4-15B).
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The rPolFNa9 and a l2  proteins; which were the most active against CSFV 
protected about 57.73%  and 62.88% of monocytes from infection (Table 4-3), the 
subtypes when in combination also produced a significant additive effect when 
compared to treatment with rPolFNa9 (p<0.001) or rPolFNal2 (p<0.05) at 200U/ml. 
Just like the other tested groups, this combined effect was not significantly different 
from the protection conferred with 400U/ml of either rPolFNa9 or otl2 (Figure 
4-15C), indicating that none of these combinations of IFNa subtypes have a 
synergistic effect.
Table 4-3 Percentage of protection following pre-treatment with a 200U/ml and 400U/ml 
of rPolFNal, a2, a4, a l4 , a9, a l2  and a combination of 200U/ml rPolFNal and a2, 
rPolFNa4 and a !4  and PolFNaS and a l2 .
rPolFN subtype treatm ent (U /m l) % Protected monocytes
a1 200 21.07
a2 200 16.43
a1 400 40.66
«2 400 41.35
a1+«2 (200) 41.81
«4 200 40.94
«14 200 44.88
«4 400 58.11
«14 400 54.59
a4+«14 (200) 56.97
«9 200 57.73
«12 200 62.88
«9 400 69.12
«12 400 79.87
a9+«12 (200) 79.63
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□  a 1  2 0 0 U /m l
□  a 2  2 0 0 U /m l
□  a 1  4 0 0 U /m l
□  a 2  4 0 0 U /m l 
a 1 + a 2  (2 0 0 U /m l)
C D  U ntreated
□  « 4  2 0 0 U /m l
□  « 1 4  2 00 U /m l
□  « 4  4 0 0 U /m l
□  a 1 4  4 0 0 U /m l
■  a 4 + a 1 4  (2 0 0 U /m l)  
C D  U ntreated
□  « 9  2 0 0 U /m l
□  a 1 2  2 0 0 U /m l
□  a 9  4 0 0 U /m l
□  a 1 2  4 0 0 U /m l
■  a 9 + a 1 2  (2 0 0 U /m l)  
I d  U ntreated
Figure 4-15 Additive effect of selected rPolFNa subtypes against CSFV infection.
Monocytes were either untreated or treated with 200U/ml and 400U/ml of each individual 
rPolFNa subtype or 200U/ml of two rPolFNa subtypes in combination and infected with 
CSFV Alfort at an MOI of 7 TCIDSO/cell. Figure A, B and C show cells treated with rPolFNal 
and/or rPolFNa2, rPolFNa4 and/or rPolFN a l4  and rPolFNa9 and/or a l2  respectively. The 
percentage of protected monocytes was assayed using FCM by gating on the population of 
viable E2 positively stained monocytes. Data shows the results of one independent 
experiment repeated in triplicate. The P-value represents the level of significance; *=P<0.05 
and **=P<0.01, One-way ANOVA and the error bars represent the standard deviation of 
mean values.
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4.7 Discussion
The aim of this chapter was to identify the antiviral activity of the different 
expressed rPolFNa subtypes, in order to determine subtypes which provide the best 
protection against CSFV infection in vitro.
4.7.1 Effect of commercial PolFNa monocyte treatm ent preceding or following 
CSFV infection in vitro.
In order to identify the effect of a commercial PolFNa protein before and after 
CSFV infection, cells were infected for 2hrs with CSFV to allow adsorption of virus, 
after which the cells were washed to remove any infectious viral particles, and 
replaced with fresh culture media. This created an environment that would only 
allow horizontal transmission of virus from infected to uninfected cells in the 
absence of viral inoculum. Due to this brief exposure to CSFV, treatment of 
monocytes with 20U/ml PolFNa offered efficient protection against CSFV showing a 
reduction in the percentage of infected cells and amount of new virions released into 
the supernatant. Despite this reduction, when comparing the level of 22 expression, 
there appeared to be more reduction in pre-treated than post-treated cells, although 
these differences were not significant when compared to the no-treatment control 
within each experiment. This could signify that, although the treatment is able to 
prevent further infection to uninfected cells, the treatment is unable to prevent or 
reduce the expression of 22 within already infected cells
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To investigate the potential effect of this commercial protein in the presence of 
CSFV infection in a more physiologically relevant system, where exposure to CSFV 
would be longer, the pre-treatment strategy was modified and cells were infected 
for 24hrs in the presence of the treatment. Although this increase in infection time 
resulted in more cells being infected (an average of 93% of the monocyte 
population), the increase in the protection observed with an increase in IFNa 
concentration suggested that the virus was sensitive to the treatment. This is similar 
to what has been shown in BVDV, where pre-treatment of cells with IFNa induced an 
antiviral state (Sentsui et al, 1998). However in a similar study by Schweizer e t  al. 
2006, they further went on to show that a prolonged IFN post-treatment of BVDV 
infected cells, although, slightly reduced the amount of viral RNA, could not 
eliminate the virus from the infected cells. They also showed that treatment of BVDV 
infected cells prior to challenge with VSV and EMCV (IFN sensitive viruses) was able 
to inhibit the replication of both viruses. This therefore suggests that, the type I 
signalling pathway (which induces an antiviral state) within these infected cells is still 
active, but that the virus has been able to overcome the induction of IFN in these 
cells (Schweizer et al, 2006).
In this chapter, although the protective effect of IFN prior to and after CSFV 
infection has been displayed, it would be interesting to further investigate if the 
prolonged post-treatment of cells with IFNa can induce an antiviral state capable of 
protecting cells against infection with unrelated viruses.
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4.7.2 The anti-CSFV effect of sixteen rPolFNa subtypes on monocytes
IFNs in general are pleiotropic cytokines with effective immunoregulatory and 
antiproliferative properties as well as antiviral effects, making them well suited to a 
wide range of therapeutic applications (Kerr & Stark, 1992; Samuel, 1991; Samuel, 
2001). As a result of these pleiotropic properties, the effect of rPolFNa subtypes in 
preventing CSFV infection was assessed to investigate any potential differential 
antiviral effect conferred by the subtypes.
As discussed above, a protective effect was observed following commercial IFNa 
pre-treatment assays on monocytes. Using the pre-treatment model, unsurprisingly, 
further investigations on the anti-CSFV effect of the different rPolFNa subtypes 
revealed a differential effect between subtypes, with the exception of rPolFNa? 
which was not included in the assay (due to insufficient quantities). This differential 
effect can be explained (in part) by the fact that IFNa subtypes are known to bind to 
type I receptors activating distinct but related JAK/STAT signal cascades and resulting 
in the transcription of several IFN-stimulated genes. Although they activate similar 
receptors, different genes are differentially regulated by these subtypes thereby 
providing each subtype with different biological activities that lead to different 
clinical effects (Pfeffer et al, 1998). This result supports other observed IFNa 
differential effects seen in other studies. Moll et. al.2011 showed that hulFNa4 and 
hulFNa2 exhibited better antiviral activities against influenza infection in human 
lymphatic endothelial cells than huFNal (Kelley & Pitha, 1985b; Moll et al, 2011) 
while varying rPolFNa antiviral effects against VSV and PRV have been seen in WISH 
cells and PK15 cells respectively (Cheng et al, 2006). Another study by Yeow et. al. in
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mouse showed that mouselFNal exhibited greater antiviral activities against mouse 
cytomegalovirus infection in vivo than mouselFNcxA and a9. (Yeow et al, 1998a). With 
regards to humans and mouse, these differences have been attributed to protein 
modifications that would most likely affect the receptor binding affinities of these 
subtypes.
Suggestions that subtypes bearing a C-terminal deletion possess lower activities 
(Cheng et al, 2006) was not supported by results obtained, with subtypes rPolFNalB 
and rPolFNalG being the exception to this rule, as they are both long subtypes with 
low activity, although these two subtypes are recombinant clones which do not bear 
a 100% similarity with sequences deposited on GenBank. Other reasons might relate 
to amino acid modifications of specific sites that might influence the biological 
activity and receptor binding site of the subtypes.
The hulFNa currently constitutes a complex gene family with 13 different 
members (Golovleva et al, 1996; Pestka et al, 2004; Rubinstein, 2007) while 17 IFNa 
genes have so far been described in mouse (van Pesch & Michiels, 2003b). Using 
previous structural analysis identifying amino acid regions involved in the biological 
activities of both mouse and human IFNa types, specific regions which might impact 
the function of the different rPolFNa subtypes were identified. Although these 
regions were found to be conserved in the rPolFNa subtypes, other unidentified 
regions might be involved in the differential effect observed with the different 
rPolFNa subtypes (Oritani et al, 2001; Radhakrishnan et al, 1996; van Pesch & 
Michiels, 2003b; Zwarthoff et al, 1987).
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A repeat pre-treatment assay performed on six subtypes (rPolFNaZ, a9, a l l ,  
a l4 , a l6 , and a l7 )  representing each activity group revealed similar anti-CSFV 
activity levels as before, with an increase in activity being observed at increasing 
concentrations with the exception of rPolFNa2 and to  a lesser extent rPolFNa9. The 
variations observed between the two batches of protein preparation could be as a 
result of experimental error introduced during the biological quantification of the 
protein subtypes via the VSV/PK15 bioassay. Non-uniformity of the 96-well plate or 
pipetting errors could also have introduced variations in the quantification of the 
protein preparations. This could have been reduced by variation in sample 
positioning on the 96-well plate during quantification, but due to the large number 
of samples, complete randomization was not feasible. The method of staining with 
crystal violet (CV) and the washing of the cell monolayer could have also introduced 
a variation during quantification. There is currently no commercial kit available for 
the quantification of PolFNa proteins, however, as discussed in chapter 3, the 
bioassay was acceptable for quantifying the expressed proteins as the intra-plate and 
inter-plate coefficient of variance were 8.66% and 8.36% respectively.
An alternative strategy may involve the addition of chemicals such as MTS (3- 
[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulphophenyl]-2H- 
tétrazolium,inner salt) (Buttke et al., 1993). This tétrazolium salt is taken up by live 
cells and metabolically reduced to a soluble red formazan product that can be read 
at an abosorbance of 492nm. Although this method requires fewer cell 
manipulations and has been shown to be robust as, it works best when a high 
cytopathic effect (CPE) is produced upon virus infection. As such, a better virus-cell
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combination where cells are more efficiently killed by the challenge virus would be 
ideal for the biological assay (Khabar et al, 1996).
Comparing the differential activity data to the phylogenetic relatedness of the 
subtypes suggested that subtypes are not related based on activity or gene length,
although it can be said that mostly subtypes with similar gene length fall within
\
similar subclade with the exception to rP o lF N a7 /ll in group I and a5 in group II; 
short and long gene lengths respectively falling within the same subclade.
Subtypes selected using this phylogenetic analysis also showed differential anti- 
CSFV activity with the exception of rPolFNaZ and a9, which showed a completely 
different pattern of activity with a new batch of expressed protein. These subtypes 
appeared to have an opposite anti-CSFV activity with the new batch of expressed 
protein compared to the initial batch. Possible explanations for this batch to batch 
variability could include problems with protein storage resulting in proteolysis or 
structural degradation of protein or improper quantification of recombinant protein 
which would result in bias in the anti-CSFV activity. Despite this, it can be suggest 
that rPolFNcxl2, rPolFNaM and rPolFNal? appear to be good representatives of 
active anti-CSFV rPolFNa subtypes.
4.7.3 The activity of rPolFNa subtypes against CSFV over tim e
Investigating the potency of the consistently active subtypes; rPolFNa!2, 
rPolFNaM and rPolFNal? over time resulted in somewhat contradictory results. It 
was observed that when monocytes were infected and treated at the same time with 
CSFV at an MOI of 5, the active subtypes were still able to efficiently protect
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monocytes from this level of infection. Both rPolFNaM and rPolFNal?, which had 
relatively lower activities, showed a gradual decline in activity over time while 
rPolFNal? still retained the same level of activity observed at the start of the 
infection, indicating this subtype; rPolFNal? may exert a longer lasting protection as 
well as a higher level of protection. However, with the introduction of more viral 
infectious particles (MOI of 7), all these subtypes protected only half of the cells from  
infection when treated simultaneously, indicating that the protection offered by 
rPolFNa subtypes is influenced by the number of infectious particles the monocytes 
are exposed to. The results suggest that although a limited protection was observed 
at Ohrs, by 24hrs the IFN(s) have been given enough time to bind to the IFNAR 
thereby invoking the appropriate antiviral response in the monocyte. It also appears 
that beyond 48hrs pre-treatment, subtypes were able to offer better protection to 
the monocytes. This may however, be an artifact due to a large reduction in viable 
monocytes following this length of time in culture. A study on the induction profile 
of interferon stimulating genes (ISG), in response to Influenza A infection, showed 
that, the ability of different recombinant hulFNa's to induce ISG mRNA correlates 
with the anti-viral activity of the specific subtype. It was further shown in this same 
study that, irrespective of their varying potencies, the kinetics of ISG stimulation by 
different hulFNa subtypes were comparable (Moll et al, 2011). Similarly studies by 
Yamamoto et.al. using a hepatocellular carcinoma cell line (HAK-3) suggested that 
the relative antiviral effect of five rhulFNa subtypes; IFNal, a2, a5, a8 and alO , 
correlated with the induction of 2,5,OAS (Yamamoto et al, 2002). However, in 
contrast, the differential antiviral effect of these rhulFNa's against hepatitis C virus
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(HCV) did not correlate with 2'5'OAS induction suggesting that this antiviral activity 
was not dependent on the JAK-STAT pathway (Koyama et al, 2006).
Based on their relative biological activity, rPolFNal2, a l4  and a l7  were 
categorized as high, medium and low, and this ranking correlated with the observed 
anti-CSFV effect. Their differing protective effects were observed irrespective of the 
interval between treatment and exposure of cells to CSFV. Therefore, it is probable 
that the anti-viral effect of these three rPolFNa subtypes correlates with their ability 
to induce ISG, further work should be conducted to investigate the ISG induction 
profiles of the different polFNa subtypes
4.7.4 Additive effect of selected rPolFNa subtypes
Previous studies have shown that when type I and II IFN were used in 
combination against Pseudorabies virus (PRV) (Yao et al, 2007) or FMDV (Moraes et 
al, 2007), a synergistic effect was observed.
Therefore, it was investigated, whether syngergistic effects against CSFV were 
observed by combining rPolFNas. To assess this, different types of PolFNa subtypes 
from the high, medium and low anti-CSFV activity categories were selected. The 
results of this study suggested an additive rather than a synergisitic effect, as the 
degree of protection offered by the combinations were similar to that observed 
when the concentration of each individual rPolFNa subtype was increased to a 
similar level. While the level of protection induced by combinations improved 
compared to individual subtypes, the rank of protection remained the same between 
the three tested categories. Similarly when moderately active hulFNa2 and highly
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active hulFNaS were used at an equal ratio to treat human hepatocarcinoma cells 
(Huh7), an additive antiviral effect against VSV infection was observed (Koyama et al, 
2006). This same additive effect was observed when these two hulFNa subtypes 
were tested on liver cells infected with VSV. However, when hulFNa2 and hulFNaS 
were used at a 60:40 ratio, a synergistic effect was observed. In this same study, they 
also observed that this synergistic activity appeared to correlate with the induction 
of 2'5'OAS (Yamamoto et al, 2002).
It can therefore be speculated from these findings that the additive effect 
observed in the present study reflects a suboptimal combination of these rPolFNa 
subtypes. Future work involving the use of these rPolFNa subtypes at different ratios 
may identify optimal conditions for synergism. Also, investigating the induction of 
ISGs, such as PKR and 2'5'OAS, may shed light on possible pathways involved in the 
induction of these ISGs.
As previously discussed, a number of studies have documented a synergistic 
effect between type I and type II IFNs. This is mostly likely to occur because these IFN 
types bind to distinct IFN receptor complexes (Pestka, 2000), resulting in the 
transcription of differentially regulated ISGs (Sainz Jr et al, 2004). Future work 
should therefore also focus on determining whether synergism occurs with 
combinations of rPolFNas and rPolFNy.
4.8 Conclusion
The results presented in this chapter have shown that pre-treatment of porcine 
monocytes with a commercially available PolFNal protein induced an antiviral state
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which provided a significant degree of protection against CSFV infection, although 
this treatment was unable to completely prevent infection in all cells.
Investigation of the anti-CSFV effect of different rPolFNa subtypes revealed a 
range of activities. rPolFNal2 subtype was the most active against CSFV infection in 
monocytes, with a longer duration of activity than the other subtypes tested. The 
results showed that not all the subtypes bearing a C-terminal deletion possessed 
lower anti-viral activity, but that these activities might relate to other amino acid 
modifications that might influence the biological activity, such as the receptor 
binding site. Further work using site-directed mutagenesis to modify rPolFNa 
subtypes would help elucidate the specific regions involved in inducing the observed 
anti-CSFV activity and therefore help to better characterize the biological properties 
of these proteins.
Combination of rPolFNa subtypes showed an additive rather than a synergistic 
effect, but it may be speculated that by identifying the optimal ratio to combine 
rPolFNa subtypes or by combining them with IFN-y a complete protective effect 
against CSFV could be achieved.
This study also emphasized the importance of careful biological quantification of 
IFN protein, and more importantly that the use of Crystal Violet as a cell-staining 
method in biological assays should be replaced by a method that involves fewer cell 
manipulations.
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CHAPTER 5
INVESTIGATING THE EXPRESSION OF DIFFERENT 
PolFNa SUBTYPES BEFORE AND AFTER CSFV 
INFECTION OF PIGS
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5.1 Rationale
Infection by viruses leads to the activation of cellular transcription factors and 
secretion of synthesized IFNs; these induced IFNs are central to antiviral innate 
immunity. The secreted proteins can act in an autocrine manner by binding to the 
inducing cell thereby activating an antiviral response (Marie et al, 1998). They can 
also act in a paracrine manner by binding to type I receptor complexes on 
neighbouring uninfected cells to induce responses with the ability to inhibit viral 
multiplication, suppress cellular metabolic processes and stimulate the expression of 
ISG (Aguet et al, 1984; Uze et al, 2007). The effect of these responses varies between 
the different subtypes. For instance in humans, IFNa2 and -a 2 1  induce higher levels 
of IP-lOs (a chemokine responsible for recruiting T h l cells and NK cells to 
inflammatory sites) as compared to IFN al in DC (Hilkens et al, 2003). The in vitro 
anti-PRRSV activity of PolFNa induced in MARC-145 cells has been shown to vary too, 
with PolFNal and a2 exhibiting a higher antiviral activity than PolFNa4, -a8 and a !3  
(Sang et al, 2010).
Among the murine type I IFNs, some subtypes; IFNa4, a l l  and a l2  exhibited 
higher biological activity as compared with IFNa7/alO  which showed a lower activity 
(van Pesch et al, 2004). Also among the PolFNa subtypes, there is evidence of varying 
antiviral activity between the different IFNa subtypes, and this antiviral activity is cell 
and virus dependent (Sang et al, 2010).
Upon CSFV infection in vivo, high amounts of systemic IFNa have been identified
in pig serum during the acute phase of infection, and this is correlated to virulence of
the strain (Summerfield et al, 2006). Despite this, no protection is observed in
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infected pigs, although IFNa has been shown to inhibit CSFV in vitro (Xia et al, 
2005b).
To understand the antiviral potency of IFNas against CSFV, therefore it is 
important to analyze the individual antiviral activity of the different subtypes as well 
as which subtypes may be induced, and when, during infection. This may result in the 
identification of the subtype/(s) that could be considered for prophylactic protection 
against CSFV.
5.2 Detection of differential PolFNa expression by subtype-specific 
differential polymerase chain reactions.
Although members of the PolFNa subclass share high sequence similarity
especially within their ORF and putative type I IFN receptor (IFNAR) binding site, the
differential effect of the different subclasses of PolFNa against different viral
infection has been reported (Sang et al, 2010; van Pesch et al, 2004). Previous studies
by Cheng e t  al. 2007 also showed the possibility of differential expression of PolFNa
by PCR using subtype specific primers.
Therefore, this approach was used to identify PolFNa gene expression following
CSFV infection. For the initial optimization of the PCR conditions required, two long
and one short PolFNa subtype were selected; PolFNa 2, a l2  and a l6 . These genes
were selected from the cloned prPolFNa plasmids available at the time (described in
chapter 3) and served as positive control templates for each PCR.
To design the subtype specific primes, the nucleotide sequence of the ORFs
(including a few bases before and at the end of the reading frame to improve
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stringency) of all 17 subtypes obtained from Genbank (Table 5-1) were aligned using 
the Clustal W  method on the MegAlign programme (DNASTAR Lasergene 10).
Specific forward and reverse PCR primers for subtype PolFNalG were designed 
based on non-conserved regions within this alignment (Figure 5-1) while primers for 
PolFNa2 and PolFNal2 were derived from previous publications by Cheng et ol. 
2007.
Primers and PCR conditions were optimized and validated using confirmed 
prPolFNa plasmids as positive control templates to show subtype specific 
amplification.
Table 5-1 Sequences of PolFNaZ, PolFNalZ and PolFNalG subtype specific PCR primers 
and melting temperatures.
Subtype Primer Primer sequence 5'-3' Tm (°C)
Expected
DNA
product
(bp)
PolFNa2
Forward C A ACCT CAG CCTT CCT C AC A 62
549
Reverse G AAT CT GT CT CACAG GTTT C 58
PolFNal2
Forward CCT CAG CCTT CCT CACG GT 62
509
Reverse CT CAT G ACTT CT G CCCT GAT 60
PolFNalG
Forward GTT CAG ACCCACAG CCT G 58
485
Reverse T CCT CCT G AGT CT GT CTT G C 62
The melting temperature of primers calculated as follows: 2°C X (A+T) + 4°C X (G+C)
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Chp 5. Differential expression of PolFNa
To identify optimal PCR conditions that would specifically detect each PolFNa 
subtype, the MgS04 concentrations and annealing temperatures were optimised. 
Five different MgS04 concentrations were tested; Im M , 1.5mM, 2m M / 2.5mM, 
3mM, 3.5mM, while the annealing temperature was varied between 55-63°C on a 
PCR specific for PolFNa2 (2.7.5.1). A PCR mastermix was prepared containing 
PolFNa2 specific primers, 50ng of prPolFNa2 plasmid DNA as the positive control 
template and PCR grade water as the negative control template.
Following analysis of the amplified DNA product on a 1% agarose gel, DNA 
fragments consistent with the expected sizes of 549bp was amplified with the 
majority of the MgS04 conditions used (Figure 5-2). Also, 2mM appeared to be the 
lowest concentration of MgS04 that gave the best amplification at all tested 
annealing temperature conditions. This was therefore selected as the optimal 
concentration required for the reaction.
The individual subtype specific PCR primer pairs were then optimised to 
determine the optimal annealing temperature required for each subtype specific 
PCR.
201
Chp 5. Differential expression of PolFNa
(A)
55*C 56LX: 57UC
2  £ 2  E 2  £ 0 2  E 2  E 2 E r, 2 E 2 E 2 E u 
E ^ E ^ E ^ i ^ E ^ .  E ^ E ^ h E^.  E ^ E ^ F_ f ^ T - i f N < N < Y > f o 2 v - i H f N r i r o r r i Z H H N i N m m Z
1000bp^ _^ 
750'bp —  
500bp
5 9 DC 6 1 GC G3cC
(B)
2  E 2  E 2  E 2  E 2  E 2  E 2  E 2  E 2 E
P  i n  P  L O  P  L D  P  L O  P  L O  P  L O  p  LT ) p  L O  p  L O
xH-s- i c > t r N < Y ) r ô ^ 1r - i r s i f N j m r n T- i x- i cNi rNrooô
IC M ÎG -b p ___
7 5 0  b p ___
5 0 0 ' b p ___
Figure 5-2 Amplification of PolFNctZ in the presence of varying MgS04 concentrations and 
annealing temperatures. PCR was performed with the PolFNaZ subtype-specific primers 
and 50ng of prPolFNaZ plasmid DNA.
A lOpI aliquot of the amplified PCR product was electrophoresed on a 1% agarose gel 
alongside a Ikb DNA ladder (Promega, UK); labelled L, while mM represent the final MgSC^ 
concentration used in each PCR. The no template control samples were lablelled NTC.
5.2.1 Optimising PolFNaZ subtype specific PCR
Using the above optimal MgS04 concentration of 2mM, another gradient PCR 
experiment was designed to determine the optimal annealing temperature required 
for specific detection of PolFNa2 but not the other subtypes. The PCR was conducted 
using the PolFNa differential PCR thermal profile w ith a gradient annealing
temperature of 55°C- 63°C (taking the melting temperature of the forward; 62°C and
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reverse 58°C primers into consideration). A 50ng concentration of prPolFNa2, a l6  
and «13 were selected as templates for the PCR reaction and a no template control 
containing PCR grade water was used as the negative control.
61°C 62°C 63°C
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Figure 5-3 PolFNaZ differential gradient PCR with annealing temperature range 61, 62 and 
63°C.
The specificity of the PolFNaZ subtype-specific primers were tested using 50ng of DNA 
plasmids encoding prPolFNaZ, 13 and 16 as templates. A lOpI aliquot of the amplified PCR 
products were electrophoresed on a 1% agarose gel alongside a Ikb DNA ladder (promega, 
UK); L. Lanes. Samples were annealed at 61°C, 62°C and 63°C respectively. Products from 
prPolFNaZ, a!6 and a!3 templates were loaded on the gel alongside the no template 
control; NTC.
Following analysis of the amplified DNA product on a 1% agarose gel (Figure 5-3), 
two DNA fragments were identified w ith both prPolFNaZ and a !6  templates but not 
the prPolFNcxl3 template.
1. A fragment of approximately 6Kb in size, probably the prPolFNa plasmid 
template(6.06kb), found in all the lanes
2. Another fragment consistent with the expected size of the amplified PCR 
product;549bp,
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Under these conditions this PCR was not specific for the amplification of 
PolFNa2, as these primers were able to amplify a 549bp product with prPolFNalG as 
template.
A second gradient PCR was performed with higher annealing conditions; 63°C, 
64°C and 65°C. To confirm the differential property of this primer pair, clones 2e, 3, 
5, 6, 7and 8 representing prPolFNa2, a l6 , a l3 , a8, clone 7d and a l2  respectively 
were selected as templates for the PCR reaction and a no template control 
containing PCR grade water was used as the negative control. A lO^il aliquot of the 
amplified products were analysed on a 1% agarose gel as before.
Results from the gel analysis (Figure 5-4) revealed that at 63°C, there was 
amplification with prPolFNa2 and prPolFNal2 templates but not with any of the 
other templates. At 64°C, the amplification of the 549bp product with prPolFNcx2 
appeared to have been lost but replaced with a less amplified, bigger sized product, 
between the lOOObp and 750bp mark band while there was still a probable 549bp 
product with prPolFNal2 template, but with less amplification. All the other 
templates gave no specific product except for the 6kb sized fragment, which is most 
likely, the input plasmid template.
At 65°C, the bigger almost lOOObp non-specific fragment was still observed with 
prPolFNa2 templates while the other template gave no specific DNA product 
amplification except for the ~6kb product seen with all templates at all 
temperatures.
Among all the six prPolFNa templates tested with the three different annealing 
temperatures, 63°C appeared to be optimal but still not differential as there was
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amplification of the target prPolFNal2 template and the non-target prPolFNal2 
template. Analysis of the primer sequences did not reveal any apparent reason why 
these primers specific for prPolFNa2 should amplify products from a prPolFNal2 
template. Although these templates bear slight differences to the Genbank 
sequences, the prPolFNa2 and a l2  templates are the same as the corresponding 
Genbank sequences in the region where the primers anneal. It appears this primer 
pair is not selective for PolFNa2 templates.
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Figure 5-4 PolFNaZ differential gradient PCR with annealing temperature range 63, 64 and 
65°C. PCR was performed with the PolFNaZ subtype-specific primers and 50ng of plasmid 
DNA.
A lOpI aliquot of the amplified PCR product was electrophoresed on a 1% agarose gel 
alongside a Ikb DNA ladder (Promega, UK); L. Samples annealed at 63°C and at 64°C were 
shown in figure A while Figure B represent samples annealed at 65°C. Products from 
prPolFNaZ, al6, al3, a8, clone 7 and prPolFNa!2 templates were loaded on the gel 
alongside the no template control; NTC
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5.2.1.1 Optimising PolFNalG subtype specific PCR
So as to determine the specificity of the differential amplification of PolFNalG, a 
gradient PCR was set up using the PolFNa differential PCR thermal profile and 
conditions (2.7.5.1). Six different annealing temperatures were tested; 56°C, 58°C, 
590C, 60°C, 62°C and 63°C.
A 50ng concentration of clones 2e, 3, 5, 6, 7and 8 representing prPolFNa2, a l6 ,  
a !3 , a8, clone 7d and a !2  respectively were selected as templates for the PCR 
reaction and a no template control containing PCR grade water was used as the 
negative control. Amplified products were analysed on a 1% agarose gel.
Results showed that the PolFNalG primers amplified all the prPolFNa subtypes 
producing a 485bp DNA product at all temperature conditions tested except for the 
prPolFNa2 template for which a product of >750bp (Figure 5-5) was detected. A 
second gradient PCR was then performed using higher annealing temperatures; 64°C, 
66°C, 68°C, 70°C and 71°C.
Since the previous results showed that the PolFNalG specific primers do not 
detect prPolFNa2, only prPolFNalG, a l3  and clone 7d were selected as templates. A 
no template control containing PCR grade water was used as the negative control 
and the amplified product was analysed on a 1% agarose gel (Figure 5-6).
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Figure 5-5 A PolFNalG differential gradient PCR with annealing temperature range 56°C, 
58°C, 59°C, 60°C, 62°C and 63°C.
PCR was performed with the PolFNalG subtype-specific primers and 50ng of plasmid DNA. A 
lOpI aliquot of the amplified PCR product was electrophoresed on a 1% agarose gel 
alongside a Ikb DNA ladder (Promega, UK) labelled L. Samples annealed at 56°C, 58°C and 
59°C were shown in figure A while Figure B represent samples annealed at 60°C, 62°C and 
63°C. Products from prPolFNa2, alG, al3, a8, clone 7 and prPolFNal2 templates were 
analysed together with the no template control; NTC
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From the gel analysis (Figure 5-6), it was observed that at 640C, the PolFNalG 
primers amplified a 485bp fragment from all the templates tested, w ith clone7d 
giving the least amplified product. At 68°C, the primer was unable to amplify a DNA 
fragment from clone 7d template but amplified from prPolFNalG and a !3  templates. 
At a higher temperature of 70°C, PolFNalG primers amplified the prPolFNalG 
template better than prPolFNalB template, although a faint band was still observed. 
When this PCR was repeated w ith an annealing temperature of 7 l°C  no amplified 
DNA product from all the tested templates (including prPolFNalG) was observed on 
the gel (data not shown). It appears this primer pair is not selective for PolFNalG 
templates.
64°C 66°C
LO 00
X—1 T—I
d d
"Ü
0)C
_o
u
U  LD roI  T—I T—I
z  d d
~o
c
_0
u
u
68°C
l d  onT—I
t i t i
~U
OJ
c_o
u
LO no 
O d
70°C
~o
<DCo
u
u
Figure 5-6 PolFNalG differential gradient PCR with annealing temperature range 64°C,
66°C, 68°C and 70°C.
PCR was performed with the PolFNaZ subtype-specific primers and 50ng of plasmid DNA. A 
lOpI aliquot of the amplified PCR product was electrophoresed on a 1% agarose gel 
alongside a Ikb DNA ladder (Promega, UK) labelled L. Samples annealed at 64°C and 66°C 
were shown in figure A while Figure B represent samples annealed at 68°C and 70°C. 
Products from prPolFNalG, a l3  and clone7d templates were analysed together with the no 
template control; NTC.
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5.2.1.2 Optimising PolFNalZ subtype specific PCR
Finally the specificity of the prPolFNal2 was tested on a gradient PCR using the 
PolFNa differential PCR thermal profile (2.7.5.1) and six different annealing 
temperatures covering the melting temperature of the forward and reverse primer; 
56°C, 58°C, 60°C, 62°C, 64°C and 67°C.
Plasmids prPolFNa2, a l6 , a lB , a8, clone 7d and a l2  were selected as positive 
control templates for the PCR reaction and a no template control containing PCR 
grade water was used as the negative control. Amplified product was then analysed 
on a 1% agarose gel.
The PolFNal2 subtype-specific primers appeared to amplify a fragment 
consistent with the expected size of 509bp from all the tested plasmid templates and 
at all temperatures. Although at 67°C, there was better product amplification with 
prPolFNalG and prPolFNal2 templates. It appears that the PolFNal2 primer pair 
isn't selective for prPolFNal2 genes.
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Figure 5-7 6 A PolFNalG differential gradient PCR with annealing temperature range 56°C/ 
580C, 60°C, 62°C, 64°C and 67°C.
PCR was performed with the PolFNalZ subtype-specific primers and 50ng of plasmid DNA. A 
lOpI aliquot of the amplified PCR product was electrophoresed on a 1% agarose gel 
alongside a Ikb DNA ladder (Promega, UK) labelled L. Samples annealed at 56°C, 58°C and 
60°C were shown in figure A while Figure B represent samples annealed at 60°C, 62°C and 
63°C. Products from prPolFNaZ, alG, al3, a8, clone 7 and prPolFNalZ templates were 
analysed together with the no template control; NTC
5.3 D ifferentia l IFN expression via high-throughput sequencing
The use of high-throughput sequencing platforms has helped improve the 
understanding of the pathogenesis of viruses, such as the detection of virus variants 
in HIV-1 (Henn et al, 2012), differentially expressed genes in PRRSV infections (Xiao 
et al, 2010) and identification of genetic mutations as seen in acute myeloid 
leukaemia (Grossmann et al, 2011). This approach is also rapid and cost effective and
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was, therefore, selected as an alternative method for analysing the PolFNa 
transcriptional response following experimental infection of pigs with CSFV.
5.3.1 Elevated Type I IFN response in CSFV infected serum samples.
The expression of type I IFN in pigs following infection with CSFV was initially 
confirmed using a biological IFN assay that detects all type I interferons.
Serum and EDTA blood samples were collected from three pigs before and after 
intranasal infection with highly virulent CSFV Brescia at a dose of 106TCID5o. These 
samples were analysed to identify the influence of CSFV infection on type I IFN 
expression at different stages of infection as follows:
1. Initially, the amount of CSFV viral RNA in the blood of the infected pigs was 
quantified by a CSFV quantitative RT-PCR (2.6.4.2),
2. And the induction of type I IFN protein expression was confirmed using a type 
I IFN biological assay (2.4.5).
As expected, no viral RNA was observed in blood samples at 3days prior to
challenge but at 4dpi, all pigs tested positive for CSFV RNA (Figure 5-8A). At +9dpi,
levels of viral RNA in bloods of all pigs peaked at approximately 105'8 copies/p! EDTA
blood, then decreased gradually until euthanasia at +15dpi. Similarly, from the type I
IFN bioassay (Figure 5-8B), there were very low amounts of IFN type I detected at 3
days before infection and +2dpi; 19U/ml and 21U/ml respectively. The amount of
type I IFN gradually increased over time and peaked at +7dpi to an average of
963U/ml in pigs 34 and 38 while at this time point, pig 36 had higher levels of type I
IFN expression; 4953U/ml. This high level of type I IFN expression decreased after
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+7dpi until euthanasia at +15dpi. When comparing the data from both assays it was 
observed that despite the early onset of an innate type I response, the amount of 
viral RNA copies in infected animals continued to increase.
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Figure 5-8 Relationship between the type I IFN response and viral RNA levels in blood 
following experimental infection of pigs with CSFV.
Serum sample and EDTA blood were collected from three pigs (pigs34, 36, 38) at 2-3 day 
intervals prior to and during infection with 106TCID5o of CSFV Brescia. (A) The amount of CSFV 
viral RNA per pi of EDTA blood was quantified by the CSFV quantitative RT-PCR. (B) The amount 
of expressed type I IFN was quantified by the MxCAT type I IFN assay.
5.3.2 Preparation of amplicon libraries for high-throughput sequencing of porcine 
samples
These results strongly supported other studies, suggesting that an elevated
amount of systemic type I IFN response does not correlate w ith protection nor result
in the reduction in viral RNA copies (Ruggli et al, 2009; Summerfield et al, 2006). It
was important, therefore, to identify the IFNa expression profile in infected animals
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before and at the peak of the immune response. This was hoped to shed some 
insight into which subtypes might be constitutively expressed, induced or suppressed 
during CSFV infection. Combing this information with knowledge of the anti-CSFV 
activity of the individual PolFNa subtypes may inform on reasons why this type I 
interferon response is unable to control the viral infection.
The differential expression of specific PolFNa genes in PBMC isolated from pigs 
before infection and at the peak of the type I response was investigated via high- 
throughput sequencing. This ultra deep sequencing method provides a unique 
system that allows the detection of low level nucleic acid variants in mixed transcript 
populations. Using cDNA samples to produce amplicon DNA libraries, this technique 
can be used to obtain the sequences from single mRNA molecules within samples. 
Determining the number of molecules with sequences corresponding to each of the 
IFNa subtypes would allow the relative quantification of each IFNa variant in the 
sample.
5.3.2.1 Quality control of RNA for deep sequencing analysis and cDNA library 
preparation.
Total RNA from porcine PBMC cells collected from pigs at 3dpc and +7dpi was 
extracted using a column-based method which removed genomic DNA 
contamination and small RNA species such as 55 and tRNA (2.7.3). Using the 2100 
Bioanalyzer instrument (Agilent, UK) and the RNA nano kit (Agilent, UK), the RNA 
quality and quantity were assessed (2.7.3.1).
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During sample analysis, the bioanalyzer software compares the unknown samples 
to molecular weight standards to determine the concentration of the unknown 
samples. The bioanalyzer RNA Integrity Number (RIN) software algorithm also allows 
the assessment of RNA quality by designating numbers from 1 to 10, with 1 being 
the most degraded and 10 being the most intact (Schroeder et al, 2006). The 
information generated was used in determining the quality of the RNA used for 
further sequence analysis (Table 5-2).
The RIN of all samples collected at 3dpc were exactly 10 indicating good quality 
RNA while samples collected at +7dpi were either 7.5 or 8.5 indicating the presence 
of some RNA degradation. At this time point there was also evidence of leucopenia 
as there was a decrease in the white blood cell count, 2x l04cells/pil at +5dpi to 
5 x l0 3cells/nl at +14dpi, which may have contributed to degradation of RNA in these 
samples.
A 10\x\ aliquot of the RNA samples was reverse transcribed into complementary 
DNA (cDNA) using the ROCHE transcriptor high fidelity cDNA synthesis kit (2.7.4).
Table 5-2 Table of sample concentration and RNA integrity number obtained from six RNA 
samples extracted from porcine PBMC collected during an experimental infection of pigs 
with CSFV.
Pig
Sample concentration 
(ng/ul) RNA Integrity Number (RIN)
Pig 34 dpc3 354 10
Pig 36 dpc3 446 10
Pig 38 dpc3 355 10
Pig 34 dpi+7 133 8.5
Pig 36 dpi+7 81 7.5
Pig 38 dpi+7 149 8.7
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5.3.2.2 PolFNa deep sequencing PCR primer optimisation
The PolFNa deep sequencing PCR was optimised for the generation of amplicon 
libraries from cDNA derived from PBMC pig samples. For this PCR, specific fusion 
primers were designed as detailed in 2 .7 .6 .I. Within each primer was a 25 base GS 
FIX Titanium fusion Primer A or Primer B sequence which included a 4-base library 
key at the 5' end of the primer, a 10-base MID tag and a template specific sequence 
at the 3' end. This template specific region was designed using the sequence 
consensus from the PolFNa 1-17 sequence alignment (see Figure 5-9). Only one 
sequence was used to represent PolFNa7 and P o lFN all as the only distinguishing 
nucleotide between the two subtypes was at position 452 of the ORF, this region was 
outside the amplification region.
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Start of ORF
rS 1P 20 30
PolFlia-1 CCCAATGGCCCCAACCTCAGCCTT CCTCACWGCCCT GGT GCT
PolFNa-2 CCCAAT GGCCCCAACCT CAGCCTT CCT CACWGCCCT GGT GCT
PolFIJa-3 CCCAAT GGCCCCAACCT CAGCCTT CCT CACGGCCCT GGT GCT
PolFNa-4 CCCAAT GGCCCCAACCT CAGCCTT C&T CAC0GCCCT GGT GCT
PolFMa-5 CCCAAT CGC CCCAACCT CAGCCT TCCTCACGGCCCT GGT GCT
PolFNa-6 CCCAAT GGCCCCAACCT CAGCCT TCCTCACGGCCCT GGT GCT
PolFNa-7ortl CCCAAT GGCCCCAACCT CAGCCTT C0Î CAC@GCCCT GGT GCT
PolFHa-8 CCCAAT GGCCCCAACCT CAGCCT TCCTCACGGCCCT GGT GCT
PolFNa 9 CCCAAT GGCCCCAACCT CAGCCTT CCT CA0GGCCCT GGT GCT
PolFNa-tO CCCAAT GGCCCCAACCT CAGCCT TCCTCACGGCCCT GGT GCT
PolFNa 12 CCCAAT GGCCCCAACCT CAGCCTT CCT CACGGfrjCCT GGT GCT
PolFNa-13 CCCAAT G GCCCCaSIcCT CAGCdcjr C C I CAC0GCCCT GGT GCT
PolFNa-14 CCCAATGGCCCCAOCCT CaScEÇJT CCTCACGGEjCCT GGT GCT
PolFNa-15 CCCAAI GGCCCCAACCT CAGCCT T CCT CA0GGCCCT GGT GCT
PolFNa tG CCCAAT GGCCCCAACCT CAGCCT TCfrlT CACGGCCCT GGT GCT
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PolFNa-1 CCAGGI CCAGAAGGCI CAAUCCAI GGC I Cl GUI UCAI GAGA I GC1 CCAGCAGACCI I CCAGCI Cl I CAÜC
PolFNa-2 CCAGGTCCAGAAGGCTCAAGCCAT GGCT CT GGT GCAT GAGATGCT CCAGCAGACCTT CCAGCT CTT CAGC
PolFNa-3 CCAGGTCC AGAAGGCTCAAGCCAT GGCT CT GGT GCATGAGATGCT CCAGCAGACCTT CCAGCT CTT CAGC
PoirNa-4 CCAGGTCC AGAAGGCTCAAGCCAT GGCT CT GGT GCATGAGATGCT CCAGCAGACCT T CCAGCT CT T CAGC
PolFNa-5 CCAGGTCC AGAAGGCTCAAGCCAT GGCT CT GGT GCATGAGATGCT CCAGCAGACCT 0C CAGCT CTT CAGC
PolFHa-G CCAGGTCC AGAAGGCTCAAGCCAT GGCT CT GGT GCAT GAGATGCT CCAGCAGACCT T CCAGCT CT T CAGC
PolFNa-7or11 CCAGGT CCAGAAGGCT CAAGCCAT GGCT CT GGT GCATGAGATGCT CCAGCAGACCT T CCAGCT CT T CAGC
PolFNa-3 CCAGGT CCAGAAGGCT CAAGCCAT GGCT CT GGT GCAT GAGATGCT CCAGCAGACCTT CCAGCT CTT CAGC
PolFNa-9 CCAGGT CCAGAAGGCT CAAGCCAT GGCT CT GGT GCATGAGATGCT CCAGCAGACCT T CCAGCT CT T CAGC
PolFNa-10 CCAGGT CCAGAAGGCT CAAGCCAT GGCT CT GGT GCAT GAGATGCT CCAGCAGACCTT CCAGCT CTT CAGC
PolFNa-12 CCAGGT CCAGAAGGCT CAAGCCAT GGCT CT GGT GCATGAGATGCT CCAGCAGACCTT CCAGCT CTT CAGC
PolFNa-13 CCAGGT CCAGAAGGCT CAAGCCAT GGCT CT GGT GCATGAGATGCT CCAGCAGACCT T CCAGCT CT T CAGC
PolFNa-14 CCAGGT CCAGAAGGCT CAAGCCAT GGCT CT GGT GCATGAGATGCT CCAGCAGACCTT CCAGCT CTT CAGC
PolFNa-15 CCAGGT CCAGAAGGCT CAAGCCAT GGCT CT GGT GCATGAGATGCT CCAGCAGACCTT CCAGCT CT T CAGC
PolFNa-16 CCAGGTCCAGAAGGCTCAAGCCAT GGCT CT GGT GCAT GAGATGCT CCAGCAGACCTT CCAGCT CTT CAGC
PolFNa-17 CCAGGT CCAGAAGGCT CAAGCCAT GGCT CT GGT GCATGAGATGCT CCAGCAGACCTT CCAGCT CTT CAGC
Figure 5-9 Alignment of PolFNa 1-17 sequences showing non conserved region amplified 
and sequenced by 454 deep sequencing .
The PolFNa sequences obtained from Genbank were aligned using the clustal W option on 
the Megalign DNAstar Lasergene software programme. PolFNa forward (blue) and reverse 
primer (green) were selected from regions with high homology within the alignment such 
that a 264bp non-conserved region would be amplified via PCR.
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The titanium fusion primers were designed such that a 264bp non-conserved 
region within the different subtypes was amplified (Table 5-3). Each forward and 
reverse primer although similar, contained distinctive MID tags such that a different 
primer pair was used in the PCR amplification of each experimental sample.
Table 5-3 Primer sequence of the PolFNa deep sequencing fusion primers
Fwd=Forward Rev=Rev. Black sequences represent the 25 base GS FIX Titanium fusion 
Primer A or Primer B. Red sequence represents the 10-base MID tag. Blue or green sequence 
represent the forward or reverse template specific sequence respectively.
Primer name Primer Primer sequence 5'-3'
(MIDI) 
DpSqMIDl IFNaF Fwd CGTATCGCCICCCTCGCGCCATCAG ACGAGTGCGT CCCAA TGG CCCCAWCCTCA
(MID2)
DpSqMID2_IFNaF Fwd CGTATCGCCTCCCTCGCGCCATCAG ACGCTCGACA CCCAA TGG CCCCAWCCTCA
(MID3) 
DpSqMIDB IFNaR Rev CTATG CGCCTTG CCAGCCCGCTCAG AGACGCACTC GT CTG CTG G AG CAT CT CAT G
(MID4) 
DpSqMID4 IFNaR Rev CTAT G CG CCTT G CCAGCCCG CT CAG AGCACTGTAG GTCTG CTGG AG CAT CT CAT G
(MID5)
DpSqMIDSJFNaR Rev CTATG CG CCTT G CCAG CCCG CTC AG ATCAGACACG GTCTG CTG GAG CATCTCATG
A control sample/template; PolFNaT, consisting of equivalent proportions of 
each prPolFNal-17 plasmid with a final total concentration of 10ng/pl of DNA was 
prepared. Each sample was amplified by a different combination of primers (Table 
5-4). This control was used to ensure that the PCR amplification by the different MID  
fusion primers and the relative quantification by deep sequencing was equivalent for 
all of the IFN subtypes.
The PCR products generated from the cDNA and PolFNaT templates would 
therefore include similar amplicon target region but different MID tags. To also 
exclude any bias from primer pairing, two amplicon libraries were generated from  
each sample using the same reverse primer but two different forward primers.
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Table 5-4 Primer combinations used for amplification of IFNalpha subtypes from different 
porcine and control samples.
Sample
No.
Sample ID Fwd.
Primer
Rev.
Primer
1 aPolFNaT M ID I MID3
2 bPolFNaT M ID I MID4
3 cPolFNaT MID 1 MID5
4 dPolFNaT MID 2 MID3
5 ePolFNaT MID 2 MID4
6 fPolFNaT MID 2 MID5
7 Pig34dpc3 (MID1&3) M ID I MID3
8 Pig36dpc3 (MID1&4) MID 1 MID4
9 Pig38dpc3 (MID1&5) M ID I MID5
10 Pig34dpc3 (MID2&3) MID 2 MID3
11 Pig36dpc3 (MID2&4) MID 2 MID4
12 Pig38dpc3 (MID2&5) MID 2 MID5
13 Pig34dpi+7 (MID2&3) MID 2 MID3
14 Pig36dpi+7 (MID2&4) MID 2 MID4
15 Pig38dpi+7 (MID2&5) MID 2 MID5
16 Pig34dpi+7 (MID1&3) M ID I MID3
17 Pig36dpi+7 (MID1&4) M ID I MID4
18 Pig38dpi+7 (MID1&5) M ID I MID5
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The PCR conditions used to amplify the non conserved regions were initially 
optimised using the PolFNa deep sequencing PCR (2.7.6.2) w ith M ID I and MID3 
primers and a gradient annealing temperature range from 55°C to 80°C. For the PCR 
reaction, PCR grade water was included as a no template control and lOng of plasmid 
DNA from two prPolFNa subtypes: prPolFNaM and a l7  (representing a long and 
short form of the PolFNa subtypes) was used as template (Figure 5-10). Generated 
amplicons were analysed on a 1% agarose gel.
PolFNal4
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Figure 5-10 Amplification of PolFNal4 and PolFNal? product using the PolFNa deep 
sequencing PCR with gradient annealing temperature ranges from 55, 60, 65, 70, 75 and 
80°C.
PCR was performed using the PolFNa deep sequencing PCR with MIDI and MID3 deep- 
sequencing fusion primers, lOng of plasmid DNA and PCR grade water as negative control 
(NTC). Samples were analysed alongside a lOObp DNA ladder; L (Promega, UK). A 299bp 
amplified PCR product generated following PCR was electrophoresed on a 1% agarose gel.
Although amplification was observed at all tested annealing temperatures, the
best amplicon generated from both the prPolFNa!4 and prPolFNal7 template was
219
Chp 5. Differential expression of PolFNa
at 60°C. This PCR amplification produced a fragment consistent with the expected 
size of 299bp; the size of the non-conserved region (244bp) and fusion primer 
forward and reverse primer (75bp). A repeat of this reaction at 60°C (annealing 
temperature) using lOng plasmid DNA of all the seventeen prPolFNa subtypes as 
template confirmed cross amplification of a 299bp product w ith all tested prPolFNa 
subtypes but w ith different intensities (Figure 5-11).
Figure 5-11 Amplification of PolFNal-17 product using the PolFNa deep sequencing PCR 
with an annealing temperature of 60°C.
PCR was performed using the PolFNa deep sequencing PCR with MIDI and MID3 deep- 
sequencing fusion primers, lOng of plasmid DNA alongside a lOObp Promega DNA ladder (L) 
and PCR grade water as negative control (NIC). A lOpI aliquot of the amplified 299bp PCR 
products was separated by electrophoresis on a 1% agarose gel.
Finally, to confirm equal amplification by the different forward and reverse fusion 
primer pairs, each fusion primer pair was used to amplify DNA products from 
prPolFNal and prPolFNal? plasmid templates; representing the short and long 
PolFNa subtypes. Visual examination of the PCR products separated on a 1% agarose
PolFNa 1 -1 7  at60°C
lOOObp-....
750bp—
SOObp—
250bp
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gel indicated amplification of the expected 299bp fragment across both tested 
subtypes (Figure 5-12).
Figure 5-12 Amplification of PolFNaZ and PolFNal? using the PolFNa deep sequencing PCR 
and the different primer pairs.
PCR was performed using the PolFNa deep sequencing PCR with MIDI, MID2, MID3, MID4 
and MID 5 deep-sequencing fusion primers, lOng of prPolFNa2 (lanes 1, 3, 5, 8, 10, 12) and 
prPolFNal? (lane 2, 4, 6, 9, 11, 13) plasmid DNA alongside a lOObp Promega DNA ladder (L) 
and PCR grade water as negative control (NTC). A lOpI aliquot of the amplified 299bp PCR 
product was separated electrophoresis on a 1% agarose gel.
5.3.2.3 Generation of PolFNa amplicon libraries
Following this primer optimisation, an amplicon library was generated from each 
cDNA sample (synthesised from pig 34, 36 and 38 PBMC samples collected at 3dpc 
and +7dpi) using the ROCHE fast start fidelity kit and the assigned MID-fusion primers 
as detailed in Table 5-4. A total of 6 amplicon libraries; aPolFNaT - fPolFNaT were 
generated using the PolFNaT template (control sample) and the assigned MID fusion 
PCR primer. The PCR was performed using the thermal profile specified by the 
manufacturer at the optimised annealing temperature of 60°C.
A 7|il aliquot of the amplified PCR products was electrophoresed on a 1% agarose 
gel. A product of the expected size of 299bp was observed with all the samples
40 0 b p
SOObp
SOObp
lOObp
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collected at 3dpc. In contrast, there was a poor product amplification observed with 
samples collected at +7dpi. This was surprising as high levels of type I IFN were 
detected in serum at this time point. This could indicate that the type I IFN detected 
in serum was largely IFN(3 rather than alpha, alternatively, this could be attributed to 
the low quality of the starting RNA.
A product of the expected size of 299bp was also observed w ith PolFNaT samples 
amplified by the six MID fusion primers, and the analysis on the gel showed an equal 
amplification irrespective of the primer (data not shown).
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Figure 5-13 Generation of amplicon libraries pigs 34, 36 and 38 using the PolFNa deep 
sequencing PCR and the different primer pair.
PCR was performed using the PolFNa deep sequencing PCR with MIDI, MID2, MID3, MID4 
and MID 5 deep-sequencing fusion primers (Table 5-4), lOng of plasmid DNA alongside a 
lOObp Promega DNA ladder (L) and PCR grade water as negative control (NTC). A lOpI 
aliquot of the amplified 299bp PCR product was electrophoresed on a 1% agarose gel. The 
primer pair for each amplicon is in bracket.
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5.3.3 Analysis of cDNA libraries created from CSFV infected pigs; before and after 
CSFV infection.
A total of 10pg of each amplified DNA product was submitted for Roche 454 
GSFLX Sequencing at the Central Sequencing Unit (AHVLA, Weybridge). In order to 
determine the relative proportion of subtypes expressed in the amplified samples, an 
equal number of molecules from each amplicon was sequenced. To allow for 
multiplexing; which would reduce sequencing cost, samples were combined as pools 
(Table 5-5) and each sample was uniquely identified using the MID tag (see Table 
5-4) at the S' end of each sequence read.
Table 5-5 Sample pools for 454 sequencing
Sample within each pool
Pooll aPolFNaT ePolFNaT
Pool2 bPolFNaT fPolFNaT
Pool3 cPolFNaT dPolFNaT
Pool4 Pig34dpc3 (MID1&3) Pig36dpc3 (MID2&4)
PoolS Pig36dpc3 (MID1&4) Pig38dpc3 (MID2&5)
P0 0 I6 Pig38dpc3 (MID1&5) Pig34dpc3 (MID2&3)
Pool? Pig36dpi+7 (MID2&4) Pig34dpi+7 (MID1&3)
PoolS Pig38dpi+7 (MID2&5) Pig36dpi+7 (MID1&4)
Pool9 Pig34dpi+7 (MID2&3) Pig38dpi+7 (MID1&5)
Using the BLAST+ alignment software (Camacho et al, 2009), reads obtained 
from the plasmid control samples and experimental pigs samples (pig 34, 36 and 38 
3dpc and +7dpi) were compared with a database containing the sequence data from
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the prPolFNal-17 plasmids (these DNA sequences were determined by Sanger 
sequencing. See details in chapter 3: sections 3.2.2 & 3.2.3) and from PolFNa 
GenBank sequences, respectively (Table 3.1.). Reads with the highest similarity to a 
particular subtype were then assigned to the subtype. The query required for this 
analysis involved two steps:
1. The raw data obtained following sequencing of each pool (Table 5-5) was 
split into individual samples using the MID identifier; which is unique for 
each sample. This query allowed for one mismatch in the MID sequence 
to allow for possible PCR or sequencing errors.
2. The sequences were then aligned with the database of PolFNa subtypes, 
based on the highest percentage similarity, sequences were assigned to 
specific subtypes.
The deep sequencing data obtained from each pool (Table 5-5) yielded a number 
of reads, of these 51.3% were of high quality (i.e reads with intact MID forward and 
reverse tags and reads with at least 260 nucleotides) (see Table 5-6). Most of the low 
quality reads were either truncated, contained gaps or lacked a MID tag and as such 
were excluded from further analysis. The count of the high quality reads were used 
for the analysis of PolFNa subtypes in the a-fPolFNaT control templates and the 
proportion of each subtype in the PBMC pigs samples from 3dpc and +7dpi. From 
this analysis, it was observed that pool 2 had the least number of high quality reads; 
21.47%.
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Table 5-6 Result of the number of reads from the 454 deep sequencing analysis of 
prPolFNal-17 plasmids and CSFV experimental pig PBMC samples.
Pool
Total 
number of 
reads
High quality 
reads
Samples in 
each pool
High quality 
reads per 
sample
% High quality 
reads in each 
pool
Pooll 53087 28149
aPolFNcxT 15613
53.02
ePolFNcxT 12536
Pool2 20298 4357
bPolFNcx 1968
21.47
fPolFNcxT 2389
PoolB 17054 11327
cPolFNaT 6842
66.42
dPolFNaT 4485
Pool4 21248 13308
Pig34dpc3 7775
62.63
Pig36dpc3 5533
Pools 24668 13871
Pig36dpc3 7999
56.23
Pig38dpc3 5872
P0 0 I6 23682 12617
Pig38dpc3 7096
53.28
Pig34dpc3 5521
Pool? 23887 13453
Pig36dpi+7 6775
56.32
Pig34dpi+7 6678
Pools 22805 11768
Pig38dpi+7 6549
51.60
Pig36dpi+7 5219
Pool9 26257 10790
Pig34dpi+7 5933
41.09
Pig38dpi+7 4857
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5.3.3.1 Sequence analysis of the proportion of each PolFNa subtype detected in 6 
PCR amplicon libraries, aPolFNaT to fPolFNaT, generated from control 
template PolFNaT
Following analysis of the number of sequence reads obtained from the a-PolFNaT
to fPolFNaT control templates (Table 5-7), it was observed that only one read/DNA
molecules found in the aPolFNaT amplicon was assigned to PolFNalS; no DNA
molecules with the sequence expected for the PolFNalS subtype were detected in
the other control samples.
As the total amount of sequence data varied across samples, a percentage of
each subtype in the total read was used to compare the amount of each PolFNa
subtype across the six reactions on the control template.
Table 5-7 Number of PolFNa subtype specific sequences obtained following 454 
sequencing of the PolFNaT control amplicon samples.________________________________
Subtype
Number of reads of each subtype from Control PolFNaT
aPolFNTa bPolFNTa cPolFNTa dPolFNTa ePolFNTa fPolFNTa
PolFNa_l 3704 537 2174 1522 3829 816
PolFNa_2 141 14 60 29 82 16
PolFNa_3 1444 260 910 475 901 215
PolFNa_4 112 22 92 38 120 16
PolFNa_5 149 14 56 37 139 18
PolFNa_6 1368 113 503 397 1316 137
PolFNa_7/ll 188 11 64 48 161 23
PolFNa_8 4776 529 1409 660 2399 472
PolFNa_9 423 56 284 188 456 96
PolFNaJLO 257 42 133 113 258 47
PolFNa_12 1362 197 576 278 734 157
PolFNa_13 265 19 82 42 145 32
PolFNa_14 1050 102 300 500 1695 278
PolFNa_15 1 0 0 0 0 0
PolFNa_16 111 13 30 23 52 17
PolFNa_17 262 39 169 135 249 49
Total number of 
reads per amplified 
sample
15613 1968 6842 4485 12536 2389
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Although the a-fPolFNaT control template contained an estimated equal amount 
of each PolFNa subtype, results from the sequence data showed that each template 
contained varying amounts (in terms of DNA molecules) of the seventeen PolFNa 
subtypes, as well as varying number of total reads per template.
Once the amount of PolFNa subtype in a sample was expressed as a percentage 
of the total number of reads, it appeared that there were more of particular subtype, 
especially PolFNal and a8 with 30.2% and 22% respectively in comparison to some 
others which appeared to fall below 11% (see Figure 5-14). When comparing the 
percentage of reads from each PolFNa subtype; irrespective of the six PolFNaT 
templates, a one-way ANOVA revealed that PolFNa2, a4, a5, a9, alO , a 7 / l l ,  a !3 , 
a !5 , a !6  and a !7  were not significantly different when compared to each other, but 
were significantly different to the other subtypes (p<0.0001). Subtypes PolFNa3, a6, 
a !2  and a !4  were also not significantly different between each other but were 
significantly different to the other subtypes (p<0.0001), the only exception was 
between PolFNa9 & PolFNaG and PolFNa9 & PolFNal2, which had lower significant 
differences (p<0.05). PolFNal and PolFNaS were significantly different to each other 
and every other subtype.
The results suggested that either: (1) each subtype was amplified with a different 
efficiency by each primer, or (2) an equal number of each plasmid subtype was not 
combined in the PolFNaT pool. The former option was considered unlikely as the 
target regions of the primers are conserved across the different subtypes. The results 
also indicate the six templates contain a relatively similar level of PolFNa subtypes.
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Figure 5-14 Percentage of polFNa subtypes following 454 deep sequencing of aPolFNaT to 
fPolFNaT control templates (the template is a mixture of prPolFNa 1-17 plasmids).
5.3.3.2 Sequence analysis of CSFV infected pig PBMC samples
The same method of analysis was used to analyze data generated from the
sequenced amplicons, which were amplified from reverse transcribed RNA extracted
from PBMCs collected before and during CSFV infection of pigs (see Figure 5-15). In
this instance, the relative proportion of subtypes expressed in each pig before and
after CSFV infection was assessed.
From the data, it appears that, at 3dpc, there is no huge shift in the pattern of
PolFNa subtype expression between the three pigs; pig 34, 36 and 38. On the graph
(Figure 5-15A), each column represents the mean of two data sets, which were
derived from amplicons generated using two different MID primer sets on the same
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cDNA template. The size of the error bars on these columns across the different 
subtypes can therefore suggest that the different MID primers were not selective for 
a particular PolFNa subtype; i.e the two MID primer pairs used had similar levels of 
amplification. The data shows that, 3days prior to CSFV infection, a similar amount of 
all the different subtypes is expressed. P o lF N a7 /ll appear to be present at double 
the amount. However this is likely a reflection that these two subtypes cannot be 
distinguished by this method. The exceptions are PolFNaS, which was barely 
detectable, and PolFNal and 3, which were present at slightly higher levels than the 
others. Looking across the different expressed subtypes 3days before infection, we 
can deduce from this result that there is no substantial PolFNa differential 
expression at 3dpc of CSFV infection.
In contrast at day +7 of the CSFV infection, quite a few changes in the relative 
proportion of PolFNa subtypes were produced (Figure 5-15B). There appeared to be 
a relative increase in the amount of PolFNaS in all the three pigs. Other noticeable 
changes were seen with the relative increase in the percentage of PolFNaS by pig 34 
and PolFNal3 and a l4  by pig 36. Most of the other observed changes in PolFNa 
expression are not consistent.
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Figure 5-15 Differential in vivo expression of PolFNa subtypes in CSFV infected PBMC 
samples.
This data shows the percentage of the relative PolFNa subtype reads obtained from PCR 
amplicons. The amplicons were generated following a deep sequencing PCR on pig PBMC 
samples (collected form pig 34, 36 and 38) using two different MID fusion primer. Error bars 
representing the standard deviation of mean values of data from the two PCR amplifications.
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5.4 Discussion
5.4.1 Detection of differential PolFNa expression by subtype specific differential 
polymerase chain reactions.
Using similar mouselFNa subtype-specific PCR, some studies have been able to 
identify subtypes like mouselFNa4 as an immediate early response gene important in 
regulating the production of type I IFN(Fung et al, 2004). This method has also been 
used to suggest the absence of constitutive expression of PolFNa genes in PK15 cells 
(Cheng et al, 2007a). Hence, the study in this chapter was aimed at identifying and 
differentiating between the expression profiles of the 17 polFNa subtypes following 
CSFV infection via PCR. For the initial optimization of the subtype-specific PCR, three 
PolFNa subtypes were selected; PolFNa2, a l2  and a l6 . It is important to note that 
specific primers to two of these subtypes; PolFNa2 and PolFNal2 have been 
previously designed in another study (Cheng et al, 2007a). Using sequences from  
GenBank, primers specific to PolFNalG were designed (Table 3.3), so as to provide 
the best possible discriminating power and to distinguish these highly similar coding 
sequences. The specificity of each primer was tested on recombinant prPolFNa 
plasmid templates (these temples were the previously cloned PolFNa plasmids; 
prPolFNal-17, see Chapter 3: 3.2).
Following several annealing temperature modifications, an optimal PCR condition 
was not achieved as there was an observed cross-amplification of other PolFNa 
subtype templates across the different subtype-specific PCRs. This could be 
attributed to the high degree of homology shared between PolFNa subtypes thereby
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making it difficult to achieve specificity. Also, it is possible that the purity of the 
template could have influenced the outcome of the results due to cross­
contamination during handling. However, care was taken to reduce these by 
preparing PCR master-mixes in designated clean rooms while the addition of 
templates was in a PCR laminar flow cabinet.
The proposed use of this method would be in large biological studies, to help 
identify the expression profiles of PolFNa in samples containing a possible mixture of 
different PolFNa subtype following CSFV infection. So far the method has proven 
quite laborious, not reliable and time consuming when considering the number of 
PCR assays required in determining the PolFNa expression profile in one 
experimental sample. This method is also not quantitative as it only shows the 
presence of a specific gene by amplification and not the starting amount, but this 
could be achieved by normalizing against a host gene. The use of a SYBR green PCR 
could have made this method quantitative and proven beneficial as studies have 
used this method in identifying the presence of single nucleotide mutations 
(Maruyama et al, 2003). In a study by Papin et.a l, using the dissociation profile 
analysis of the SYBR green PCR, they were able to discover the presence of West Nile 
virus variants with three or more nucleotide substitutions (Papin et al, 2004). In 
another study by Whalley e t  al., it was possible to identify the presence of three 
hepatitis B virus variants in clinical specimens (Whalley et al, 2001). Despite this 
distinguishable property, because this intercalating SYBR green dye would bind to 
any double-stranded DNA (Giglio et al, 2003), the quantification of host gene
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expression where there are so many similar variants would have complicated this 
approach. Due to these limitations, an alternative strategy was considered.
5.4.2 The differential in vivo expression levels of PolFNa subtypes following CSFV 
infection.
A type I IFN bioassay on the serum collected from infected pigs at several time
points before and after infection, and a CSFV quantitative RT-PCR on blood samples
collected at these time points, revealed a production of type I IFN at +4dpi of the
CSFV infection, as well as the presence of CSFV viral RNA. The type I response peaked
at +7dpi and gradually reduced while the amount of viral RNA produced continued to
increase and remained elevated until the pigs were euthanized. This clearly supports
earlier studies on the non-protective response of type I IFN induced following CSFV
infection (Summerfield et al, 2006).
Although porcine type I IFN consists of not just PolFNa subtypes, for the purpose
of this study we focused on the PolFNa response induced during infection as they are
known to have antiviral activity in vitro, and are induced in response to the virus in
vivo. As shown in chapter 3, there is a differential antiviral effect conferred by the
rPolFNa subtypes with rPolFNal2 being the most protective against CSFV in vitro. As
identification of PolFNa expression was unsuccessful using subtype specific PolFNa
PCR, the use of next generation sequencing technology was applied.
PBMC samples were chosen from time points, 3days before infection where
there was no observed type I response in serum and at 7days post infection when
the peak type I response was reached. PolFNa amplicon DNA libraries were created
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from these samples using deep sequencing MID fusion primers and via emulsion type 
PCR, each DNA molecule within the amplicon was sequenced using the GS FIX 
titanium amplicon sequencing method. Amplicon libraries generated from a pool of 
the 17 prPolFNa plasmid subtypes (PolFNaT) served as a known control template.
Although this method generated an average of 26000 reads, over 50% of the data 
were of low quality and as such were not included in the analysis. These reads were 
most likely generated through PCR error as they were either truncated (incomplete 
expected gene lengths), or lacking a MID tag identifier. During the detection of HIV-1 
drug resistant mutations using 454 sequencing, studies by Shao e t  al. revealed that 
PCR amplification of samples was a common source of error while the introduction 
of inserts and presence of deletions (especially in sequence regions with identical 
bases) were from sequencing (Shao et al, 2013). In another study on the genotyping 
of Pneumocystis jirovecii, it was revealed that as high as 37% of the recombinant 
sequences were introduced during the elongation step of the PCR amplification 
(Beser et al, 2007). In both studies these artifacts were reduced by modifying the PCR 
conditions. Therefore further modifications of the PCR conditions used in this study 
could help reduce this high percentage of error.
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Analysis of the a-fPolFNaT control template
Analysis of the a-fPolFNaT control template revealed similar amplification 
efficiencies by different MID fusion primers as the percentage of reads for each 
PolFNa subtypes was not hugely different across the six amplicon libraries. The only 
exception was seen in the number of PolFNal, a8 and to a lesser extent PolFNaS, 
a6, a l2  and a l4  reads, this may be attributed to PCR or sequencing error.
Also during the deep sequencing PCR optimization, results from the PCR 
amplification of the different prPolFNal to prPolFNal? plasmid samples using the 
M ID I and MID3 fusion primer pair shows that, the intensity of the amplicons 
produced from each individual prPolFNa subtypes were different. Clearly from the 
gel (Figure 5-11), prPolFNal and prPolFNaS templates produced the best 
amplification, suggesting that the concentration of these plasmid templates were 
more compared to concentration of other plasmids. This ties up with the result from  
the deep sequencing results which shows a highly significant proportion of PolFNal 
and PolFNaS subtypes across the templates. Therefore, the varying percentage of 
PolFNa subtype reads suggests an unequal amount of starting template.
The result also showed that there is a variation in the amount of each PolFNa 
subtype across the six amplicon libraries. This suggests that the PCR amplification 
could have introduced errors or recombinants in the sequenced amplicon. Similar 
variation in PCR amplification has been shown in a study on two different HIV genes, 
the study revealed that up to 5.4% of the amplified products were recombinants 
introduced by PCR amplification (Meyerhans et al, 1990).
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The analysis also revealed that PolFNalS was not present in the control 
template, except for one read; in sample aPolFNaT. Further analysis of this one read 
showed that it bore a 90.94% similarity with PolFNalS with a few mutations and 
gaps. The gel analysis of the individual plasmid samples also showed that prPolFNalS 
was detected by the M ID I and MID3 fusion primer; this therefore excludes the 
possibility that this subtype was not amplified by the primers. The poor 
representation of polFNalS across the six templates (a-fPolFNaT) was therefore 
most likely due to pipetting error during the control template preparation i.e the 
sample was not added into the plasmid pool. In future, the control template should 
also be properly controlled for to ensure that the starting amount of the different 
prPolFNa plasmid is equivalent.
Nevertheless, an overall view of the data in comparison with the gel results from  
the control template suggests there is very little variation in the amplification of 
PolFNa subtypes by the different sequencing primer pair.
Analysis o f the experimental RNA sampled
Pooling data from three different pigs might over- or underestimate the 
expression of the different polFNa subtypes as the pigs responded differently to 
CSFV infection; based on data from the type I IFN bioassay. The type I IFN bioassay 
showed the absence of type I IFNs at three days before infection, never the less, 
analysis of theses 3dpc experimental samples shows the presence of all the PolFNa 
subtypes. The increase in the proportion of P o lF N a7 /ll subtypes seen at 3dpc will
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most likely be a total of the PolFNa? and a l l  reads, as the primers amplify a 
conserved region between these two subtypes.
The result from the 3dpc could therefore suggest two things:
1. That all the PolFNa subtypes except PolFNaS, are expressed at similar 
levels in PBMC cells in the absence of CSFV infection, and
2. That there is no notable shift in the pattern of this expression across 
different animals.
Constitutive expression of PolFNa in swine pDC and monocyte cell populations 
purified from healthy pig PBMCs has been observed in some studies (Amadori et al, 
2010; Razzuoli et al, 2010). This goes on to further support the findings of expression 
before CSFV infection shown in this chapter. In these studies, they suggested that the 
prevalence of cells like pDC's and monocytes purified from healthy pig PBMC (which 
are both known to secrete IFNa) could have been affected by weaning; a condition 
considered as very stressful leading to the induction of high pro-inflammatory 
responses (Razzuoli et al, 2010). Constitutive expression has also been suggested to 
help improve the responses of healthy pigs to cytokines and viruses, as well as help 
to regulate the genes that code for proinflammaory cytokines thereby efficiently 
controlling the inflammatory response in tissues (Begni et al, 2005). Therefore the 
presence of IFNa RNA observed at 3dpc may help to improve the anti-viral response 
of pigs to CSFV infection.
The data from the samples collected at +7dpi showed a variation in the number 
of PolFNa subtype reads obtained from each pig sample. The gel analysis of pigs 34,
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36 and 38 +7dpi amplicon libraries (Figure 5-13) also show a poor amplification of 
PolFNa subtypes using the different primer pairs. From previous results, it has been 
shown that the amplification by these MID fusion primers is relatively similar. 
Therefore, in addition to possible PCR and sequencing error, this observed variation 
could be a reflection of the poor quality of these +7dpi templates. At this time point; 
+7dpi, there was also evidence of leucopenia (data not shown) seen as a decrease in 
the white blood cell count and this may have contributed to degradation of RNA. 
However, this variation could also reflect the difference in response induced by the 
pigs to CSFV as shown in the type I IFN bioassay.
Despite this variation, the increase in the relative proportion of PolFNaS, 
PolFNalS and PolFNaM may further suggest that expression of these subtypes is 
induced more (in comparison to other subtypes) upon infection by CSFV. This results 
supports an in vitro study by Razzuoli and colleagues where they showed the 
expression of PolFNaS gene after stimulation of PBMCs with Newcastle disease virus 
(Razzuoli et al, 2010). Also comparing the results from the type I bioassay with this 
result, it may imply that the increase in type I response of pig 36 seen at +7dpi is as a 
result of the increase in the proportion of PolFNal3 and a !4 .
Although PolFNaS has been previously categorized as a highly active subtype 
(chapter 3), this high anti-CSFV property may have been compromised if its induction 
was only observed at this late time point.
The amount of starting RNA used for this study was not normalized, as a result 
the relative amount of subtypes expressed cannot be compared across the two time 
points of infection. Despite this, the results from the +7dpi samples suggest that
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some subtypes are better induced upon infection by CSFV and that there is a subtle 
differential expression of PolFNa subtypes after infection.
The study in this chapter demonstrates that it is possible to use a deep 
sequencing method to differentiate the proportion of PolFNa subtypes present. 
However these results are preliminary and analysis of more time points post CSFV 
infection as well as more pigs will provide a better insight into the expression of 
these subtypes before and after CSFV infection. Samples should also be properly 
normalized to enable conclusions to be made about induction or repression of 
PolFNa expression.
5.5 Conclusion
Several studies have shown the differential expression of IFNa subtypes in 
Humans, mice and pigs (Chen et al, 2004; Hiscott et al, 1984; Kelley & Pitha, 1985a; 
Pitha & Au*, 1995). These studies have provided useful insights into understanding 
the anti-viral role of IFNa against different viruses as well as understanding the 
induction and regulation of these genes.
This differential expression has been shown by using an IFNa subtype specific 
PCR (Cheng et al, 2007a; Fung et al, 2004; Loseke et al, 2003). In this study, attempts 
at using a similar polFNa subtype specific PCR as designed by Cheng proved 
unsuccessful.
The use of deep sequencing of in vivo samples was then applied as an alternative
strategy for this differentiation. Although the data obtained in this study is
preliminary, the results confirmed a subtle differential interferon expression pattern
239
Chp 5. Differential expression of PolFNa
following CSFV infection, and therefore indicates that deep sequencing can be used 
to study the expression patterns of these closely related polFNa subtypes.
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CHAPTER 6
GENERAL DISCUSSION AND CONCLUSION
Chp 6. Discussion and Conclusion
6.1 Overview
CSFV, as a viral pathogen, manipulates host-cell immune defenses, resulting in 
efficient viral replication without inducing IFNcx/p secretion in the infected cells 
(Bauhofer et al, 2005; Bauhofer et al, 2007; Fiebach et al, 2011; Summerfield et al, 
2006). In contrast to in vivo studies, where high levels of systemic type I IFN observed 
in the serum of pigs at the acute phase of CSFV infection do not confer protection 
(Summerfield et al, 2006), in vitro studies have shown the ability of a cloned 
recombinant PolFNa to inhibit CSFV infection (Xia et al, 2005a). In order to explore 
possible reasons why these levels of induced interferon are non protective, and to 
identify which PolFNa subtype might be effective as an anti-CSFV agent, this thesis 
investigated the anti-CSFV activity of the cloned and expressed PolFNa subtypes and 
identified which of the subtypes were induced upon infection of in vitro and in vivo 
models of CSFV infection.
6.2 Cloning and expression of seventeen PolFNa subtypes
The PolFNa family comprises of at least seventeen different subtypes, which 
possess different expression patterns and antiviral activity depending on the cell type 
and infecting virus (Cheng et al, 2006; Sang et al, 2010). As a result it was important 
to further elucidate the presence of a differential antiviral activity of these subtypes 
against CSFV.
In this study, seventeen prPolFNa subtypes were successfully cloned. Upon 
analysis of the first five of these seventeen subtypes clones, (prPolFNa2, a 8 , a l2 ,
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«13 and «16), it was observed that their similarity to GenBank reference sequences 
from the Sscrofa 10.2 genome was 98-100%. Studies by Sang e t  al. indicated that 
expressed, polymorphic type I IFN subtypes showed altered In vitro antiviral activity 
against both PRRSV and VSV (Sang et al, 2011), which raised the possibility that the 
nucleotide differences in the recombinant clones may influence the anti-CSFV 
activity exerted by the resultant proteins. The other twelve subtypes, therefore, 
were synthesized commercially and bore a 100% identity with the PolFNa sequences 
in the Sscrofa 10.2 genome. All the cloned and synthetic genes encoded proteins 
containing a 23amino-acid putative signal sequence that would result in mature 
proteins comprising of 166amino-acids or 158amino-acids. The only exception being 
prPolFNalS which had an amino-acid deletion at position 22 of the mature protein, 
thus making this subtype a 165amino-acid protein. They also contained five 
conserved cysteine (Cys) residues at positions Cys24, Cys52, Cys109, Cys122 and Cys162 
suggested to be involved in the formation of intramolecular disulfide bonds (Chen et 
al, 2004; Sang et al, 2010; van Pesch et al, 2004).
It is important to point out that the low expression level of these rPolFNa 
proteins in a mammalian cell system, CHO cells, greatly hampered this study. The 
insufficient quantities expressed often resulted in limited number of comparable 
repeats and in the case of rPolFNa?, prevented the analysis of the anti-CSFV activity 
of this protein. Similar studies involving the expression of both human (hu)IFN«2b 
and a laboratory designed rPolFNa have successfully used Pichia pastoris in the 
production of large quantities of functional IFNa proteins (Huang et al, 2012; Shi et
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al, 2007). Future studies would, therefore, benefit from the expression of large 
quantities of rPolFNa protein in Pichia pastoris.
Analysis of these seventeen rPolFNa proteins by western blot revealed a slower 
than expected migration of rPolFNcx9. This might be related to the presence of an N- 
glycosylation site, which has also been reported in studies on mouselFNa, where 
subtypes with this N-linked sugar migrate more slowly (van Pesch et al, 2004). 
Murine IFN|3 carries three N-glycosylation sites, one of which is within a region 
involved in IFN type I receptor binding. Mutation or deletion of these sites has been 
reported to result in a range of effects from a weak negative effect on antiviral 
activity, to a considerably reduced activity (Sommereyns & Michiels, 2006). It has 
also been suggested that a significant property of glycosylation is to enhance the in 
vivo stability of the protein (Fraser-Reid et al, 2001; van Pesch & Michiels, 2003b). 
Further analysis of these rPolFNa proteins by treating with N-glycosidase F peptide; 
which would remove all N-glycans, would help determine if this site becomes 
glycosylated during the production of these subtypes; as this post-translational 
modification is not mandatory for all N-glycosylation sites (Lodish H, 2000).
An extensive in silico analysis of the polFNa subtypes was performed by 
comparing the amino-acid sequence with those of hulFNa2; as other studies have 
shown that this hulFNa subtype bears a close antigenic relationship with polFNa 
subtypes (Karayianni-Vasconcelos et al, 1993; Piasecki, 1988). This analysis revealed 
several sites that might influence the antiviral property of rPolFNa. For example, the 
presence of five helical regions, that influences the biological and receptor binding 
activity in human IFNa2b. Among these regions, the AB loop and D helix have been
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mapped to the binding site for IFNAR2 while the C helix has been mapped to IFNAR1 
(Mogensen et al, 1999; Radhakrishnan et al, 1996). Although some of the human 
IFNa2b residues within these helical regions differ from residues in the prPolFNa 
subtypes, within the prPolFNa subtypes, these identified helical regions appear 
mostly conserved. This, therefore, suggests that some other residues, are involved in 
the receptor binding and biological activity of rPolFNa subtypes. A closer look at the 
alignments of the prPolFNa subtypes revealed some changes which were particular 
to some subtypes, for instance in a conserved region of the prPolFNa AB loop (a 
region suggested to influence biological activity (Radhakrishnan et al, 1996)), Phe38 
and Gln40 changed to Ser38 and His40 in prPolFNa4, a7 and a l l  while Phe38, Gln40 
and Leu43 changed to Ser38, His40 and Phe43 in prPolFNa6 , a !2  and a !4 . Mutating 
these amino-acids could induce changes in the antiviral activity of these subtypes 
and would highlight their role in PolFNa activity. A recent study, comparing the 
activities of a laboratory generated IFNa protein; CoPolFNa (designed using the 
consensus sequence of the 17 PolFNas) and a naturally occurring PolFNa derived 
from a pig, showed that the CoPolFNa possessed higher antiviral activity in 
comparison to the PolFNa protein. In their study, they speculated that, the presence 
of an Argl56 residue in the CoPolFNa could improve the binding affinity of this 
protein to IFNAR2. (Huang et al, 2012). From both the anti-VSV and anti-CSFV data 
obtained in this study, it was difficult to draw a conclusion on residues that might 
influence the observed anti-viral activity. Further site mutagenesis studies on 
variable regions of the protein might inform on what these influencing residues are.
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6.3 Biological quantification of expressed rPolFNa
Having cloned, expressed and purified a range of seventeen rPolFNa proteins, it 
was important to determine the biological activity of these proteins to enable their 
use in further investigations.
A classical method for quantifying the inhibitory or antiviral activity of proteins 
has involved using a cytopathic effect reduction assay (Zhou et al, 2011). For this 
method, the relative potency of serially titrated test/IFNa containing samples was 
compared with a serial titration of the known IFN reference standard. The end point 
reciprocal titer of the IFN sample, which is defined as the dilution that exhibits 50% 
cytopathic effect, is compared to that of a reference sample and this is used in 
determining the relative antiviral activity of the polFNa sample (Cheng et al, 2006; 
Familletti et al, 1981; Vogel et al, 2001). Due to the number of polFNa samples 
tested in this study, the method was modified slightly and the relative activity of the 
samples was extrapolated directly from a standard curve of a known rPolFNal 
reference included in the assay. From the initial optimization of this assay the intra 
plate coefficient of variance ranged from 16.93 - 19.98% (of highly concentrated 
samples and samples of low concentration respectively), while the inter-plate 
coefficient of variance was 18.86%. This compares to reports of other bioassays for 
the detection of IFN activity, where coefficients of variance above 50% have been 
documented (Ferreira et al, 1979; Giard & Fleischaker, 1984). However, after further 
repeats and optimization, the intra-plate coefficient of variation of the tested 
rPolFNa samples in this study was 8 .6 6 %, while the inter-plate coefficient variation 
tested on one of the subtypes; rPolFNalS was 8.36%. This low variation provided
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confidence in the validity of the results obtained for the assay, similar levels have 
been recorded in other type I bioassays (Canosi et al, 1996; François et al, 2005). An 
alternative strategy (as discussed in chapter 4), involving the use of chemicals such as 
MTS (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulphophenyl]- 
2H-tetrazolium,inner salt) could be used to determine CPE in cells and hence help 
improve this assay (Khabar et al, 1996).
More recently, an antiviral assay based on inhibition of replication of an 
engineered fluorescent vesicular stomatitis virus reporter strain, a dsRed2-strain, on 
A549 human lung epithelial cells has been developed for the quantification of human 
type I, II, and III interferon activities. This assay was shown to be more reproducible 
and more sensitive, as the results were quantified by fluorescent scanning (at the 
appropriate wavelengths) as compared to crystal violet staining and washing of cell 
layers which tend to increase variation due to cell loss (Voigt et al, 2013). This assay 
could, therefore, be applied for the quantification of rPolFNa subtypes and may help 
reduce the variation commonly observed with antiviral assays.
Nevertheless, the VSV/PK15 assay optimized in this study was successfully used 
in the quantification of the seventeen cloned and expressed rPolFNa subtypes and 
gave a good indication of the relative activity of each subtype. Indeed, similar work 
on the activity of fourteen rPolFNa subtypes on a VSV/PK15 system was reported in 
2010 and suggested that rPolFNa!2 and rPolFNa6  had very high anti-VSV activity, 
while rP o lFN all and rPolFNa? showed lower activity (Sang, et al., 2010). These data 
correlate very well with the data obtained from the anti-VSV assay performed in this
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study, where rPolFNa6 , a l ,  a l l  and a l  had the highest activity per ml of protein 
preparation while rPolFNalS, a l l ,  a5 and a l  provided lower activities.
The expressed rPolFNa proteins were quantified using a PolFNa ELISA, the 
concentration determined was used to determine the specific activity of each protein 
i.e. anti-VSV activity/nanogram quantified. Once activity was expressed in this way, it 
appeared that rPolFNalO showed the highest anti-VSV specific activity, suggesting 
that the protein is highly active with a better affinity for the IFNAR compared to the 
other subtypes.
These results may also have been affected due to the fact that the PolFNa ELISA 
was not sensitive enough for the proper estimation of different polFNa subtypes. 
The mAbs used in this ELISA were prepared against the complete rpolFNal as 
previously described by Lefevre (Diaz de Arce et al, 1992; Lefevre et al, 1990) 
suggesting that they might not recognize and therefore bind the epitopes of all of the 
PolFNa subtypes. Indeed, Diaz de Arce and colleagues reported that the PolFNa 
ELISA (when used for the quantification of serum samples) showed some 
discrepancies resulting in the under estimation or non detection of some samples 
(Diaz de Arce et al, 1992). In another study on hulFNa mAbs, it was shown that 
different hulFNa subtypes possess different antigenic diversity. Testing the 
neutralizing biological activity of a panel of four mAbs that bind to four distinct IFNa 
epitopes, indicated that these antibodies differed in their ability to neutralize 
different hulFNa subtypes (Overall & Hertzog, 1992). This further supports the result 
of the PolFNa ELISA shown in this study, suggesting that the mAbs did not recognize 
the epitopes on all the tested polFNa subtypes, and also indicating that these
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subtypes possess different antigenic profiles. Further work on identifying subtype 
specific epitopes on the different polFNa subtypes could help in the design and 
development of a more sensitive PolFNa ELISA for the screening of different polFNa 
subtypes.
6.4 In vitro differential anti-CSFV effects of rPolFNa subtypes
Having semi-quantified the antiviral activity of these seventeen rPolFNa proteins 
using a VSV/PK15 assay and shown the sensitivity of CSFV to a commercial rPolFNal, 
the anti-CSFV activity of these proteins in vitro was further assessed.
Using monocytes, the results not only showed that these seventeen subtypes 
possessed a differential antiviral activity, but that these subtypes could be further 
categorized based on their anti-CSFV activity into high medium and low activity 
groups.
In an earlier study by Cheng e t  al, where the anti-VSV and anti-PRV
(Pseudorabies Virus) activity of eight rPolFNas were tested on WISH cells and PK15
cells respectively, it was demonstrated that the antiviral activity of PolFNa subtypes
with C-terminal deletions (short type) were lower when compared to longer
subtypes (Cheng et al, 2006). They suggested that this region is important for type I
receptor binding, and that its absence may influence protein structure thereby
making it unstable. In another study by Sang e t  ai. however, where the anti-PRRSV
and anti-VSV activities of fourteen PolFNa subtypes were tested on MARC-145 cells,
it was shown that the longer subtypes did not always have higher anti-viral activity
(Sang et al, 2010). This report supports the results from the anti-VSV and anti-CSFV
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data obtained from this study and confirms that the length of the subtype does not 
always correlate with activity.
Further anti-CSFV activity assays on selected subtypes went on to confirm that 
rPolFNal2 (high activity), rPolFNal4 (medium activity) and rPolFNal? (medium 
activity) appeared to be good representatives of active rPolFNcx subtypes. When the 
duration of activity of these subtypes was tested against CSFV over time, rPolFNcxl2; 
a highly active subtype still appeared to confer efficient protection even after 24hrs. 
This led to the suggestion that this subtype is highly active against CSFV and could be 
a candidate for further pharmacological studies towards future therapeutic use 
against CSFV.
IFNcx subtypes are known to bind to type I receptors with different affinities, 
resulting in the transcription of several IFN-stimulated genes (ISG), some studies 
have suggested that the weak affinity to which hulFNal binds to IFNAR2 corresponds 
to the weak activity demonstrated by this subtype (Kumaran et al, 2007a; Moll et al, 
2011) while hulFNa2; which was suggested as the most potent, binds with greater 
affinity (Kumaran et al, 2007a). In this study, when two rPolFNa subtypes with similar 
potencies were used in combination, an additive effect was observed. Indeed, this 
might reflect that they bind with similar levels and as such induce similar levels of 
ISG. In addition, as discussed in chapter 4, this additive effect might also reflect a 
suboptimal combination of these rPolFNa subtypes. Other studies against viruses like 
FMDV and PRV suggesting a synergistic effect between type I and type II IFNs have 
been documented (Moraes et al, 2007; Yao et al, 2008). Further work combining
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subtypes at different ratios of potency, or combinations with a different IFN subtype 
might further elucidate these relationships.
Studies on the hulFNa and IFNAR interaction have revealed that this weak 
binding affinity of hulFNal may be attributed to an amino-acid within the AB loop, 
which prevents proper interaction with the IFNAR2, while hulFNa2 binds better to 
IFNAR1, because the BC loop and part of the C helix of hulFNcx2 has a large 'contact 
surface' with the receptor (Kumaran et al, 2007b). Similarly engineered human (Blatt 
et al, 1996) and porcine (Huang et al, 2012) IFNot cytokines, with better antiviral 
activities also posses this high binding affinity and better induction of ISG compared 
to naturally occurring IFNot subtypes. It would be interesting, therefore, to identify 
the different ISG induced by different rPolFNa subtypes upon CSFV infection. This 
would further inform us on the individual role of these PolFNcts in response to CSFV 
infection. The structural analysis of rPolFNotl2 and IFNAR binding could also identify 
regions conferring high affinity for the receptor and clarify which residues could be 
substituted to improve the antiviral activity in not just rPolFNa!2 but other less 
active subtypes.
Although this study has shown the in vitro effect of PolFNcx subtypes on 
monocytes, a comparative study on other CSF primary target cells; such as 
endothelial cells may reveal other properties and functions displayed by these 
rPolFNa subtypes against CSFV.
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6.5 Differential expression of PolFNa subtypes in an in vivo model of CSFV 
infection
Following the in vitro assays used to initially test the anti-CSFV potency of 
rPolFNa subtypes, in vivo studies were performed on PBMC samples to further 
characterize the differential properties of the PolFNa subtypes in a more 
physiologically relevant model. Attempts to use subtype specific PCR to identify the 
differential expression of PolFNa subtypes proved unsuccessful. Two of the primers 
used in this study had been used successfully in a study by Cheng e t  ai. for the 
differentiation of PolFNa subtypes (Cheng et al, 2007a), in addition, primers specific 
to PolFNalG were designed and included. Following several attempts at optimising 
PCR conditions, no differential specificity among the subtypes was provided by the 
1 assays. This non-specificity could have been because these subtypes are highly 
similar, or from cross contamination of the control prPolFNa plasmids used during 
the PCR setup. Other limitations with this assay were the cost of setting up enough 
PCRs to identify all the different subtypes, as well as the time involved. As mentioned 
in chapter 5, an alternative method would be the use of a SYBR green PCR, although 
new specific PCR primers as well as new control plasmids would be required to 
ensure specificity. Another strategy could be the introduction of locked nucleic acids 
(LNA) (Veedu et al, 2008; Vester & Wengel, 2004) in the primer sequence to increase 
the stringency of the PCR assay. These nucleosides are a group of nucleic acid 
monomers (+A, +T, +C and +G) that contain a modified ribose ring. The 2 '0  methyl 
group on this ring is connected to the 4' atom by a methylene bridge. This bridge 
locks the ribose in a C3' endo conformation that restricts the flexibility of the ribose
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ring thereby increasing the affinity to a complementary nucleotide strand. These 
nucleic acids could replace a discriminating nucleic acid in a probe (You et al, 2006), 
and in this case improve the stringency of the assay. This method has been used to 
improve the template binding strength of primers where picogram amounts of 
templates are available (Ballantyne et al, 2008). In another study investigating the 
expression profiles of hulFNa subtypes on PBMC, monocytes, myeloid DC, pDC, 
monocyte derived macrophages and monocyte derived dendritic cells, the use of a 
molecular probe with a LNA was implemented. This method successfully quantified 
the expression of hulFNa in these cells (Hillyer et al, 2012). In one study in particular, 
these LNA monomers were used to design allele-specific PCR (AS-PCR) primers and 
applied in a SYBR Green PCR assay. AS-PCR is a type of single-base substitution PCR 
where the specific primer for the desired allele differs from the primer of the other 
allele at the 3' end (Bottema & Sommer, 1993). This SYBR AS-PCR was then used to 
successfully detect and quantify wildtype and mutant alleles in samples (Maertens et 
al, 2006). This approach of using both the SYBR green and AS-PCR with an LNA probe 
might, therefore, prove useful in the differentiation of PolFNa subtypes. By designing 
the probe in a highly non-conserved region, LNA monomer can be used to replace 
subtype specific differentiating nucleotides.
In this study, the alternative method for investigating the in vivo PolFNa 
expression following CSFV was via high throughput deep sequencing and this proved 
quite successful for the relative quantification of the in vivo expressed PolFNa 
subtypes. As a control for this experiment, a control plasmid containing a pool of the 
seventeen prPolFNa plasmid was also analysed.
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Using the BLAST+ analysis software (Camacho et al, 2009), no thresholds were set 
and reads were assigned to specific subtypes based on high percentage similarity. 
Due to the high homology of PolFNa subtypes, it is possible that PCR and sequencing 
errors could have introduced some mutational changes in the samples (Shao et al, 
2013), resulting in the misrepresentation of the subtypes. Also, the high percentage 
of low quality reads, which was not typical to a sample type, suggested problems 
associated with PCR and sequencing errors. Literature has confirmed that the PCR 
amplification step can introduce errors in the reads and distort the information 
represented by the cDNA libraries (Metzker, 2010; Shao et al, 2013; Wang et al, 
2009b). This therefore shows a limitation with this method.
Some studies have suggested normalizing the cDNA library by using commercial 
kits that improve random sequencing and detection of rare genes (Wang et al, 
2009a) as a method of optimization, this did not seem necessary for the purpose of 
this study as this would misrepresent the relative expression of some of the poorly 
expressed subtypes.
Results from the analysis of 3dpc samples suggested that all the PolFNa subtypes 
except PolFNaS were relatively expressed at the same level in PBMC cells in the 
absence of CSFV infection, and also no notable shift in the pattern of PolFNa 
expression across the three pigs was observed.
As discussed previously, studies have shown that the constitutive expression of 
IFNa is a mechanism by which cells use to improve immune responses. In contrast to  
previous studies, where the constitutive expression of PolFNa in healthy pigs was 
related to weaning (Amadori et al, 2010; Razzuoli et al, 2010), a study on swine DCs
254
Chp 6. Discussion and Conclusion
showed that, in these cells, intracellular PolFNa is expressed constitutive!^ in the 
absence of stimulus, but secreted following infection with FMDV (Bautista et al, 
2005). It can therefore be suggested that, although the type I response was below 
the detection level of the MxCAT assay at 3dpc, the presence of PolFNa subtype 
mRNA expression seen at 3dpc suggests that these PolFNa subtypes (except for 
PolFNaS) are expressed to some extent within the PBMC population but the protein 
is not secreted out of the cells, or is only present at levels below detection with the 
MxCAT assay.
The quality of the total extracted RNA used for this in vivo analysis was quantified 
using the Agilent 2100 Bioanalyzer and the RNA integrity number (RIN) values 
obtained was used to determine the quality of the samples. According to Schroeder 
e t  al., samples with RIN values from 7 and below denote degradation (Schroeder et 
al, 2006). Although the samples collected from +7dpi had RIN values above 7, gel 
analysis of the amplicon libraries generated from these samples show poor 
amplification unlike samples from 3dpc. This led to the suggestion that leucopenia, 
which was observed as a reduction in the count of white blood cells at this time 
point, may have resulted in poor RNA quality in these samples.
To understand why at the peak of IFN type I induction in the pigs (+7dpi), no 
reduction in viral RNA or protective response was observed, PBMCs from this time 
point were collected and analysed. Although data generated following the deep 
sequencing analysis of these processed +7dpi samples showed a high amount of 
variation, there was a relative abundance of PolFNa9 reads in pig 34 as well as a 
relative increase in the amount of PolFNal3 and a l4  reads in pig 36. It could be that
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the relative abundance of these subtypes in pig 36 at +7dpi is related to the high type 
I IFN induction from the Mx CAT bioassay at this time point. Also, the relative 
increase in polFNaS (a highly active subtype in vitro) at this time point of infection 
may suggest a late response. It is important to also point out that, PolFNaS 
appeared to have been induced better following infection, while in pig 34, PolFNa9 
appeared to make up a greater proportion of the PolFNa present at +7dpi than 
before infection (3dpc). However, based on the variation observed with the +7dpi 
data, it is difficult to come to a conclusion on whether any subtype is induced more 
than another at that time point.
Irrespective of this, it is known that CSFV Npro induces the proteosomal 
degradation of IRF-3 thereby preventing early IFNa induction (Bauhofer et al, 2007), 
and pDC's (which constitutive^ express IRF-7) upon activation produce 
proinflammatory cytokines and IFNa; which is characteristic of CSFV infection 
(Carrasco et al, 2004; Kerkmann et al, 2003; Prakash et al, 2005). Therefore, the 
result suggests that the PolFNa expression seen at this later time point of infection 
might have been induced by the pDC population (which expresses IRF-7 
constitutively) within the PBMC. Indeed, the result at +7dpi appears inconclusive, it 
can still be suggested that there may be a relative differential expression amongst 
these PolFNa subtypes.
Further work assessing the expression profile of these PolFNa subtypes at earlier 
time points, for instance at +2, +4 or +6 dpi may provide a better understanding 
behind the kinetics of the PolFNa expression. Also increasing the numbers of pigs in 
future experiments will strengthen analysis of any possible differential PolFNa
256
Chp 6. Discussion and Conclusion
response. It would also be of interest to look at other cell types; specifically pDC 
which are known to constitutively express IRF7 independently of IRF-3, and in this 
case still express in the presence of CSFV Npro.
It is important to highlight that studies in both mouse (Baig & Fish, 2008; Gerlach 
et al, 2009; Yeow et al, 1998b) and human (Hillyer et al, 2012) have proposed that 
the in vitro antiviral activity of IFNa does not always correlate with the observed in 
vivo effect and also that the expression profile of the IFNa response depends on the 
infecting virus and target cell. Care must be taken, therefore, when trying to 
correlate the data of the in vivo and in vitro expression profile of a given PolFNa type 
prior to and after CSFV infection. Most importantly, for future consideration of the 
therapeutic use of rPolFNa!2 against CSFV, it is important to note that this in vitro 
antiviral activity conferred by this protein may not be replicated in vivo.
6.6 Therapeutic application of PolFNa against CSFV infection
Since PolFNal2 displayed a high anti-CSFV activity over time, it is likely to be a
good candidate for developing a metaphylactic treatment to protect against CSFV in
pigs. To develop this, several conditions including the method of delivery, time of
administration as well as the route of administration would need to be investigated.
For effective cytokine delivery to pigs, a viral based system could be considered. One
of the most commonly used viral vectors is the replication-defective human
adenovirus type 5 (Ad5) vector. This vector has been demonstrated as safe for
vaccine delivery, and has the ability to deliver foreign genes at a high level, hence
leading to its common use (Hammond & Johnson, 2005; McCullough & Summerfield,
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2009). One study using this viral vector showed that intramuscular inoculation of pigs 
with an Ad5 vector expressing PolFNcx/p induced a rapid antiviral response that was 
able to confer protection against FMDV within a day (de Avila Botton et al, 2006).
Alternatively, rPolFNa could be used as an adjuvant. This has been tested in a 
study where a cloned PolFNa plasmid incorporated into cationic liposomes was 
intramuscularly injected along with a low-dose IgG-FMDV vaccine into pigs. This 
inoculation induced the endogenous production of IFNa and provided complete 
protection against the virus (Cheng et al, 2007b).
These examples resulted in the safe and efficient delivery of interferon against 
virus, however, for the efficient therapeutic application of rPolFNal2 against CSFV, 
further experimental analysis would be required.
6.7 Conclusion
As a non-protective, high systemic IFNa response is observed at later stages of
CSFV infection, there were three underlying hypotheses to be tested in this thesis (i)
that IFNa subtypes possess differential anti-CSFV effects (ii) that these subtypes
could induce a synergist effect when used in combination and (iii) that these
subtypes are differentially expressed following CSFV infection.
The results of this study showed, for the first time, the successful cloning,
expression, purification and biological quantification of seventeen PolFNa subtypes
which was essential for further characterization of the subtypes.
Using a monocyte infection model, a novel differential anti-CSFV activity
conferred by sixteen of these rPolFNa were confirmed in vitro, amongst which
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rPolFNal2 was selected as the most potent against the virus and worthy of further 
investigation as an antiviral agent. This confirmed the first hypothesis that the 
PolFNa subtypes possess differential effects.
It was also demonstrated that the rPolFNa subtypes with similar levels of activity 
confer additive effects against CSFV infection in vitro when used in combination 
negating the second hypothesis that these subtypes induce a synergistic effect, 
although, it is possible that combination with other PolFNa types may induce a 
synergistic antiviral effect against CSFV.
Using a novel deep sequencing approach, the data from this study suggested that 
PolFNa subtypes except PolFNaS are expressed at similar levels in PBMC before 
infection. Following CSFV infection, differential patterns of expression pattern of the 
seventeen PolFNa subtypes relative to each other were observed in vivo. This, 
therefore, supports the final hypothesis that these subtypes are differentially 
expressed following CSFV infection.
It is hoped that findings from this study could contribute towards the further 
prevention of CSFV infection in vivo and the use of PolFNal2 as a metaphylactic 
treatment.
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Appendix to Chapter 1
Following from chapter one, this section was included to provide more insight in 
the involvement of some key activators of the innate immune system, and their role 
in the induction of type I IFN.
Nucleic acid sensors regulating type I IFN
During viral replication, different forms of nucleic acid can be generated; 
commonly described as pathogen associated molecular patters (PAMPS), these 
PAM PS are sensed by several host pattern recognition receptors (PRRs) and in 
response, trigger the induction of type I IFN (Hornung & Latz, 2010). These nucleic 
acid receptors all possess distinct functions within cells (Keating et al, 2011), some of 
which are described below.
In DNA-dependent pathogen responses, TANK-binding kinase-1 (TBK1); a 
cytoplasmic sensor of DNA, directly phosphorylates IRF-3 thereby activating this 
regulatory factor (Sharma & Fitzgerald, 2011). This type I response has been seen in 
DNA viruses like HSV-1 and murine gamma herpesvirus 68 (Miyahira et al, 2009).
Another important stimulator of IFN genes; STING found in the transmembrane 
region of the endoplamic reticulum has been identified as essential in the induction 
of IFN-p (Ishikawa & Barber, 2008; Sun et al, 2009). This protein possesses a C- 
terminal region which extends into the cytoplasm where it recruits TBK-1 thereby
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promoting the phosphorylation of IRF3 by TBK1 and as such induction of type I IFN 
response (Ishikawa et al, 2009; Unterholzner, 2013).
Although the above mentioned sensors do not directly recognize cytoplasmic 
DNA, recently, upstream cytoplasmic DNA sensors suggested to bind directly to DNA 
have been identified.
DNA-dependent activator of IFN-regulatory factors (DAI), which binds directly 
with DNA, has been suggested to bind with TBK-1 and IRF3 to activate NF-kB 
(Takaoka et al, 2007). Although studies have shown that this protein plays important 
roles in human fibroblasts during cytomegalovirus infection (DeFilippis et al, 2010), 
studies show that DAI deficient mice displayed normal immune responses to DNA 
vaccines or DNA virus infection (Ishii et al, 2008). This led to the suggestion that DAI 
may play cell-type specific roles in DNA sensing (Unterholzner, 2013).
Furthermore, studies have shown the involvement of RNA polymerase III in the 
transcription of AT-rich dsDNA into S'-triphosphate-containing dsRNA (Ablasser et al, 
2009). This dsRNA then acts as a ligand for the cytoplamic RNA sensor; RIG-1 thereby 
inducing the expression of IFNp (Chiu et al, 2009). This mechanism is thought to 
induce IFN responses to viruses such as HSV-1 and adenovirus (Chiu et al, 2009). In a 
study by Ablasser et al, 2009, it was shown that RNA pol III played an indirect role in 
regulating type I IFN in response to Epstein-Barr virus (EBV). This polymerase
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transcribes EBV viral RNA, which in turn activates type I IFN induction via RIG-1 
therefore suggesting an RNA pol III dependent IFN induction (Ablasser et al, 2009).
IFN-y inducible protein 16 (IFI16), is part of the pyrin and FUN domain protein 
family and activates TBK1-IRF3 dependent IFN|3 induction by recruiting STING 
(Unterholzner et al, 2010). This protein is found in the cytoplasm, but predominantly 
in the nucleus (Li et al, 2012). Hence, depending on the location of its DNA ligand, the 
protein is able to sense DNA in either the nucleus or the cytoplasm, as seen with 
HSV-1 where the detection of this DNA-virus is in the nucleus. These studies suggest 
that foreign DNA can also be sensed in the nucleus (Orzalli et al, 2012; Unterholzner, 
2013).
Another putative DNA sensor, DDX41, was identified by Zhang et al. 2011. In this 
study, it was revealed that this helicase; DDX41 binds DNA and interacts with STING 
using its DEADc polypeptide domain (Asp-Glu-Ala-Asp) and in return induces IFN 
response (Zhang et al, 2011). It has also been suggested that DDX41 binds to 
bacterial cyclic di-nucleotides (which act as signaling molecules) using the DEADc 
domain, thereby promoting the binding and activation of STING (Parvatiyar et al, 
2012).
The identification of nucleic acid sensors and their mode of action has provided 
an insight into how viruses evade the innate immune system. Better understanding
293
of these pathways could provide novel strategies on how the immune system can be 
used to limit viral infections.
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